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SUMMARY STATEMENT 
 
This thesis examines the overarching theme of inhaled corticosteroid (ICS) dose 
response effects on a variety of asthma outcome measures; with further importance 
placed on the application of these findings to personalising ICS dosing for the 
individual asthmatic. 
 
The introduction provides a detailed summary of the current recommendations for the 
treatment of adult asthma, with particular reference to the mechanism of action and 
clinical utility of ICS for the treatment of asthma.  Current methods of assessing ICS 
dose response are presented, as well as the common influences that affect these 
responses.  Novel therapeutic theories and the identification of specific asthmatic 
phenotypes are also introduced, in order to demonstrate the shift towards 
personalising treatment for asthma. 
 
The first two studies examine the dose response of ICS on two specific factors that 
influence asthma.  The third study presents an examination of pharmacological 
manipulation of the ICS dose response using an additional agent.  The following two 
studies address: how asthma outcomes relate to each other in patients receiving ICS; 
in addition to an overall assessment of the ICS dose response across a broad range of 
both ICS moieties and outcome measures.  The final study examines for any 
detrimental effect of an ICS dose ramp on bone metabolism, an important potential 
long-term adverse effect of higher ICS dosing. 
 
The discussion draws together all the results obtained in relation to ICS dose response 
in asthma, and how these apply to current clinical practice for the individual patient.  
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Furthermore, hypotheses are generated for areas of future study based on the findings 
from this work. 
  
17 
	 	
LIST OF ABBREVIATIONS 
 
ABPA Allergic bronchopulmonary aspergillosis 
ACD Asthma control days 
ACQ Asthma Control Questionnaire 
ACT Asthma Control Test 
ACTH Adrenocorticotrophic hormone 
AHR Airway hyper-responsiveness 
AIRE Asthma Insights and Reality in Europe study 
AMP Adenosine monophosphate 
AMPUL Asthma Management Project University Leiden group 
ANOVA Analysis of variance 
AQLQ Asthma Quality of Life Questionnaire 
ARIA Allergic Rhinitis and its Impact on Asthma 
ATS American Thoracic Society 
Ax Area under the curve 
B-17-MP Beclometasone-17-monopropionate 
B2ADR Beta-2 adrenoceptor 
BDP Beclometasone dipropionate 
BMI Body mass index 
BP Blood pressure 
BTS British Thoracic Society 
Bud Budesonide 
CFC Chlorofluorocarbon 
CI Confidence interval 
CIC Ciclesonide 
CONSORT Consolidated Standards of Reporting Trials 
COPD Chronic obstructive pulmonary disease 
CTx, 1CTP C-terminal cross-linked telopeptides of type 1 collagen 
CV Coefficient of variation 
DALY Disability adjusted life year 
des-CIC Desisobutyryl-ciclesonide 
DPI Dry powder inhaler 
ECP Eosinophilic cationic protein 
Eos Eosinophils 
ERS European Respiratory Society 
EVH Eucapnic voluntary hyperventilation 
FEF25-75 Forced expiratory flow between 25-75% of FVC 
FeNO/NO Fractional exhaled nitric oxide / nitric oxide 
FEV1 Forced expiratory volume in 1 second 
FEV6 Forced expiratory volume in 6 seconds 
FF Fluticasone furoate 
FP Fluticasone propionate 
Fres Resonant frequency 
FVC Forced vital capacity 
GCP Good Clinical Practice 
18 
	 	
GINA Global Initiative for Asthma 
GMFD Geometric mean fold difference 
GOAL Gaining Optimal Asthma Control study 
GORD Gastro-oesophageal reflux disease 
GR Glucocorticoid receptor 
GRE Glucocorticoid response element 
HDAC2 Histone deacetylase 2 
HFA Hydrofluoroalkane 
HPA Hypothalamic-pituitary-adrenal (axis) 
HR Heart rate 
HRQoL Health related quality of life 
ICS Inhaled corticosteroid 
IgE Immunoglobulin E 
IL Interleukin 
IMPACT Improving Asthma Control study 
IOS Impulse oscillometry 
LABA Long acting beta-2 agonist 
LAMA Long acting muscarinic antagonist 
LTRA Leukotriene receptor antagonist 
MANOVA Multivariate analysis of variance 
MCID Minimum clinically important difference 
MF Mometasone furoate 
MHRA Medicines and Healthcare Regulatory Authority 
MMAD Mass median aerodynamic diameter 
NF-κβ Nuclear factor - kappa beta 
NIH National Institutes of Health 
NRAD National review of asthma deaths 
OR Odds ratio 
OUCC Overnight urinary cortisol/creatinine ratio 
PC20 Provocative concentration causing 20% fall in FEV1 
PD10,15,20 Provocative dose causing 10, 15 or 20% fall in FEV1 
PEF/PEFR Peak expiratory flow / rate 
pMDI Pressurised metered dose inhaler 
P1NP Procollagen type 1 N-terminal propeptide 
P3NP Procollagen type 3 N-terminal propeptide 
Ppb Parts per billion 
R20 Airway Resistance at 20 Hertz 
R5 Airway Resistance at 5 Hertz 
R5-R20 Airway Resistance between 5 and 20 Hertz 
RCP Royal College of Physicians 
RCT Randomised Controlled Trial 
SABA Short acting beta-2 agonist 
SPT Skin prick test 
STAMINA Steroid Titration Against Mannitol in persistent Asthma study 
TH2 T-helper 2 
TNF-α Tumour necrosis factor alpha 
19 
	 	
CHAPTER 1:  
INTRODUCTION AND 
LITERATURE REVIEW 
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DEFINITION AND EPIDEMIOLOGY OF ASTHMA 
 
‘Asthma is a heterogeneous disease, usually characterised by chronic airway 
inflammation.  It is defined by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in intensity, 
together with variable expiratory flow limitation.’   This is the consensus statement on 
the definition of asthma from the Global Initiative for Asthma (GINA) guidelines9.  
There is a similar theme to the statements defining asthma from both the British 
Thoracic Society (BTS)10 and American Thoracic Society (ATS)11 by way of 
confirming that the diagnosis of asthma is largely a clinical one for which there is no 
gold standard threshold for accurate identification of the disease.  Indeed they affirm 
the common strands of pulmonary symptomatology with variable airflow obstruction, 
along with perhaps the additional identification of airway hyperresponsiveness (AHR, 
higher sensitivity/twitchiness to stimuli) and airway inflammation upon patient testing 
– considered the two key hallmarks of the underlying pathophysiology of asthma12.  
Indeed both of these features of asthma have been consistently shown to improve with 
inhaled corticosteroid (ICS) treatment6,13-15, which I will discuss in more detail later in 
this introduction. 
 
It is vitally important that we correctly diagnose asthma in an individual so that we 
can approach their treatment options effectively.  Whilst this is an obvious statement, 
it is often difficult to achieve in practice.  The symptomatology of asthma is widely 
variable, both in terms of frequency of occurrence and in the total number and 
severity of symptoms any given individual might display16,17.  Furthermore, simple 
tests for airflow obstruction in asthma are widely available – including serial peak 
expiratory flow rate (PEFR) measurements and spirometry – but their predictive value 
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in diagnosing asthma is only moderate, or worse if trying to identify mild 
disease10,11,18,19.  Bronchial provocation testing as a measure of airway 
hyperresponsiveness; and level of exhaled nitric oxide as a measure of airway 
inflammation, have also been used to try to increase the accuracy of asthma 
diagnosis20-22.  However, these investigations are by no means perfectly diagnostic of 
asthma and still remain largely limited to university hospitals and research facilities, 
due to their complexities of administration and interpretation, and have not therefore 
made it into widespread primary care use at the present time.  Ultimately when one is 
tasked with diagnosing asthma, a combination of symptoms and airway measurements 
are required to assist in determining the probability that any individual does actually 
suffer from it.  Indeed helpful decision making trees and probability tables have been 
included in the most recent iteration of the BTS asthma guidelines10. 
 
Asthma is recognised to be a condition of international importance and impact.  The 
Global burden of Asthma document16 developed for the Global Initiative for Asthma 
(GINA) has not been updated since 2004.  Nevertheless, even at that time there was a 
conservative estimate that 300 million people in the world were suffering from asthma 
– equating to approximately 5% of the total population of the world.  However, this 
worldwide prevalence of clinical asthma is not evenly distributed, with higher rates of 
asthma apparent with increasing ‘westernisation’ of lifestyle and urbanisation of 
communities.  Indeed, the mean prevalence of clinical asthma in the UK and Republic 
of Ireland in 2004 was 16.1% - one of the highest in the world.  Given that the 
prevalence of asthma continues to increase, this may well equate to an additional 100 
million people suffering from asthma worldwide by 202516. 
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Not only is the prevalence of asthma significant, there is also an attendant economic 
burden as well as significant morbidity and mortality associated with the disease.  
Asthma was the 25th leading cause of disability-adjusted life years (DALYs) lost 
worldwide in 2001 at 15 million – similar to the impact of diabetes and liver 
cirrhosis16.  In the UK, asthma care and services cost the NHS almost £900 million 
(accounting for both hospital services and prescribed medication costs), and asthma is 
responsible for at least 12.7 million lost working days every year (Asthma UK). 
 
Most concerning of all is that there remains an associated mortality with asthma, and 
this despite it being an eminently treatable condition, with all deaths from asthma 
being theoretically preventable for this reason.  Previous confidential enquiries into 
asthma deaths in Scotland23 and Wales24, both between 1994-1996, identified a 
variety of reasons for this: including inappropriate routine prescribing, patient 
behaviours and circumstance, as well as disease severity; albeit in the Scottish report 
there had been an overall improvement since the early 1980’s.  Fast-forward to 2014 
when the Royal College of Physicians delivered their National Review of Asthma 
Deaths (NRAD) confidential enquiry report25, which, despite the findings of these 
historic reports, still makes for sobering reading regarding ongoing, preventable 
asthma deaths. 
 
The Royal College of Physicians in their NRAD report presented key findings in four 
main areas: NHS services; medical and professional care; prescribing and medicines 
use; as well as patient factors and perception of risk of poor control.  It found that 
57% of those who died were not under specialist asthma care.  Worryingly, only 39% 
of patients who died were actually labelled as having ‘severe’ asthma according to 
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current guidelines, i.e. the remainder were labelled as either ‘mild’ or ‘moderate’ – 
suggesting we still cannot accurately identify those at greatest risk.  Patient factors 
were again highlighted, such as persistent smoking exposure, non-attendance for 
clinic review and poor recognition of the risk of not having good asthma control 
perhaps for psychological or psychiatric reasons.  Furthermore, and particularly 
germane to this thesis, are the findings of over-prescription of asthma reliever 
medication in addition to under-prescription of preventer medication such as ICS in 
patients who died.  Indeed it has previously been shown that regular usage of ICS in 
asthma can both prevent hospitalization over the long-term26 as well as prevent 
asthma deaths27.  Moreover, suboptimal asthma control has been shown to increase 
the likelihood of having an asthma exacerbation in the future28,29.  A large European 
survey of 8000 asthma patients in primary care30 concluded that asthma control 
remains poor, with symptoms and exacerbations commonly seen – yet many patients 
felt that despite this their asthma could be considered ‘controlled’.  This apparent lack 
of insight into the risks associated with uncontrolled disease by patients, had 
previously been demonstrated in another large European study in 1999 by Rabe et al – 
the Asthma Insights and Reality in Europe (AIRE) study31. 
 
While great strides have been made to improve asthma care over the past 20-30 years, 
we are not there yet.  We still cannot completely and accurately identify who has 
asthma and who does not.  Furthermore, we are still under-prescribing (and patients 
are underusing) the most beneficial treatment for asthma – namely ICS – along with 
inappropriate usage of other asthma medications, such as over-reliance on rescue 
inhaled bronchodilator therapy.  We therefore need to better identify: who to treat, 
taking into account the variation of intrinsic pathophysiology as well as external 
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factors (e.g. obesity); and what the optimal medication strategy is for a given 
individual.  I aim to improve clarity on some of these issues with specific regard to 
the mainstay of asthma treatment - inhaled corticosteroid therapy - in the remainder of 
this thesis. 
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CURRENT PHARMACOLOGICAL TREATMENT 
RECOMMENDATIONS FOR PERSISTENT ASTHMA 
 
Once the diagnosis of asthma has been made in an individual, we need to consider 
what (level of) treatment will be required, with the ultimate aim of gaining complete 
control of their asthma symptoms, thereby reducing the risk of asthma exacerbations.  
Complete control as defined by the BTS includes: no daytime symptoms, no night-
time awakening due to asthma, no need for rescue medication, no asthma 
exacerbations, no limitations on activity including exercise, normal lung function, and 
minimal side effects from medication10.  For the remainder of this section I will be 
discussing the current pharmacological treatment recommendations pertaining to 
adults with asthma, as the studies in my thesis all pertain to adult persistent asthmatics 
over 18 years of age. 
 
The BTS advocate a stepwise approach to the pharmacological management of 
asthma.  Progression upwards through the treatment steps from 1-5 is aligned to 
worsening symptomatology as well as the sequelae of those symptoms, i.e. excess 
reliever use, oral steroid use, and exacerbations.  There is certainly evidence that 
when guideline determined symptom control is used stringently (as part of a 
randomised controlled clinical trial) for altering the type and dosing of inhaled asthma 
therapies, then significant overall improvements in asthma control are seen.  For 
example, in the ‘GOAL’ study, patients were managed according to GINA/National 
Institutes of Health (NIH) guideline targets for totally controlled and well controlled 
asthma32.  By using this approach, the majority of patients improved from being 
uncontrolled to being controlled according to the guideline definitions.  The BTS have 
included in their guideline a choice of symptom-based questionnaires to be used for 
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this purpose.  Not all have been well validated, however.  Those that have been well 
validated for assessing asthma control include the Asthma Control Questionnaire 
(ACQ)33,34 and the (Mini)-Asthma Quality of Life Questionnaire (AQLQ)35 
(Appendix II – asthma questionnaires). Indeed, in a post-hoc analysis of the GOAL 
study by Meltzer and colleagues29, ACQ was the strongest predictor of a future 
exacerbation.  Oddly, the BTS seem to favour the use of a not well-validated 
questionnaire, namely the Royal College of Physicians (RCP) 3 questions36, purely on 
the basis that it may be simpler to use, without knowing whether or not it is the better 
test.  Moreover, it is not at all clear how well these recommendations are adhered to in 
the UK, in terms of optimising asthma therapy, and particularly in primary care where 
the majority of asthma patients are cared for and where the bulk of the 
recommendations apply.  However, where this has been examined in other countries 
of similar socioeconomic status to the UK, for example Israel37 and Kuwait38, asthma 
guideline adherence rates in primary care have been found to be low. 
 
Mild intermittent asthma is at the bottom rung of the BTS asthma treatment ladder 
(Figure 1) at step 1, where symptoms are experienced less than once per week, and 
patients are generally treated with an ‘as required’ inhaled short-acting Beta-2 agonist 
(SABA), usually salbutamol.  SABAs cause rapid bronchodilation of the airways 
through relaxation of the airway smooth muscle upon activation of their surface beta-
2 adrenoceptors (B2ADRs), and thus are ideal for symptom control in asthma.  
However, they do nothing to counteract the underlying inflammatory processes that 
cause an individual to have hyper-responsive airways, which then constrict when 
exposed to inhaled stimuli. 
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Figure 1.  Summary of stepwise asthma treatment titration from BTS/SIGN 
asthma guidelines 2014. 
 
The persistence of mild asthma symptoms heralds step 2 of asthma treatment.  It has 
been shown that even in mild asthma, there is ongoing airway inflammation39.  
Furthermore as symptoms, and therefore inflammation, become more persistent, there 
is an increased risk of exacerbation and death – even in those patients deemed to have 
mild disease25.  It is for these reasons that ICS are recommended at this seemingly 
early stage.  It is not surprising that ICS have become the backbone of asthma 
controller therapy due to their wide-ranging effects not only on asthma symptoms, but 
also on their ability to control the underlying inflammatory process that heralds these 
symptoms in the first place.  They have been shown to reduce asthma symptoms40-42, 
improve lung function43,44, decrease the frequency and severity of exacerbations45-47, 
as well as improve quality of life48.  Moreover, the therapeutic index of ICS for 
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treating mild asthma is favourable, as asthma control can usually be achieved with 
low doses in this group, thus negating any significant local or systemic side effects49.   
Some uncertainty does emerge when treating mild asthma, due to the ongoing 
argument as to whether or not mildly symptomatic patients should receive continuous 
or intermittent ICS therapy.  The argument for intermittent ICS use is largely borne 
out of a widely demonstrated lack of compliance to regular inhaled medications, 
perhaps because in mild asthma the symptom burden is insufficient to reinforce the 
need for regular therapy.  Boushey et al prospectively examined this question in the 
Improving Asthma Control (IMPACT) study50.  They compared three groups of mild 
asthma patients, randomising them to one of: regular budesonide, regular zafirlukast 
(a leukotriene receptor antagonist), or intermittent budesonide to be used when asthma 
symptoms occurred – all in a randomised, placebo-controlled fashion.  They found no 
difference in their main outcome measure of change from baseline in two-week 
average morning PEF, with similar small increases across the groups.  Furthermore, 
there was no difference in the number of exacerbations across the groups over the 
one-year follow-up period.  However, they did observe improvements in 
inflammatory outcomes, namely sputum eosinophilia and exhaled nitric oxide 
(FeNO), in the regular budesonide group, but not in either of the other two groups.  
This is important, as previous studies have reported that regular ICS treatment may 
prevent progressive loss of pulmonary function51,52 and chronic airway remodelling 
which might be due to unopposed ongoing airway inflammation39.  Pointedly, we 
have already seen that an approach of regular ICS therapy reduces both frequency of 
exacerbations26 and mortality27.  Nevertheless, the authors of the IMPACT study do 
concede that whilst an intermittent ICS treatment strategy may be viable, it cannot yet 
be recommended on the basis of the current available evidence, which remains the 
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standpoint of most recent guidelines10,11. 
It is important to also mention at this juncture that there is no role for long-acting 
beta-2 agonists (LABAs) as single-agent asthma controller therapy, without ICS.  
There is wide agreement in the literature that LABA monotherapy should be avoided 
in asthma.  This is on the basis of studies that have shown significant adverse events 
and mortality using this approach53-58.  The main reasons given are: over-reliance (on 
beta-2 agonists) and under-treatment (with ICS) masking inflammation and severity 
of disease; tolerance to treatment; and increased airway hyper-responsiveness to 
allergens.  Beta-2 agonists may also activate non-canonical (Gs-cAMP independent) 
Beta-arrestin mediated pro-inflammatory signaling pathways via extracellular signal 
regulated kinases (ERK1/2)59.  In knockout mice Beta-arrestin-2 regulates the 
development of allergic asthma60.  In the antigen driven mouse model, depletion of 
adrenaline - the natural ligand for the B2ADR - prevented the development of 
asthma61.  Replacement of B2ADR signaling by administration of formoterol (LABA) 
restored the asthma phenotype, showing that agonist-induced activation of B2ADRs 
results in development of asthma.  Therefore, giving ICS with LABA might obviate 
any pro-inflammatory effects of the LABA, while retaining the airway stabilizing 
activity of the LABA.  It is therefore recommended that if a LABA is prescribed, this 
should always be in conjunction with background ICS therapy. There is much less 
agreement, however, on the optimum role of LABA prescribed in addition to ICS62.   
Moving onto step 3 of the BTS treatment ladder, we are now faced with a choice of 
treatment approaches when symptoms remain uncontrolled by regular low to 
moderate dose ICS. The two main strategies are to either increase the dose of ICS, or 
to add another asthma controller drug, which in the main is LABA therapy.  There 
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have been a number of studies showing that adding LABA to ICS versus increasing 
the ICS dose alone is of greater therapeutic benefit45,63,64.  Furthermore, it is 
recommended that ICS/LABA should be given in single combination inhalers where 
possible, to avoid any likelihood of inadvertent LABA monotherapy10.  Albeit, a 
number of studies have concluded that there is no therapeutic advantage to using this 
single inhaler/dual therapy approach over concurrent LABA and ICS inhalers65,66.  
There are several other options for add-on therapy to ICS, including leukotriene 
receptor antagonists (LTRAs)67, theophyllines68 or slow-release beta-2 agonist 
tablets69; but these have not been as extensively studied in terms of asthma outcomes 
than when compared to adding LABA to ICS.  While the evidence base behind the 
current BTS guidelines certainly advocates LABA/ICS combination before increasing 
ICS dose further, there is more recent evidence from a large ‘real-life’ study 
suggesting there might be no difference between these approaches in a broad primary 
care population70.  Bateman et al. found that the odds of asthma control and rates of 
severe exacerbation over one outcome year were comparable between increased ICS 
dose versus added LABA groups.  This is relevant because there may be bias in 
previous studies on the basis of their tight inclusion criteria, requiring both the 
presence of prior reversibility to SABA upon study entry and the use of lung function 
outcomes such as PEF that may have favoured the LABA component over ICS.  
Ultimately, I think that we need to concentrate on the individual patient presenting 
before us, to decide what the optimum treatment regime might be for them, 
particularly when randomised controlled trials and population statistics are 
conflicting. 
We now move to the more severe end of the asthmatic spectrum at step 4.  There are 
very few randomised controlled trials to inform how we approach management of 
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these patients, with extrapolation from trials of add-on therapies being the basis for 
any decisions.  If patients are already on an ICS/LABA combination, with an ICS 
beclometasone dipropionate (BDP) equivalent dose of 800µg/day, then it is suggested 
any of: increasing ICS dose up to 2000µg/day, or adding in any of LTRAs, 
theophyllines or slow-release beta-2 agonist tablets – bearing in mind the greater side 
effect profiles of these latter two.  Equally, at such high doses of ICS, then the risk of 
side effects from these increases too49.  The long-acting muscarinic antagonist 
(LAMA) tiotropium has also been shown to be beneficial when added in here71,72.  It 
is important to remember at all stages of asthma therapy and in particular at this level 
of treatment, one has to be assured of an adequate inhaler technique (with the use of a 
spacer device if necessary) as well as being quite ruthless in assessing patients’ 
adherence to medication73. 
Finally we get to step 5 of the BTS asthma treatment ladder.  These severe asthma 
patients who are refractory to standard medications arguably represent a completely 
different phenotype in asthma.  However, the treatment options for these individuals, 
when it comes to maximizing anti-inflammatory treatment, are very limited.  
Furthermore, the role of comorbidities is greater in this patient group.  Currently the 
BTS recommend using the lowest controlling dose of oral corticosteroids as the next 
step for patients uncontrolled at step 4.  Clearly oral steroid side effects are much 
greater than that from ICS, and a variety of organ systems should be screened for 
these side effects when oral steroid treatment is either continuous, or courses are 
frequent10.  For a small group of severe allergic asthmatics, there is the option of anti-
IgE therapy – omalizumab – that is a monoclonal antibody that binds to circulating 
IgE and reduces serum IgE levels74.  It can provide significant benefits in terms of 
reducing asthma exacerbations and the need for oral steroid therapy75.  However, this 
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treatment is limited to patients who display a clear allergic component to their asthma 
(with either skin-prick or specific serum IgE positivity to allergen) as well as having 
an elevated serum total IgE level within pre-defined upper and lower limits for which 
the anti-IgE therapy can be used.  It goes without saying that these patients should be 
assessed and treated in specialist centres (as should all step 5 patients).  Because of 
the significant benefits seen in these carefully selected patients, GINA9 have recently 
put omalizumab on equal footing with oral steroids as the joint first line choice for 
step 5 (in suitable patients) – a move which I believe is likely to be adopted by the 
BTS in the future, given its excellent side effect profile compared to oral steroids.  
Another monoclonal antibody, the anti-IL5 agent mepolizumab, has recently become 
available for patients with severe eosinophilic asthma76.  Indeed blood eosinophil 
levels are receiving more attention once again in asthma due to their effects on 
increased likelihood of exacerbation77 and because they can be therapeutically 
targeted by mepolizumab through its anti-IL5 actions. Other steroid-sparing agents 
(e.g. methotrexate) can be used but there is little evidence for them in asthma per se. 
Overall, ICS remain the cornerstone of asthma controller therapy throughout all but 
the first asthma treatment step.  Work is still needed to accurately identify when and 
in whom ICS therapy should be altered, the doses required to completely control both 
symptoms and underlying airway inflammation, as well as exploring novel add-on 
therapies or ICS sparing agents. 
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PHARMACOLOGY OF INHALED CORTICOSTEROIDS 
 
General immunosuppressive effects 
 
Inhaled (gluco-) corticosteroids are the most valuable group of drugs for combating 
the widespread inflammatory effects in asthmatic airways.  As such they have 
revolutionised the way we treat asthma, in particular enabling the reduction in need 
for regular oral corticosteroids78 with their significant attendant side effect profile.  
Corticosteroids exert their anti-inflammatory effects through a variety of 
mechanisms79.  They both increase and decrease different gene transcription pathways 
in the cell nucleus that are involved in the pathological processes of asthma, largely to 
decrease the overall level of inflammation as well as exerting effects on other 
receptors.  These include genes encoding for: B2ADRs, anti-inflammatory cytokines 
(e.g. IL-10, IL-12), inflammatory cytokines (e.g. IL-2 to IL-6, IL-13, TNF-α), 
inflammatory enzymes (e.g. inducible nitric oxide synthase [iNOS], inducible 
cyclooxygenase [COX-2]), adhesion molecules (e.g. ICAM-1), and many others.  
Furthermore, they reduce the numbers of a variety of inflammatory cells including 
eosinophils, T-lymphocytes, dendritic cells, macrophages and mast cells along with 
reducing the levels of cytokines and other inflammatory mediators that drive their 
production.  Corticosteroids additionally have effects on restoring endothelial cell 
integrity and reducing cytokine production from these cells – this is important, as the 
airway epithelial cells are the main targets for ICS.  Moreover, corticosteroids have 
anti-proliferative properties80 that they exert on airway smooth muscle, particularly as 
smooth muscle airway proliferation leads to increased AHR and potentially airway 
remodelling in asthma.  Most of these effects occur rapidly, for example, a visible 
reduction in the level of eosinophils can be seen within 6 hours81. 
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Effects on glucocorticoid receptors 
 
The mode of action of corticosteroids commences following their diffusion across the 
cell membrane into the cytosol where they bind with glucocorticoid receptors (GR).  
Having done this, the activated GRs translocate into the nucleus of the cell to generate 
their effects on gene expression described above82.  GRs bind in pairs to 
glucocorticoid response elements (GRE) in the promoter region of genes that are 
steroid responsive, with this interaction then switching on (or off) gene transcription.  
The main anti-inflammatory interactions are to switch off the multiple activated 
inflammatory genes that encode for chemokines, cytokines and adhesion molecules 
that have been switched on by pro-inflammatory transcription factors e.g. nuclear 
factor-κB (NF-κB), which activate downstream inflammatory genes, ultimately 
resulting in acetylation of core histones that facilitate the gene transcription.  
Activated-GRs reduce this histone acetylation through inhibiting NF-κB interacting 
with its co-activators, as well as through recruiting histone deacetylase-2 (HDAC2) to 
the activated inflammatory-gene complex.  This then results in suppression of all 
activated inflammatory genes within the nucleus.  Corticosteroid resistance, such as is 
seen in severe asthma or smoking asthmatics, is thought related to both a reduction in 
HDAC2 activity and expression83.  Furthermore, reduction in the translocation of GRs 
via p38 MAP kinase phosphorylation is also thought to be important in corticosteroid 
resistance84. 
 
Effects on beta-2 adrenoceptors 
 
Beta-2 adrenoceptors (B2ADRs) are one of a family of G-protein coupled receptors 
located on the cell membranes of smooth muscle cells in the airway.  They are 
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primarily activated by the body’s circulating catecholamines (e.g. adrenaline), or for 
the purposes of asthma treatment, this activation occurs via more selective synthetic 
substitutes – beta-2 agonists (i.e. SABAs and LABAs) - for relaxing airway smooth 
muscle and relieving airway constriction i.e. bronchodilation.  However, in addition to 
the primary function of the B2ADR, there is a complex synergy between these and 
GRs - each benefitting the other when activated simultaneously85.  We have already 
seen that gene transcription is switched on or off by activated GRs, and in fact one of 
these targets is the gene encoding for the B2ADR itself.  Gene transcription for the 
B2ADR is increased by corticosteroids, resulting in greater expression of these cell 
surface receptors86,87.  Furthermore, corticosteroids prevent, and indeed reverse, the 
down-regulation of B2ADRs that can be seen with chronic beta-2 agonist dosing88-90.  
Corticosteroids also enhance the coupling of B2ADRs to G-proteins to improve their 
effects, as well as protecting against uncoupling from exposure to inflammatory 
mediators91,92.  Pointedly, corticosteroids have the ability to increase retention of 
LABA molecules on the airway surface93, thus enhancing their clinical effect further.  
On the other side of the coin, beta-2 agonists themselves can reciprocally enhance the 
effects of the GR80.  This process has been shown to improve the anti-inflammatory 
effects of corticosteroids at the nuclear level80.  Moreover, studies have shown that the 
presence of both corticosteroid and beta-2 agonist moieties delivered at the same time 
to the airway has a synergistic effect on GR nuclear receptor translocation94 and 
transcription95, thus enhancing any anti-inflammatory effects further.  This is one of 
the proposed reasons for the steroid-sparing effect of LABA therapy seen when added 
to ICS96. 
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Pharmacokinetics and pharmacodynamics of different inhaled corticosteroids 
 
Having considered the pharmacological effects of ICS as a whole, there is further 
complexity regarding the variety of different types of currently available ICS.  (There 
is an even further level of granularity when also considering different delivery 
devices, but these are beyond the scope of this thesis so will not be mentioned in 
detail).  The ideal pharmacological profile of an inhaled corticosteroid encompasses 
both efficacy and safety properties97.  The properties of ICS considered advantageous 
for improved efficacy include: small particle size (increasing the fraction of dose 
delivered to the lung – particularly with particle sizes with a mass median 
aerodynamic diameter [MMAD] <2µm), high GR binding affinity, long pulmonary 
residence time and lipophilicity of the drug (all of which increase and prolong the ICS 
efficacy i.e. potency).  Properties considered advantageous for an improved safety 
profile include: ‘on-site’ activation in the lung (reducing oropharyngeal effects), low 
oropharyngeal exposure, negligible oral bioavailability (usually achieved as a result of 
high first pass metabolism through the liver for ingested ICS), high systemic protein 
binding (reducing systemic adverse effects) and rapid systemic clearance. 
 
Currently available ICS for asthma (British National Formulary, March 2015) 
include: fluticasone propionate (FP), fluticasone furoate (FF), budesonide (Bud), 
beclometasone dipropionate (BDP), ciclesonide (CIC), and mometasone furoate 
(MF).  FP is available as both a dry powder inhaler (DPI) and hydro-fluoroalkane 
(HFA) suspension delivered via pressurised metered dose inhaler (pMDI).  HFA has 
replaced chlorofluorocarbons (CFCs) as the propellants in inhalers for legally 
imposed environmental reasons.  FF is a very new ICS that is given only in 
combination with a LABA for asthma as a DPI.  Bud is delivered as a DPI in the UK.  
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(HFA)-BDP is delivered in a solution pMDI both singly and in combination with 
LABA – the solution formulation delivers a greater fine particle fraction to the lungs 
than suspension formulations.  I have summarised the pharmacokinetic and 
pharmacodynamic properties of these currently available ICS in Table 1.  Each one 
displays quite a number of the desired attributes for an ‘ideal ICS’, however; none of 
them present the ‘full house’ of qualities.  Of note FP, FF, and CIC all display high 
levels of lipophilicity, improving pulmonary residence time and efficacy.  BDP 
actually has a higher lipophilicity than FP, however, its active component 
beclometasone-17-monopropionate (B-17-MP), presented following conversion by 
esterases in the airway, has much lower lipophilicity than FP.  CIC is the other ICS 
that is converted ‘on-site’ in the lungs to its active moiety desisobutyryl-ciclesonide 
(des-CIC), and to a greater degree than BDP.  The highest receptor binding affinity, 
and long pulmonary residency of FF make this a once daily medication, whereas the 
remaining majority requires twice-daily administration (excluding CIC). 
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Adverse effects 
 
ICS generally have a very good therapeutic index when it comes to adverse effects, 
particularly when used at low to moderate doses, as is the case in most asthmatics.  
The two main local side effects are that of dysphonia (hoarseness) and oral 
candidiasis.  Dysphonia has been described in >50% of certain patient cohorts using a 
pMDI to deliver their ICS, but resolved on removal of treatment111.  Oral candidiasis 
can also be a problem due to local delivery of a high proportion of the delivered ICS 
dose depositing on the oropharynx, rather than making a successful journey into the 
lung.  However, this tends to be a problem mainly in the elderly, after oral 
corticosteroid use, or using one’s ICS more than twice a day112.  Furthermore, 
candidiasis (but not dysphonia) can be prevented by the use of a spacer or mouth 
rinsing112.  There is no suggestion of an increased risk of pneumonia due to ICS use in 
asthma, as has been suggested in chronic obstructive pulmonary disease (COPD)113. 
 
When it comes to systemic adverse effects of ICS, they are certainly not as marked as 
can be seen with oral corticosteroid therapy.  Indeed, whilst it may be possible to 
observe a measureable biochemical abnormality with ICS therapy, it is unclear how 
well this translates into a clinically important problem.   However, once ICS dosing 
becomes very high, of the order of more than 1500µg/day (or 750µg/day for FP)49 
then systemic adverse effects can be seen.  The main issue relates to suppression of 
the hypothalamic-pituitary-adrenal (HPA) axis by reducing corticotrophin production 
from the anterior pituitary gland leading to a reduction in cortisol secretion from the 
adrenal glands.  This leads to the issue whereby on sudden discontinuation of ICS, 
patients may suffer an ‘adrenal crisis’ whereby the adrenal glands can no longer 
produce sufficient cortisol at times of stress – which is a potentially life-threatening 
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condition.  However, overall, studies have been inconsistent in confirming this 
problem.  There is some evidence that high doses of ICS can lead to posterior sub-
capsular cataracts49,114 as well as weaker evidence for the emergence of ocular 
hypertension and glaucoma115.  Additionally bruising and thinning of the skin is seen 
with higher doses of ICS, which is again more apparent in the elderly116.  In addition 
to adrenal suppression, another subject of intense debate and study with regard to 
systemic adverse effects from ICS therapy is that of bone demineralisation, 
osteoporosis, and thus increased fracture risk – where this is already a problem with 
regular oral corticosteroids causing rapid reductions in bone formation markers such 
as osteocalcin117,118.  Studies on whether or not ICS deleteriously affects bone 
turnover are conflicting119-121.  The impairment of growth in childhood by ICS is also 
an area of debate and controversy in this regard, but beyond the scope of this thesis as 
all subjects presented here have reached adulthood already. 
 
Whether or not there are significant adverse effects with ICS therapy, the important 
issue is to ensure that asthmatic patients are treated with the lowest dose of ICS that 
controls their disease, as the potential therapeutic benefits of ICS certainly outweigh 
the risks of adverse effects for the large majority of patients. 
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MEASURING DOSE-RESPONSE TO ICS IN PERSISTENT ASTHMA 
 
Lung function / Airway calibre 
 
Measures of pulmonary function include peak expiratory flow rate (PEFR), 
Spirometry and Impulse Oscillometry (IOS).  PEFR and Spirometry (in particular 
FEV1) are well established as outcomes of treatment response in asthma, whereas IOS 
is only just emerging as such with the rejuvenated interest in the role of the peripheral 
‘small’ airways (<2mm) in asthma122. 
 
PEFR and spirometry are readily available and easy to perform in both primary and 
secondary care, and even as domiciliary measurements.  Spirometry is also very 
reproducible, making it ideal for serial measurements123.  Importantly, it has been 
shown that the odds of having asthma symptoms increase with decline in FEV1124, 
albeit the overall predictive value of FEV1 for this reason has been suggested to be 
only 70%125.   It is also important to know the minimum change in any outcome 
measure that relates to a perceptible change in patient wellbeing – otherwise known as 
the minimal clinically important difference (MCID) – as a gauge of the clinical 
relevance of any measured difference.  Santanello and colleagues suggest that PEFR 
has a MCID of around 19L/min, where for FEV1 a change of 0.23L is thought 
clinically relevant126.  While these degrees of improvement are readily surpassed 
when steroid-naïve asthmatics are commenced on ICS even at low dose, the dose 
response for lung function beyond low dose ICS is remarkably flat.  This is neatly 
demonstrated in two Cochrane reviews both examining dose responses to FP, with the 
first comparing increasing doses of FP to placebo44 that shows large improvements in 
FEV1 for all doses versus placebo.  Whereas the second study compares different 
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doses of FP127 showing more meagre improvements between doses that don’t meet the 
putative MCID for FEV1.  An earlier meta-analysis, again using FP, also showed this 
plateauing of the dose-response between 100-200µg for both PEFR and FEV1, with a 
peak effect at around 500µg of FP.  Indeed 600µg of FP was roughly equivalent to a 
change of 0.71L in FEV1 (MCID=0.23L) and 50L/min in PEFR (MCID=19L/min) 
over placebo.  This early plateauing of the dose-response curve for ICS versus lung 
function has been repeated in other studies128, but there is the caveat of a significant 
inter-individual variability with regard to these responses.  Importantly, there does not 
seem to be a significant difference between different ICS with regard to the point at 
which this plateau in dose-response for lung function occurs, as demonstrated in 
another Cochrane review comparing FP, Bud and BDP129. 
 
Impulse oscillometry (IOS) is a non-effort dependent measure of airways resistance 
performed during relaxed tidal breathing (PEFR and Spirometry are both effort-
dependent), and can provide differential measures of total airway resistance at 5Hz 
(R5), central large airway resistance at 20Hz (R20) and derived measures of 
peripheral small airway resistance (R5-R20 and Ax).  There are no studies examining 
the dose-response to ICS in asthma with IOS outcomes.  However, in a study 
comparing HFA-BDP with CFC-BDP (i.e. extra-fine particle ICS versus standard size 
particle ICS), IOS indices improved with both formulations in line with improvements 
in FEV1130.  Pointedly, however, for HFA-BDP there was a significantly greater 
improvement in the peripheral ‘small’ airway measurement of R5-R20 than seen for 
CFC-BDP.  There are no data on what any MCID might be for IOS measurements at 
the present time. 
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Airway hyper-responsiveness (AHR) 
 
AHR is defined as an abnormal response of the airways to a stimulus that results in 
excessive airway constriction in asthmatics, where the same stimulus would have little 
or no effect on the airways of a healthy individual.  AHR is therefore well recognised 
as a hallmark of the asthmatic process.  Yet AHR is still not fully understood in terms 
of its causal pathophysiological mechanisms.  However, we do know it is broadly 
affected by underlying (allergic) airway inflammation131-134, hyper-contractility of 
airway smooth muscle135, and airway closure itself136 (this last particularly with 
regard to peripheral small airway closure137).  Measuring AHR is useful not only for 
aiding asthma diagnosis, when spirometry may be normal, but also in the 
classification of its severity20,138 and in tailoring ongoing management6,13.  
Furthermore, AHR has been shown to predict: ongoing decline in lung function139, the 
risk of developing asthma140, severity of asthma symptoms141, risk of exacerbation46 
and an increased level of treatment142.  Despite the clear utility of non-specific 
measures of AHR, individual patients can respond very differently to the variety of 
bronchial challenge tests that are available, presumably due to heterogeneity of the 
underlying mechanisms driving their individual (presence or absence) of AHR143.  
Moreover, even with any given test of AHR, there is significant within-individual 
variability of the test result itself, making determination of any MCID difficult.  
Indeed this has been proposed to range between 1-3 doubling dilutions/doubling doses 
of the challenge agent used to cause the same fall in FEV1144. 
 
There are two main categories of bronchial challenge testing – direct and indirect.  
‘Direct’ bronchial challenge tests include methacholine and histamine that act directly 
on the airway smooth muscle to cause bronchoconstriction.  Challenge tests termed 
44 
	 	
‘indirect’ cause bronchoconstriction through invoking the underlying 
allergic/inflammatory processes thus indirectly releasing inflammatory mediators that 
then trigger the airway smooth muscle to contract.  These indirect challenge agents 
include: adenosine monophosphate (AMP), mannitol, allergen, exercise and eucapnic 
voluntary hyperventilation (EVH).  Of these, mannitol seems to have emerged as the 
one with greatest clinical utility in terms of ease of practical implementation and good 
relationship to other challenge agents such as methacholine131.  Furthermore, because 
of their mechanism, indirect challenges have been shown to bear a greater relationship 
to airway inflammation in asthma than do the direct challenge tests131,132. 
 
There is a multitude of evidence showing that AHR responds favourably to ICS.  In 
one study examining high doses of Bud in severe asthmatics, even the lower dose of 
1200µg/day caused a 3 doubling dose improvement, whilst the higher 3200µg dose 
achieved an only slightly higher improvement of 3.2 doubling doses (of histamine)145.  
However, patients receiving the higher dose for the first 16 weeks of the study were 
almost 4 times as likely to normalise their AHR.  In a meta-analysis by Currie and 
colleagues comparing the dose-responses of a variety of ICS on AHR146, they found 
that high dose ICS (≥1000µg/day) caused a significantly greater degree of 
improvement in AHR with a 2.16 doubling shift over placebo as compared to 
low/moderate ICS dosing (<1000g/day) at a 1.25 doubling shift over placebo.  
Additionally, several ICS intervention trials6,13 have shown that by titrating (up) ICS 
dose with the target of improving AHR, compared to just targeting symptoms, then 
this results in a reduction in the number of mild exacerbations, suggesting that overall 
asthma control might be better using this method of tailored ICS treatment.  This is 
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certainly an area requiring greater study to try to pin down how best to personalise 
asthma care in relation to the variety of underlying mechanisms that cause AHR135. 
 
Airway inflammation 
 
Airway inflammation is the other main hallmark of the asthmatic disease process, 
along with AHR.  It has been identified histologically147,148 and even in ‘mild’ 
asthmatics39 as discussed previously.  Clearly endobronchial biopsies are not going to 
be widely useful as a measure of airway inflammation, due to the invasive nature and 
risks associated with this procedure.  However, surrogate markers of airway 
inflammation have been identified that have proven useful in the identification, 
monitoring and management of asthma.  The two main biomarkers that I will discuss 
here in relation to ICS therapy are sputum eosinophilia and exhaled nitric oxide 
(FeNO). 
 
The eosinophil is one of the key cells produced as part of any allergic TH2-driven 
inflammatory pathway.  They are easily identified in higher numbers than normal in 
both sputum and blood in asthmatic patients149.  To complicate matters slightly, 
eosinophilic asthma is considered one of the main phenotypes of asthma, as compared 
to non-eosinophilic asthma150.  Sputum eosinophils have been shown to be clinically 
relevant in asthma for several reasons.  Firstly they predict loss of asthma control151 
and increased exacerbation152 rate upon withdrawal of ICS therapy.  Pointedly, it has 
been shown that adjusting asthma therapy on the basis of targeting a reduction in 
sputum eosinophil levels in moderate to severe asthmatics, significant reductions in 
the number of severe exacerbations experienced in the sputum eosinophil group were 
46 
	 	
achieved – 35 versus 109 compared to those whose treatment was tailored in a 
traditional method14.  Surprisingly, the mean doses of inhaled and oral steroid used to 
achieve this landmark improvement was not higher in the sputum eosinophil group 
compared to standard therapy (therefore, not a dose-response phenomenon) – 
presumably because higher treatment doses were targeted at the right time (when 
inflammatory levels were highest), thus evening out the dosing over the 12-month 
period.  This further shows that personalising asthma therapy is both appropriate and 
effective.  A dose response to ICS for sputum eosinophils in asthma has however been 
shown for MF in a study comparing 50µg twice daily versus 400µg twice daily on 
suppression of late-phase response to allergen challenge (an indirect challenge)153, 
albeit the difference in effect between the lower and higher dose of MF was not large, 
i.e. alluding to an early plateau effect. 
 
The other non-invasive method of measuring airway inflammation in asthma is with 
fractional exhaled nitric oxide (FeNO) levels22.  Previous studies have confirmed that 
FeNO levels are higher in asthmatic patients than in healthy controls154,155, albeit there 
is still a degree of within-subject variability and between-subject overlap128.  FeNO 
has also been shown to correlate with both eosinophil levels156 and AHR132,157.  
Furthermore, higher FeNO levels in asthma are associated with a higher risk of future 
exacerbation and can predict those who are likely to respond to ICS155.  Indeed, more 
recently it has been shown to be a helpful measure of compliance to ICS therapy158.  
FeNO can now be easily measured on a hand-held device (still 2 hands rather than 
one!), with this increased portability useful for domiciliary or clinic measurement of 
FeNO levels.  In a similar vein to that of the Lancet study by Green et al targeting 
sputum eosinophils, Smith et al used FeNO measurements to guide treatment in 
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asthma comparing ICS dose adjustment according to either FeNO levels or 
conventional guidelines15.  However, they found that overall ICS doses could be 
significantly reduced while keeping the same level of asthma control i.e. no change in 
the exacerbation rate.  Furthermore, levels of sputum eosinophils were not different 
between groups.  I believe this tells us two things: firstly that FeNO responds very 
well to lower doses of ICS, and secondly that FeNO does not correlate well with 
either symptoms or lung function, which are the standards currently used in assessing 
asthma control.  In terms of a dose-response relationship of ICS to FeNO levels, 
Silkoff et al showed that dose separation of three doses of BDP was better when 
measured by FeNO as compared to no separation seen with FEV1 or methacholine 
AHR in originally steroid-naïve asthmatics – however this separation was only seen 
between the lowest (100µg/day) and highest (800µg/day) doses of BDP, again 
showing dramatic improvement on low dose ICS, but less so with higher dosing159.  
Furthermore they found that the reduction of FeNO was highly reproducible on 
stopping and then restarting the ICS.  This dose response has also been shown in 
another study, again using BDP160. 
 
Smith et al have shown that both sputum eosinophilia and FeNO are better for 
diagnosing asthma than spirometry or symptoms, with negative predictive values at 
92% for both161.  Indeed, a recent paper by Cowan et al suggests using a panel of 
inflammatory biomarkers to enable better prediction of ICS responsiveness in asthma, 
particularly as the presence of high levels of sputum eosinophils and FeNO do not 
always overlap162. 
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Symptoms, reliever use and asthma control 
 
The outcome measures of symptoms, reliever (SABA) use and asthma control (the 
definition of which varies widely between studies) are all necessarily inter-related.  
Despite being most relevant to individual asthma patients’ daily lives (where FEV1 is 
not), they are most often utilised as secondary outcomes in studies of asthma rather 
than as a priori primary outcomes.  Nevertheless, there is still good evidence of a 
dose response to ICS for these outcomes when one delves deeper into a variety of 
studies examining the utility of ICS on other asthma outcomes.  In one study of long-
term treatment with Bud 400µg/day for 1 year versus placebo in non-steroid 
dependent asthmatics40, there were significant improvements seen in both asthma 
symptoms (even though only mild to begin with) and rescue bronchodilator use over 
the course of the year.  Indeed symptoms continued to improve out as far as 9 months 
then plateaued, whereas the improvements in bronchodilator use plateaued at 3 
months – with no change with placebo for either outcome.  Asthma symptom scores 
also improved in a meta-analysis of the dose-response to several different ICS, albeit 
again with most improvement seen with the lowest doses of ICS41.  Furthermore, in 
studies that showed the advantage of ICS/LABA combination over increasing ICS 
dose alone, the ICS alone arm still showed significant improvements in symptoms and 
beta-2 agonist use42,63,129. 
 
Measures of symptoms, health-related quality of life (HRQoL) and asthma control are 
problematic to formulate, due to the heterogeneity of presentation, severity, variability 
and time course of this disease.  They need to be wide-ranging to encompass all the 
possible variations; yet specific enough to asthma, in order for any meaningful 
clinical change to be measureable upon commencement or change in asthma therapy.  
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Moreover, patients’ interpretation of their own control may underestimate the degree 
of disability they may have30, without using a formal validated measure.  A number of 
symptom diaries have been validated in this regard.  For example, Santanello and 
colleagues163 validated 2 diary scales for daytime and nocturnal symptoms in a cohort 
of 346 adult asthmatics in response to trials examining a leukotriene biosynthesis 
inhibitor, encompassing activity during the day, showing good test-retest reliability 
(0.69-0.87) and strong correlations to other outcome measures including FEV1 and 
reliever usage.  However, many measures of symptoms and other diaries in clinical 
trials are uncontrolled and not well validated, so their interpretation should be 
guarded. 
 
The next level beyond pure symptom measurement is that of health-related quality of 
life (HRQoL).  There are many general measures of HRQoL, but again for the 
purposes of greater specificity to asthma and its treatment, questionnaires have been 
developed that more closely relate to these.  The most widely used, and well validated 
of these is the Juniper Asthma Quality of Life Questionnaire (AQLQ)164,165.  This 
provides an overall score (32 questions and 4 domains), as well as the ability to tease 
out responses to individual domain components comprising symptoms, activities, 
emotions and environment.  Importantly, it has been shown to have a reliable minimal 
clinically important difference of 0.5166, which is useful for interpreting interventions 
in asthma trials, and clinical response to asthma treatment.  It has also been shown to 
correlate well with the Asthma Control Questionnaire (ACQ)33.  There is a shorter 
version of AQLQ, namely the mini-AQLQ35 which is probably more widely used due 
to greater ease of administration, but it is not quite as powerful a tool as its bigger 
brother. 
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There has been a palpable move away from just using symptoms, quality of life or 
indeed simple spirometry to guide treatment in the literature; with the recognition that 
measuring overall asthma control as being more important.  We do not yet have a tool 
that encompasses all aspects of the asthmatic disease process, namely: symptoms, 
variable airflow obstruction, AHR and airway inflammation.  Nevertheless, the reason 
this approach is more important, is that measures of overall asthma control both more 
consistently follow meaningful improvements with asthma treatments as well as, 
perhaps even more importantly, predicting loss of control and future risk of adverse 
outcomes.   In the GOAL study, Bateman et al. were able to show that by religiously 
tailoring asthma treatment to achieve ‘well-controlled’ asthma using a composite 
guideline-based measure over and above single component improvement, that greater 
achievements in quality of life could be gained32.  Furthermore, current measured 
levels of asthma control can, not only predict loss of control46, but also future risk of 
exacerbations28,29.  Once again the most commonly used of these composite measures 
of asthma control are the Asthma Control Questionnaire (ACQ)33 and the Asthma 
Control Test (ACT)167 (Appendix II).  The ACQ comprises patient recall of the 
previous 7 days for breathlessness, nocturnal wakening, symptoms on waking, 
activity limitation, wheeze, frequency of SABA use, and pre-bronchodilator FEV1 
%predicted.  There is a 7-point scale for each with no weighting applied, with higher 
scores indicating worse control.  Once again, it has a minimal clinically important 
difference of 0.5, and shorter versions are available with similar clinical utility to the 
full version, which are simpler to administer, for example, in primary care168.  Over 
and above the MCID of 0.5, useful cut-off points have been established for the ACQ, 
where a score of ≤0.75 equates to ‘well-controlled’ asthma using the GOAL 
classification, and a score ≥1.5 determines ‘not well-controlled’ asthma34.  Indeed, an 
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ACQ≤0.75 has a negative predictive value of 0.85, where an ACQ≥1.5 has a positive 
predictive value of 0.88, to correctly identify both ‘well controlled’ and ‘not well 
controlled’ asthma respectively.  For the ACT score, it also relates well to the GINA 
defined classification of asthma control with an area under the receiver operating 
curve of 0.84169.  Despite the importance of these composite measures of control, few 
studies have used them as a primary outcome measure29. 
 
I have summarised advantages and disadvantages of these various measures in Table 
2 regarding their utility in asthma and detection of ICS dose response. 
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Table 2.  Properties of asthma outcomes on ICS dose response. 
 
Measurement Advantages Disadvantages 
Airway Calibre 
(FEV1, PEFR) 
Simple to use. 
Reproducible. 
Recognised MCID. 
Intra-individual repeatability. 
Insensitive in mild asthma. 
Early plateau in ICS response. 
Effort dependent. 
Small airways 
(Impulse 
oscillometry) 
Non-effort dependent. 
More sensitive for peripheral 
airways than spirometry. 
Not widely available. 
Limited experience outside 
research institutions. 
Large coefficient of variation 
compared to spirometry. 
Airway Hyper-
responsiveness 
Aids positive identification of 
asthma diagnosis. 
Predicts future risk of loss of 
control / exacerbations. 
Good dose response 
relationship to ICS. 
Cumbersome to administer 
(perhaps with the exception of 
mannitol challenge). 
Not widely available. 
Inflammation 
(Sputum Eos) 
Predicts loss of control. 
Targeted therapy improves 
outcomes. 
Difficult to collect good 
samples. 
Cumbersome processing of 
samples. 
Inflammation 
(FeNO) 
Easy to measure with 
handheld device. 
Predicts ICS response and loss 
of control. 
Can monitor ICS compliance. 
Improves diagnosis of asthma 
(excellent negative predictive 
value). 
Not widely available. 
Expensive technology. 
Intra-individual variability. 
Symptoms & 
Reliever use 
Simple to measure. 
Relevant to patient. 
Wide variety of symptom 
scores / diaries, not all well 
validated. 
Early plateau in ICS dose 
response. 
Asthma control & 
Quality of life 
Well-validated tools available. 
Detects clinical change to 
treatment (validated MCIDs). 
Easy to administer. 
Predicts future loss of control / 
exacerbations. 
Does not measure airway 
inflammation or AHR. 
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Effects of extrinsic factors 
 
In addition to measurement of lung function, symptoms, AHR and inflammation in 
asthma with regard to ICS dose response; external factors can also play a part in an 
individual’s responsiveness to ICS therapy.  Such extrinsic factors include, but are not 
limited to: smoking; obesity; allergic rhinitis; and gastro-oesophageal reflux disease 
(GORD). 
 
Smoking asthmatics have worse symptoms170, and are more likely to be admitted to 
hospital with an exacerbation than non-smoking asthmatics171.  Furthermore smoking 
cessation improves asthma control in these individuals but the rates of smoking 
cessation are low172.  It has also previously been shown that smoking asthmatics are 
more resistant to the effects of ICS173,174 than their non-smoking counterparts.  
Proposed molecular mechanisms for this relative steroid resistance in asthmatics who 
smoke include: non-eosinophilic airway inflammation, impaired glucocorticoid 
receptor function with switch over from alpha to beta-glucocorticoid receptor 
subtypes, along with a reduction in histone deacetylase activity and expression which 
switches off activated inflammatory genes83,172.  The obvious solution is to stop 
smoking, but this proves difficult for many individuals.  Other approaches that may 
help include the addition of a LABA to ICS175, or indeed the use of leukotriene 
receptor antagonists176. 
 
Obesity is an increasing problem, particularly in relatively affluent countries, and so 
asthmatics are not excluded from this phenomenon.  Indeed, asthma itself has a higher 
prevalence in westernized countries, therefore, increasing the numbers of obese 
asthmatics further177.  This is important because obese individuals have been shown to 
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have a higher prevalence of asthma than non-obese asthmatics178.  Furthermore it is an 
independent predictor of worsening asthma control179.  One study showed that an 
overweight group of asthmatics had fewer asthma control days than their normal 
weight and otherwise matched counterparts180.  In vitro responses to glucocorticoids 
in overweight asthmatics revealed that dexamethasone response markers were 
blunted, including tumour necrosis factor levels, theorizing reduced clinical efficacy 
in this group181.  Additionally, bariatric surgery to aid weight loss resulted in 
improved AHR in obese asthmatics, adding more weight to the argument that obesity 
contributes to the symptoms and severity of asthma182.  There have been no ICS dose 
response studies in this regard, until reported later in this thesis. 
 
Allergic rhinitis and its association with asthma is a very large subject by itself, with 
international (ARIA) guidelines183 dedicated to its management.  It shares the 
underlying TH2 driven pathophysiology of allergic asthma, and as such the concept of 
the ‘unified allergic airway’ was coined.  Whether it is a distinct phenotype of disease 
or simply comorbidity can be debated, however, it is clear that in individuals who 
suffer both conditions concurrently, there is greater impairment of quality of life over 
those with either single disease alone.  Furthermore, Corren et al. showed that in 
patients with both asthma and allergic rhinitis, the odds ratio for hospitalisation due to 
asthma was significantly reduced when their allergic rhinitis was treated with a nasal 
steroid, OR 0.56 (95% confidence intervals 0.42-0.76)184. 
 
GORD is certainly prevalent in patients with asthma, and oesophageal acid may alter 
airway hyper-responsiveness185.  In a meta-analysis of GORD medical therapy in 326 
patients with both asthma and GORD186, it was reported that anti-reflux therapy 
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improved not only asthma symptoms, but also medication use (including ICS) by 
62%, additionally improving evening PEFR.  However another systematic review 
reported that anti-reflux therapy does not consistently improve asthma control in 
patients with both conditions187.  There have been no ICS dose response studies in this 
regard, but it is possible that in patients with both asthma and GORD, their ICS dose 
response might be attenuated. 
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MOVING TOWARDS PERSONALISED ASTHMA TREATMENT 
(PHENOTYPES) 
 
A striking observation about the most recent iteration of the BTS asthma guidelines10 
is that the overwhelming majority of the document is a management recommendation 
for ‘all-comers’ with asthma, even though it is recognised that asthma is a 
heterogeneous disease.  This is understandable to a degree, given the majority of 
patients will respond favourably to low to moderate doses of ICS alone.  However, 
there is growing interest in identifying and studying specific asthma phenotypes188, 
which may help us understand more about the pathophysiology of this heterogeneous 
disease; with the aim of leading on to the discovery and implementation of novel, 
individualised asthma therapies.  A phenotype is the presentation of outward 
characteristics that result from the expression of an organism's genes as well as the 
influence of environmental factors and the interactions between the two.  
Furthermore, an endotype is a subtype of a condition, which is defined by a distinct 
functional or pathobiological mechanism189,190.  It is difficult to be dogmatic about the 
difference between phenotypes and endotypes, as there will necessarily be a degree of 
overlap, but even mechanistic traits need to be measured by some means. 
 
The earliest form of asthma phenotyping came with the recognition of two distinct 
groups – namely ‘Allergic’ and ‘Non-allergic’ asthma.  Over the years other 
phenotypic characteristics have been used to help explain the diversity of asthmatic 
patients.  These include: childhood asthma; atopy; reversible airflow obstruction; 
intermittent vs. persistent symptoms; severity of airflow obstruction; corticosteroid 
responsiveness and others.  However, single characteristic phenotypes can be subject 
to bias.  To bring phenotypes more into focus it has been important to consider 
57 
	 	
endotypes of asthma in this regard.  To progress to this level of clarity has required 
complex statistical cluster analyses, molecular biomarkers and other genetic 
approaches to cluster asthmatic patients into easily identifiable groups – with the 
ultimate aim of personalizing treatment for each individual. 
 
Phenotypic cluster analyses191-193 have found a number of common, reproducible 
groups between studies including: benign or mild untreated asthma; early-onset 
atopic/allergic asthma; active, treated, atopic early-onset; female, symptom 
predominant; obese, non-eosinophilic; late onset, associated with nasal polyps; very 
severe, systemic corticosteroid dependent.  Importantly these have been correlated 
with treatment response and asthma control.  In the Haldar clusters191, treatment 
according to inflammation led to a reduction in exacerbations for the ‘inflammation 
predominant’ cluster, and reduced steroid dose in the ‘symptom predominant’ cluster.  
In the Siroux clusters192 there were strong associations with AQLQ for all clusters as 
well as blood eosinophilia.  Similarly, severe asthma endotypes have been 
identified194: early-onset allergic; persistent eosinophilic; obese female; neutrophilic; 
allergic bronchopulmonary aspergillosis (ABPA). 
 
Biomarkers, predominantly linked to the allergic TH2 pathway, have been identified 
as part of pheno/endotypes: eosinophils (sputum and blood); neutrophils (sputum); 
IgE; FeNO; Interleukins (5,13,17); serum periostin (drives IL-13 pathway).  As we 
have already discussed, eosinophils and FeNO predict corticosteroid responsiveness.  
The Anti-IgE therapy Omalizumab is reasonably successful in refractory atopic 
asthma, in selected individuals.  Total-IgE is elevated in allergic clusters of patients, 
but omalizumab is expensive and it remains difficult to predict responders to this 
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medication195.  Novel anti-IL5 (mepolizumab) and anti-IL13 (lebrikizumab) agents 
are showing significant promise for personalizing treatment.  Mepolizumab has been 
used in refractory eosinophilic asthma196.  It significantly reduced exacerbations and 
eosinophil counts, as well as improving AQLQ scores by 0.55 (MCID is 0.5) from 
baseline.  There was no change, however, in symptoms, FEV1 or AHR.  IL-13 drives 
the allergic TH2 pathway and levels of circulating IgE.  This has been targeted using 
Lebrikizumab197, where the authors found that treatment response to this agent could 
be differentiated further using levels of serum periostin, i.e., a greater response was 
seen (in pulmonary function) in patients with higher baseline periostin levels. 
 
Endotyping by genetic approaches has also yielded results.  The pharmacogenetics at 
the Beta-2 adrenoceptor (Arg16Gly) predicts response to SABAs and LABAs as well 
as asthma control198-201.  Additionally gene clustering has confirmed ‘TH2-high’ and 
‘TH2-low’ endotypes in terms of their display of allergic features202.  More recent 
work with sputum gene clusters shows these can predict the predominant cell type, as 
well as inhaled corticosteroid response203.  ‘Stand alone’ endotypes include aspirin 
sensitive asthma, which has demonstrated the utility of leukotriene receptor 
antagonists here204.  Allergic bronchopulmonary aspergillosis (ABPA) is another 
clearly defined asthma endotype with specific features and a tailored treatment 
regimen205. 
 
The role of co-morbid conditions impacting on asthma cannot be ignored, but do not 
necessarily fit into a particular phenotype or endotype.  However, I have already 
discussed these in the previous section.  Future areas of study in determining specific 
asthma phenotypes and endotypes may come through clearly defining the role of the 
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small airways in asthma. There are also new monoclonal anti-bodies, for example, 
anti-IL17 that hold some promise. 
 
In summary, there has been significant progress in recent years in identifying useful 
phenotypes and endotypes of asthma.  These have predominantly been within the 
umbrella of allergic asthma.  They have helped to individualise treatment options for 
narrow groups of asthmatic patients.  However, more work in clarifying these clusters 
of patients is required, as well as exploring novel areas of pathophysiology.  
Additionally, the non-allergic group of asthmatic patients has limited treatment 
options, so expansion of similar work in this group is urgently needed. 
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SUMMARY AND THESIS OBJECTIVES 
 
Asthma is a common, complex, and heterogeneous disease of the airways.  Despite 
the great utility of inhaled corticosteroids as an effective controller treatment for 
asthma in the last half-century or so, there is still significant ongoing morbidity and 
mortality that is theoretically avoidable.  We still have difficulty achieving accurate 
asthma diagnoses, predicting response to asthma therapies, finding the correct therapy 
for an individual, and perhaps most importantly, identifying those patients who are at 
greatest risk of future exacerbation and ongoing disease morbidity that require further 
pre-emptive manipulation of their asthma treatment. 
 
In this thesis, the broad theme of examination is that of inhaled corticosteroid dose 
response with incremental ICS dosing on a variety of clinical outcome measures, 
including those that are less routinely measured, i.e., airway hyperresponsiveness, 
airway inflammation and asthma control.  The overall aim, therefore, is to generate 
evidence from these studies that will add to the clinical decision-making process 
regarding individualised ICS therapy for persistent asthmatics. 
 
The first two studies will examine the dose response of ICS on two common and 
major specific factors that influence asthma.  One study examines an intrinsic factor, 
with the second study an extrinsic factor.  The intrinsic factor is airway inflammation 
as measured by daily domiciliary fractional exhaled nitric oxide (FeNO).  The 
extrinsic factor is the common co-morbidity of obesity.  Clinical outcome measures of 
symptoms, pulmonary function, airway hyperresponsiveness (AHR) and 
inflammation will be observed to determine how best to follow and utilise the ICS 
dose response in these specific groups. 
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The third study in this thesis presents an examination of potential pharmacological 
manipulation of the ICS dose response, in order to investigate whether the inverse 
agonist propranolol (a non-selective beta-blocker) had any steroid-sparing properties 
in this regard.  It had previously been shown that nadolol, another inverse agonist, 
improved airway hyperresponsiveness in steroid naïve asthmatics.  We believed, 
however, that it was more clinically relevant to examine this question in asthmatic 
patients already receiving ICS, both for reasons of safety (with regard to beta-blocker 
administration in asthmatics) and with the knowledge that low dose ICS are an 
already safe and effective treatment in mild steroid naïve asthmatics. 
 
The following two studies in this thesis address: how inflammatory outcomes relate to 
each other as well as to more routine outcomes in patients receiving ICS; in addition 
to an overall assessment of the ICS dose response characteristics across a broad range 
of both ICS moieties and outcome measures.  The final study presented in this thesis 
examines how ICS at low versus higher doses affect sensitive markers of bone 
turnover; thus addressing one of the major potential systemic effects of higher ICS 
dosing over a 1-year period. 
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CHAPTER 2:   
METHODS 
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There are detailed protocols described within each individual study presented in this 
thesis.  However, there are a number of methods common to most studies that are 
therefore described here. 
 
 
ASTHMATIC PARTICIPANT SELECTION 
 
Participants with asthma were directly recruited from the database held in the Asthma 
and Allergy Research Group (now Scottish Centre for Respiratory Research) at the 
University of Dundee.  This dataset includes all patients who have contacted the 
Asthma and Allergy Research Group in order to help with participation in clinical 
trials, and who provided their consent for their contact details to be kept securely.  It 
is kept regularly updated by administrative staff within the research group.  In 
addition to this recruitment database, patients were offered the opportunity to take 
part in clinical trials within the specialist asthma clinic at Ninewells Hospital and 
Medical School, Dundee.  Finally, general advertisements to take part in clinical trials 
of asthma were made in the hospital, university and local press to aid further 
recruitment. 
 
Patients were invited to attend for a screening visit based on their likely suitability for 
study entry based on their recorded data that included: age, onset of asthma 
symptoms, lung function, symptom scores, current treatment regimen, airway 
inflammation and airway hyperresponsiveness.  Patients were in receipt of a written 
participant information sheet that provided details of specific study involvement and 
requirements, before attending for screening.  All participants were given the 
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opportunity to ask questions and provided written informed consent in the presence of 
either a study investigator or research team member who had been delegated the task 
and had appropriate good clinical practice (GCP) training. 
 
All patients included in these studies were aged between 18 and 65 years upon study 
entry.  Furthermore, they all had a confirmed physician-based clinical diagnosis of 
asthma according to current guidelines10.  Patients were required to go through a 
screening process for their safety prior to study entry that demonstrated a normal 
physical examination by a doctor, urinalysis, and screening blood tests comprising: 
full blood count, urea and electrolytes, liver function tests and random blood glucose.  
The details of the specific study entry criteria are provided within the individual 
study. 
 
All study protocols, patient information sheets, informed consent forms and other 
study materials were scrutinized and approved by the East of Scotland Research 
Ethics Committee.  Furthermore, for clinical trials of investigational medicinal 
products, further review and approval was gained from the Medicines and Healthcare 
products Regulatory Authority (MHRA) prior to study commencement. 
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AIRWAY MEASUREMENTS 
 
Spirometry 
 
Spirometry was performed in all studies following the recommended guidelines from 
the American Thoracic Society123.  Patients were instructed to inhale fully to total 
lung capacity, and then forcibly exhale all the way out to residual volume through the 
mouthpiece attached to a mass-flow sensor.  Measures of FEV1, FVC and FEF25-75 
could then be determined in absolute terms as well as compared to the normal 
population distribution as percentage of predicted (according to age, sex, height and 
ethnicity).  All measures were performed in triplicate to within a 5% tolerance, with 
the highest achieved value recorded.  Studies used the SuperSpiro (Micro Medical; 
Rochester, Kent, UK) spirometer.  Withholding times for asthmatic therapies prior to 
screening spirometry were as follows: antihistamines, 7 days; theophyllines, 5 days; 
LTRAs, 5 days; LABAs, 2 days; Ipratropium bromide, 12 hours; salbutamol or 
bricanyl, 6 hours.  
 
Domiciliary FEV1 and peak expiratory flow rates were performed by subjects on a 
daily basis during selected studies.  Measures were once again performed in triplicate 
both morning and evening using the electronic PiKO monitor (n-Spire Health, 
Longmont, Colorado, USA) according to the manufacturer’s instructions206.  
Recorded values were stored on the electronic device, and then downloaded to custom 
computer software where they were checked for validity before being recorded for the 
subject. 
 
66 
	 	
Impulse oscillometry 
 
Impulse oscillometry (IOS) measurements were performed according to published 
guidelines207 and manufacturer’s instructions.  IOS is a non-effort dependent test of 
airway resistance and reactance performed during tidal breathing against a variety of 
sound waves of pre-specified amplitudes.  Participants were required to hold both 
cheeks gently to prevent puffing and therefore shunting of the pressure wave.  The 
impulses were applied over 30 seconds of tidal breathing.  All measures were 
performed in triplicate with mean values calculated.  The Masterscreen Impulse 
Oscillometer (Jaeger, Höchberg, Germany) was used where included as a study 
outcome measure. 
 
 
Bronchial challenge tests 
 
Direct bronchial challenge tests performed in these studies included both 
methacholine and histamine bronchial challenges.  These are used to determine both 
the presence and severity of airway hyperresponsiveness (AHR) in asthma.  These are 
termed ‘direct’ challenge agents because their mode of action is directly on airway 
smooth muscle receptors leading to bronchoconstriction.  The provocative 
concentration of challenge agent that causes a ≥20% fall in FEV1 (PC20) is the 
measure used to determine the degree of AHR.  A value ≤8mg/ml is considered 
evidence of an abnormal level of AHR to either challenge20.  Severe AHR is deemed a 
PC20≤1mg/ml. 
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Methacholine was made into increasing doubling dilution concentrations ranging 
between 0.03-32mg/ml.  For Histamine this ranged between 0.3125-40mg/ml.  
Tayside Pharmaceuticals (Ninewells Hospital, Dundee) prepared these solutions using 
benzyl alcohol as the diluent.  The tests were performed according to recommended 
guidelines with a validated computer assisted dosimetric protocol20.  Patients were 
excluded from study participation if their FEV1 was <60% predicted for safety 
reasons, i.e. to avoid life-threatening bronchoconstriction.  Suitable patients then had 
an FEV1 measurement performed using the diluent alone, where this was the baseline 
used to determine the eventual PC20.  Methacholine or histamine were subsequently 
administered in doubling cumulative doses at 5 min intervals until a 20% fall in FEV1 
was surpassed at a given dilution of challenge agent.  The actual PC20 values were 
then calculated with the aid of a computer program that logarithmically interpolated 
this from the dose-response curve208.  If a 20% fall in FEV1 could not be achieved, 
then the PC20 value was capped at 64mg/ml for statistical analysis purposes for both 
challenge agents.  Serial FEV1 measurements were made using a SuperSpiro (Micro 
Medical; Rochester, Kent, UK) spirometer connected to the computerized dosimetry 
software. 
 
Indirect bronchial challenge agents utilise and invoke the underlying inflammatory 
cascade in asthmatic airways to generate bronchoconstriction.  We used mannitol 
bronchial challenge in these studies.  Mannitol is an osmotic agent that dries out the 
airway epithelium that leads to release of inflammatory mediators that subsequently 
cause airway narrowing.  Mannitol dry powder  (Aridol, Pharmaxis, Sydney, 
Australia) bronchial challenge was performed as previously recommended209.  Using 
the supplied dry powder inhaler device, patients serially inhaled doubling doses thus: 
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0, 5, 10, 20, 40, 80, 160, and 160mg of mannitol.  FEV1 was measured 60 seconds 
after each inhalation, with the highest value of three recorded.  The test ended once a 
20% fall in FEV1 from the 0mg dose was surpassed, or when the maximum dose of 
635mg had been given.  The mannitol provocative dose to cause 10%, 15% and 20% 
falls in FEV1 (PD10, PD15, PD20) could then be calculated again using log-linear 
interpolation of the dose response curve. 
 
Withholding times for asthmatic therapies prior to screening bronchial challenges 
were as follows: antihistamines, 7 days; theophyllines, 5 days; LTRAs, 5 days; 
LABAs, 2 days; Ipratropium bromide, 12 hours; salbutamol or bricanyl, 6 hours. 
Patients were either allowed to spontaneously recover their bronchoconstriction with 
serial recording of FEV1 until within 5% of pre-challenge baseline, or they were given 
salbutamol 400µg immediately post-challenge, dependent on the study. 
 
 
QUALITY OF LIFE AND ASTHMA CONTROL MEASURES 
 
Diary cards 
 
In studies with defined treatment periods, patients were asked to complete diary cards, 
recording twice-daily measurement of domiciliary FEV1 (described above), rescue 
beta-2 agonist use and to assess their symptoms.  Symptoms were based on a rating 
scale of 0-3, comprising: 0 – no symptoms, 1 – mild symptoms, 2 – significant 
symptoms, 3 – debilitating symptoms.  These recordings were made during all run-in, 
treatment and washout periods. 
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Asthma Quality of Life Questionnaire 
 
The Juniper Asthma Quality of Life Questionnaire (AQLQ)164,165 provides an overall 
score (comprising 32 questions and 4 domains), as well as the ability to tease out 
responses to individual domain components pertaining to: symptoms; activities; 
emotions; and environment.  There is a smaller version, also used, called the mini-
AQLQ (comprising 15 questions with the same 4 domains).  Each question is on a 7 
point scale; the responses are then averaged for each of the four domains, which 
themselves are subsequently averaged to provide the final score.  A score of 7 
indicates no impairment, and anything <7 indicates increasing impairment.  
Importantly, it has been shown to have a reliable minimal clinically important 
difference of 0.5166. 
 
Asthma Control Questionnaire 
 
The Asthma Control Questionnaire (ACQ)33 comprises patient recall of the previous 7 
days for: breathlessness; nocturnal wakening; symptoms on waking; activity 
limitation; wheeze; frequency of rescue beta-2 agonist use; and pre-bronchodilator 
FEV1 as %predicted.  There is a 7-point scale for each domain with higher scores 
indicating worsening control.  Once again, it has a minimal clinically important 
difference of 0.5, and shorter versions are available with similar clinical utility to the 
full version, which are simpler to administer, for example, in primary care168.  Over 
and above the MCID of 0.5, useful cut-off points have been established for the ACQ, 
where a score of ≤0.75 equates to ‘well-controlled’ asthma, and a score ≥1.5 
determines ‘not well-controlled’ asthma34. 
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FRACTIONAL EXHALED NITRIC OXIDE 
 
FeNO was measured in the relevant studies using the portable NIOX MINO 
chemiluminescence analyser (Aerocrine, AB, Solna, Sweden) and according to the 
prevailing American Thoracic Society recommendations22.  All measurements were 
taken prior to any forced manoeuvres or bronchial challenges as these tests may alter 
the FeNO measurement themselves.  A sustained exhaled breath lasting at least 8 
seconds was required with a flow rate of 50 ml/s as guided by automatic feedback 
from the device.  Recordings were taken in triplicate with the mean value used for the 
reported result. 
 
Due to the portability of the NIOX MINO device, it was additionally used as a 
domiciliary primary outcome measure for the first study in this thesis.  Patients were 
instructed on its use, and they then took their own triplicate measures both morning 
and evening for the duration of the study. 
 
 
SKIN PRICK TESTING 
 
Skin prick testing (Merck, Middlesex, UK) was performed using 8 common 
aeroallergens in the relevant studies: trees, grass, house dust mite, weeds, feathers, 
aspergillus, cat and dog.  Each allergen was injected subcutaneously to the volar 
aspect of a forearm; having withheld antihistamines for at least 72 hours.  Saline 
(0.9% wt/vol) and histamine (1.7mg/ml) were also injected subcutaneously as 
negative and positive controls respectively.  A positive response was defined by any 
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wheal whose diameter was 3mm greater than the negative control, 15 minutes after 
the application of allergen. 
 
 
BLOOD AND URINARY BIOMARKERS 
 
Peripheral blood measurements 
 
Whole blood was taken by venepuncture from subjects prior to bronchial challenge 
procedures. Counts inclusive of blood eosinophil levels were measured using a 
Sysmex XE 2100 haematology autoanalyser (Sysmex UK Ltd, Bucks, UK).  Separate 
samples were taken for biochemical analysis and measurement of Urea and 
electrolytes, liver function tests and random glucose.  All blood samples were 
processed and analysed in the biochemistry department of Ninewells Hospital and 
Medical School, Dundee. 
 
Serum eosinophilic cationic protein 
 
After venepuncture, whole blood was rested for 60 minutes at 22 to 24oC. It was then 
centrifuged for 10 minutes at 3000 rpm, at 4oC. The supernatant was stored in a 
freezer kept at – 20oC and analysed in batches upon study completion.  
Serum ECP was measured in duplicate using a UniCAP immunoassay system (Phadia 
Ltd, Milton Keynes, UK) with a coefficient of variation (CV) of 3%. ECP 
measurements were performed in the department laboratory. 
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Overnight urinary cortisol/creatinine ratio 
 
Overnight urine was collected between 22.00h and 08.00h. Urinary free cortisol was 
measured using a commercial RIA kit (DiaSorin, Dartford, Kent, UK). The intra-
assay CV was 21%, with the inter-assay CV of 13%. Urinary creatinine was measured 
using the RATE technique on a Cobas-Bio auto-analyser (Roche Products, Sussex, 
UK), with an inter-assay CV of 4.3%. Urinary measurements were performed in the 
department laboratory. 
 
 
QUALITY CONTROL 
 
Sensitivity, specificity and coefficients of variation were monitored for individual 
batches of assays within the departmental laboratory.  Measurements carried out 
within the main Ninewells Hospital haematology and biochemistry laboratories were 
subject to NHS quality standards.  
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STATISTICAL METHODS 
 
Data were analysed throughout the studies using several iterations of SPSS statistical 
software for both Windows and Mac, the most recent of these is version 22 (SPSS 
Inc., USA).  Power calculations have been derived within the relevant studies.  For all 
studies, statistical significance for any comparison was deemed to have been achieved 
below an alpha-error of 5% (two-tailed), with 95% confidence intervals for the mean 
change given when appropriate.  Graphical representation of data was produced using 
GraphPad Prism version 5 (Graphpad Software Inc., USA).  Further statistical detail 
is provided within each study. 
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CHAPTER 3:   
INHALED CORTICOSTEROID 
DOSE-RESPONSE USING 
DOMICILIARY EXHALED 
NITRIC OXIDE IN 
PERSISTENT ASTHMA - THE 
FENOTYPE TRIAL 
 
 
Study Aims: 
 
1. To evaluate the dose response to ICS in a phenotype-enriched sample of 
persistent asthmatics upon domiciliary FeNO measurements. 
2. To assess how any FeNO response is related to other inflammatory outcome 
measures in asthma. 
3. To assess how any FeNO response to an ICS dose ramp correlates with asthma 
control. 
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ABSTRACT 
 
Background 
International guidelines advocate a standard approach to asthma management for all 
despite its heterogeneity.  ‘Personalised’ treatment for inflammatory asthma 
phenotypes confers superior benefits. 
 
Objective 
To evaluate dose-response to inhaled corticosteroids (ICS) in asthmatics with an 
elevated exhaled nitric oxide (FeNO) phenotype using domiciliary measurements. 
 
Methods 
We performed a randomised, crossover trial in 21 mild-to-moderate persistent 
asthmatics receiving ICS with elevated FeNO (>30ppb) that increased further 
(>10ppb) after ICS washout.  Patients were randomised to 2 weeks of either 
fluticasone propionate 50µg twice daily (FP100) or 250µg twice daily (FP500).  The 
primary outcome was response in diurnal domiciliary FeNO levels.  Secondary 
outcomes included: mannitol challenge; serum eosinophilic cationic protein (ECP); 
blood eosinophil count; and asthma control questionnaire (ACQ). 
 
Results 
We found significant dose-related reductions of diurnal FeNO compared to baseline - 
morning FeNO: baseline=71ppb (95%CI: 61-83ppb); FP100=34ppb (95%CI: 29-
40ppb), p<0.001; FP500=27ppb (95%CI: 22-33ppb), p<0.001; and significant dose 
separation for morning, p<0.05, and evening, p<0.001.  Time series FeNO displayed 
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exponential decay: FP100 R2=0.913, half-life=69hrs (95%CI:50-114hrs); FP500 
R2=0.966, half-life=55hrs (95%CI:45-69hrs); as well as diurnal variation.  ACQ 
showed significant improvements exceeding the minimal important difference (>0.5) 
with values in keeping with controlled asthma (<0.75) after each dose: FP100=0.48 
(95%CI:0.24-0.71), p=0.004; FP500=0.37 (95%CI:0.18-0.57), p=0.001.  All other 
secondary inflammatory related outcomes (mannitol, ECP and eosinophils) showed 
significant improvements from baseline but no dose separation. 
 
Conclusions 
There is a significant dose-response of diurnal FeNO to ICS in asthmatics with an 
elevated FeNO phenotype, which translates into well-controlled asthma.  Further 
interventional studies are warranted using domiciliary FeNO in this specific 
phenotype. 
 
Ethics Reference:  09/S0501/52 
MHRA reference:  21726/0268/001-0001 
ClinicalTrials.gov reference:  NCT00995657 
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INTRODUCTION 
 
Asthma is a common pulmonary disease that is increasing in prevalence worldwide177. 
It is characterised by intermittent, reversible airflow obstruction due to 
bronchoconstriction following a variety of stimuli, which can progress to 
exacerbations and hospitalisations, with associated mortality.  Inhaled corticosteroids 
(ICS) are widely recognised as the gold-standard asthma control treatment.  However, 
asthma is notable for its heterogeneity of presentation; and responses to inhaled 
bronchodilator and inhaled corticosteroid therapy.  Pointedly, there is no gold-
standard diagnostic test for asthma; rather it is necessary to combine investigations 
with symptoms and signs to improve diagnostic accuracy10. 
 
Asthma heterogeneity is not reflected well in current national10 and international11 
asthma guidelines which are based on symptoms and spirometry.  Variability of 
asthma outcomes also exists, that can depend on the type and/or dose of inhaled 
corticosteroid210, or parameters such as body mass index3,180 and smoking status175.  A 
variety of asthma phenotypes211 are recognised including eosinophilic, neutrophilic, 
and non-eosinophilic steroid-unresponsive asthma150.   Several landmark studies have 
examined ‘personalising’ asthma treatment based on clinical hallmarks of asthma - 
airway hyper-responsiveness (AHR)13 and airway inflammation6,14 – revealing that 
phenotype-driven asthma treatment confers benefits over standard care. 
 
Fractional exhaled tidal nitric oxide (FeNO) can now be measured both simply and 
reliably.  FeNO has previously been studied, with recent publication of guidelines212 
from the American Thoracic Society (ATS).  Smith and colleagues15 evaluated 
titrating ICS against a specific FeNO threshold (<15ppb), demonstrating that 
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maintenance ICS doses could be reduced without loss of asthma control.  A separate 
study213 found ICS doses increased when using FeNO in addition to standard care, 
with no difference in asthma control.  However, FeNO levels vary significantly 
between patients214. 
 
We wished to evaluate the dose-response to ICS in a phenotype-enriched sample of 
persistent asthmatics all displaying elevated levels of FeNO when stepped off ICS; 
along with how these responses related to other inflammatory outcomes and, most 
importantly, asthma control.  Pointedly, no studies to date have used domiciliary, 
diurnal measurements of FeNO for this purpose.  We hypothesised that by using these 
stringent phenotypic criteria; any dose-response to ICS would be more predictable. 
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METHODS 
 
Patients 
Male and female patients aged 18-65 years, with mild-moderate persistent asthma, 
who were receiving 200-1000µg/day ICS (beclometasone dipropionate (BDP) 
equivalent), were screened (Figure 2).  Recruited patients were required to have 
FeNO>30ppb with a further rise (>10ppb) following a two week washout from ICS.  
Exclusion criteria were: recent respiratory tract infection or oral corticosteroid use (<3 
months); smoking within the previous year or >10pack-years smoking history. 
 
Figure 2.  Consolidated Standards of Reporting Trials diagram. 
FeNO, fractional exhaled nitric oxide; ppb, parts per billion. 
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Study Design 
We performed a randomised, double blind, crossover study (ClinicalTrials.gov 
number: NCT00995657) of inhaled fluticasone propionate 50ug 1puff twice daily 
(FP100) and 250ug 1puff twice daily (FP500) each for two weeks via pressurised 
metered dose inhaler (Flixotide Evohaler, Allen and Hanburys, Uxbridge, UK), 
(Figure 3).  After screening, patients were stepped off second-line medications: long-
acting beta-agonists (LABA); theophyllines; leukotriene receptor antagonists; and 
converted to a fluticasone propionate equivalent of their usual ICS dose - stepping off 
this over two weeks followed by a two week ICS-free washout period.  There was 
also a two-week ICS washout period between treatments.  The primary outcome 
measure was change in daily morning and evening FeNO from post-washout baseline.  
Secondary outcomes were: domiciliary spirometry; laboratory-based spirometry; 
impulse oscillometry (IOS); AHR to mannitol challenge; asthma control questionnaire 
(ACQ) and mini asthma quality of life questionnaire (mini-AQLQ) scores; blood 
eosinophil counts and serum eosinophilic cationic protein (ECP). 
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Figure 3.  Study flow diagram. 
ACQ, Asthma Control Questionnaire; AQLQ, mini-Asthma Quality of Life Questionnaire; 
FEV6, forced expiratory volume in 6s; FP, fluticasone propionate; ICS, inhaled corticosteroid; 
Mannitol, mannitol bronchial challenge; S1, S2, screening visits; V0, pre-washout visit; 
washout periods are sequential (i.e., irrespective of FP dose); V1-4, study visits. See Figure 2 
legend for expansion of other abbreviations. 
 
 
Measurements 
Domiciliary FeNO was performed morning and evening in the patient’s home, in 
duplicate, using a handheld NIOX MINO (Aerocrine, Solna, Sweden) according to 
manufacturer’s instructions and as previously described215 at a standard flow rate 
(50ml/s).  Domiciliary forced expiratory volume in 1s and 6s (FEV1, FEV6) were 
performed in triplicate morning and evening using a handheld PiKo-6 (n-Spire Health, 
Longmont, CO, USA) to manufacturer’s instructions and after FeNO to avoid 
exaggerated FeNO measurements.  Impulse oscillometry (Masterscreen IOS, 
Höchberg, Germany) was performed in triplicate to manufacturer’s guidelines. A 
SuperSpiro spirometer (Micro Medical Ltd., Kent, UK) was used for spirometry in 
triplicate in accordance with European Respiratory Society guidelines216.  Mannitol 
challenge was performed as previously described217 with a dry powder inhaler (Aridol 
Pharmaxis Ltd, Sydney, Australia) using cumulative dose increments up to 635mg. 
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The cumulative provocative dose producing a 15% fall in FEV1 (PD15) was then 
calculated. The ACQ33 and mini-AQLQ35 were completed at study visits. Serum ECP 
was analysed in duplicate using a UniCAP system (Phadia, Milton Keynes, UK), 
coefficient of variation=3%. Peripheral blood eosinophils were measured using the 
Sysmex XE2100 Haematology autoanalyser. 
 
 
Statistical Analysis 
A power calculation determined 20 patients completing in a crossover fashion would 
ensure 90% power (two-tailed, alpha-error=0.05), to detect a 5.4ppb difference in 
FeNO between treatments (within-patient SD=5ppb). 
 
All data were examined for normality, with non-Gaussian distributions 
logarithmically transformed. All baselines were pooled as no significant differences 
were demonstrated comparing values between the ends of each washout. Baseline and 
post-treatment values for domiciliary measures were the mean of days 12-14 from 
each period. Differences between group means were analysed using repeated 
measures analysis of variance with Bonferroni correction. Paired Student’s t-tests 
were used for differences within or between groups as change from baseline. 
 
Time series plots were created for domiciliary measures (FeNO, FEV1, FEV6).  Non-
linear regression was used to describe FeNO response in both treatments, with best-fit 
curves compared using the extra sum-of-squares F-test.  Estimates of time to 25%, 
50%, 75% and 90% reduction in FeNO from baseline were calculated from the 
exponential curve half-lives. Linear regression was used for time series changes in 
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domiciliary FEV1 and FEV6 for each two-week period. Harmonic analysis using a 
Cosinor model over 24hrs (similarly described for peak expiratory flow rate218) was 
applied to the plateau (week two) phases of each of pooled baseline and treatment 
group time series to assess for diurnal variation of the domiciliary measures. Diurnal 
variation amplitudes were derived from geometric mean fold differences in diurnal 
FeNO. 
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RESULTS 
 
21 patients completed per protocol.  Screening demographics were: mean age 36.7yr 
(95%CI: 31.0-42.5yr); 15 male; mean BDP equivalent dose 441µg/day (95%CI: 332-
549µg/day); mean spirometry (FEV1, FVC, FEF25-75) as percentage of predicted were 
94.5% (95%CI: 89.5-99.4%), 108.7% (95%CI: 104.7-112.6%) and 61.3% (95%CI: 
54.1-68.6%) respectively; 17 patients had ≥1 positive skin prick test; 7, 1 and 8 
patients were receiving LABAs, LTRAs and antihistamines respectively. 
 
For the primary outcome of domiciliary FeNO, significant reductions after two weeks 
treatment were demonstrated within both FP100 and FP500 groups from pooled 
baseline, for both morning and evening values (Table 3); with significantly greater 
reduction in FeNO after the higher dose.  Time-series plots of all mean morning and 
evening FeNO values were created for both FP100 and FP500 treatments (Figure 4) 
and both washout periods (Figure 5).  Non-linear regression demonstrated that an 
exponential one-phase decay curve was the best-fit model for each of FP100 and 
FP500 time-series FeNO plots (Figure 4, Table 4).  For FP100 the fit-of-curve 
coefficient of determination R2=0.913, with a half-life (t1/2)=69.8hrs (95%CI: 50.3-
114hrs).  For FP500: R2=0.966; t1/2=54.8hrs (95%CI: 45.4-68.9hrs).  The exponential 
curves were significantly different (p<0.001), confirming the dose-response effect.  
There was significant diurnal variation of FeNO during each of the second (plateau) 
weeks (days 8-14) as follows: pooled washout (amplitude=15.6%; R2=0.521, 
p=0.004); FP100 (amplitude=24.3%; R2=0.412, p=0.01); and FP500 
(amplitude=28.9%; R2=0.439, p=0.01).  Mean domiciliary FeNO measurements were 
almost exclusively higher in the morning. 
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Figure 4.  Time series morning and evening FeNO values and one-phase 
exponential decay curves. 
FeNO values displayed as geometric means at each sequential time point for each group.  
R2=coefficient of determination (goodness of fit) of exponential decay curves to each data set.  
t1/2=half-life of exponential decay.  ppb=parts per billion. 
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Figure 5.  Sequential washouts 1&2 
with pooled washout time-series for 
FeNO. 
Values are geometric means of sequential 
diurnal FeNO levels.  No significant 
difference between overall means of days 12-
14 for each period (interrupted lines). 
ppb=parts per billion. 
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Table 4.  Exponential one-phase decay time for domiciliary FeNO. 
 
One phase exponential decay curves for FeNO significantly different between doses of 
fluticasone propionate (FP) each administered over 2 weeks (p<0.0001).  R2=coefficient of 
determination to exponential curve, *p<0.001.  Data presented as time to percentage fall in 
FeNO from pooled baseline (estimated 95% confidence intervals).  t1/2=half-life of one phase 
exponential decay. 
 
 
Domiciliary spirometry demonstrated significant improvements in morning FEV1 as 
change from baseline within both FP100: 0.18L (95%CI: 0.1-0.26L), p<0.001; and 
FP500: 0.18L (95%CI: 0.08-0.29L), p=0.004; but no significant differences in 
evening FEV1 at either dose, nor between groups for either morning or evening FEV1 
(Table 3).  Time-series morning and evening FEV1 (Figure 6) demonstrated 
significant linear patterns during pooled washout (FEV1 reduction=0.21L, R2=0.577, 
p<0.001) and both FP100 (FEV1 increase=0.08L, R2=0.157, p=0.04) and FP500 
(FEV1 increase=0.08L, R2=0.262, p=0.006).  Results for domiciliary FEV6 are 
presented in Table 3.  There was no significant diurnal variability of domiciliary 
spirometry. 
 Decay Time (Days) 
% Fall in FeNO FP 100µg daily (R2 = 0.91*) FP 500µg daily (R2 = 0.97*) 
25 1.2 (0.9, 2.0) 0.9 (0.8, 1.2) 
50 (t1/2) 2.9 (2.1, 4.8) 2.3 (1.9, 2.9) 
75 5.8 (4.2, 9.5) 4.6 (3.8, 5.7) 
90 9.7 (7.0, 15.8) 7.6 (6.3, 9.5) 
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Figure 6.  Time series for diurnal 
domiciliary FEV1. 
Sequential morning/evening mean FEV1 over 
two weeks for pooled washout (left), 
fluticasone propionate (FP) 100ug/day 
(middle), and FP 500ug/day (right).  
Superimposed solid lines represent linear 
regression slopes. 
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Mannitol PD15 demonstrated significant improvements with both FP100 and FP500 as 
doubling-dose shifts from baseline, with no difference between doses (Table 3, Figure 
7a).  There was significant reduction in serum ECP after FP500 but not FP100 (Table 
3, Figure 7b).  Blood eosinophils were significantly reduced by both doses as change 
from baseline, with no difference between doses (Figure 7c).  For IOS outcomes, 
there were no significant changes for any variable at either dose.  For laboratory visit-
based spirometry outcomes, both FEV1 and FEF25-75 demonstrated significant 
improvements from baseline, with no differences between doses (Table 3, Figure 8).  
FVC did not change significantly at either dose. 
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Figure 7.  Secondary inflammatory 
outcomes. 
(a) Mean doubling dose (DD) shift from 
baseline within groups for mannitol 
provocative dose causing 15% fall in forced 
expiratory volume in one second (PD15).  (b) 
Percentage changes within groups from 
baseline for serum eosinophilic cationic 
protein (ECP).  (c) Percentage changes within 
groups from baseline for peripheral blood 
eosinophil counts.  Error bars represent 95% 
confidence intervals. 
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Figure 8.  Standard visit spirometry. 
Mean within group differences after 2 weeks treatment from pooled baselines for: Forced 
Expiratory Volume in 1 second (FEV1) (left) and Forced Expiratory Flow between 25-75% of 
FVC (FEF 25-75) (right). FP = fluticasone propionate. All error bars equate to 95% 
confidence intervals. P-values are for within group difference as absolute change from pooled 
baseline using Student’s T-test for paired samples. Interrupted connecting lines represent 
between group differences compared by Student’s T-test for paired samples. Significance set 
at p<0.05. ns = not significant. 
 
 
ACQ score reduced significantly after 2 weeks in both groups from baseline with 
mean change exceeding the minimal important difference (>0.5), with absolute values 
after both FP100 and FP500 in keeping with well-controlled asthma (<0.75), (Table 3, 
Figure 9a).  Mini-AQLQ overall score also improved significantly with both 
fluticasone doses from baseline (Table 3, Figure 9c). By separating the mini-AQLQ 
components, the same significant pattern was demonstrated for ‘symptoms’ (Table 3, 
Figure 9b). 
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Figure 9.  Asthma control and quality 
of life outcomes. 
 
(a)  Mean Asthma Control Questionnaire 
(ACQ) score at baseline, 100µg/day, and 
500µg/day fluticasone propionate (FP).  (b)  
Mean Asthma Quality of Life Questionnaire 
(AQLQ) symptom score at baseline, 
FP100µg/day, and FP500µg/day.  (c)  Mean 
Asthma Quality of Life Questionnaire 
(AQLQ) overall score at baseline, 
FP100µg/day, and FP500µg/day.  Error bars 
represent 95% confidence intervals. 
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DISCUSSION 
 
The present study has shown a significant dose-response relationship between diurnal 
FeNO and incremental ICS dosing (fluticasone propionate 100ug/day vs. 500ug/day) 
in asthmatics expressing an elevated FeNO inflammatory phenotype.  FeNO 
responses to both doses demonstrate predictable one-phase exponential decay; with 
significantly faster decline, and greater suppression of FeNO at plateau, with the 
higher ICS dose.  Furthermore, we have demonstrated significant diurnal variability 
of FeNO levels (higher in the morning) with or without ICS therapy. 
 
This is the first study to have evaluated response of serial domiciliary diurnal FeNO in 
a dose-ranging manner with ICS.  A previous study by Silkoff et al.159 demonstrated a 
dose-response effect in asthmatics with high baseline FeNO levels using three 
separate doses of BDP, showing dose separation on FeNO between only the lowest 
(100µg) and highest (800µg) doses; albeit each treatment period was only for 1 week.  
However, that study did not examine the effect of FeNO reduction on asthma control; 
did not use domiciliary FeNO; and moreover used methacholine rather than mannitol 
challenge.  Other studies have examined FeNO either in ‘all-comers’ with asthma219, 
or asthmatics with near-normal baseline FeNO160,219 thus reducing any signal from 
this as an outcome; despite asthmatics with high FeNO (>50ppb) being more likely to 
respond to ICS than those with low FeNO (<25ppb)210,220.  In one study221 with extra-
fine hydrofluoroalkane (HFA) beclometasone, there was a plateau response at 
100µg/day, although mean baseline levels were only 33ppb, compared to 71ppb in 
this study.  Around 30% of the patients we screened for our study demonstrated high 
FeNO levels, even with ICS prescription; i.e. this phenotype may represent a 
moderately large proportion of asthma overall.  Our FeNO response quantification 
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was augmented by portable analysers in the community, an approach used before in 
children to monitor home FeNO215, but never before in adult asthmatics or for the 
prospective assessment of treatment response. 
 
We already know that personalising asthma treatment according to phenotypes has 
proven benefits on symptoms, exacerbations and asthma control over-and-above 
standard care.  The AMPUL study13 demonstrated that by guiding asthma treatment, 
using AHR to methacholine, added to symptoms and lung function, greater asthma 
control could be achieved.  Green et al14 investigated using sputum eosinophil counts 
to guide anti-inflammatory therapy, demonstrating an overall reduction in 
exacerbations.  Recently, we have utilised AHR to mannitol to guide ICS therapy6, 
showing a reduction in mild exacerbations over 12 months, along with significant 
improvements in methacholine AHR, salivary ECP, FeNO, symptoms and reliever 
use. 
 
Our domiciliary FeNO findings are supported by secondary (inflammatory) outcomes.  
Mannitol PD15 significantly improved with both doses of ICS in line with 
improvement in FeNO as previously described222, however, mannitol could not 
discriminate between ICS doses; i.e. mannitol displays ‘assay sensitivity’ for ICS 
treatment response, with a 1.84 doubling-dose shift at the lower dose, but no evidence 
of dose-response sensitivity.  However, stratifying patients to a mannitol phenotype 
(e.g. mannitol PD15 <100mg) rather than FeNO at study entry may alter this. For 
example, in a study powered on methacholine AHR there was a significant difference 
in response comparing 500ug vs. 100ug daily of HFA-fluticasone223.  Blood 
eosinophils and ECP also reduced with ICS but only at higher dose for ECP, 
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suggesting this does not exhibit sufficient assay sensitivity.  We chose our doses of 
fluticasone for this study based on previous dose-response data224,225 and the systemic 
safety of no significant cortisol suppression at the higher dose (500µg/day)226,227. 
Interestingly in a meta-analysis of studies with fluticasone, a plateau response was 
seen at 200µg/day for various outcomes, although no inflammatory outcomes were 
evaluated225. 
We also demonstrated significant diurnal variability of domiciliary FeNO levels, both 
during ICS washout and following treatment with both doses of fluticasone, 
suggesting that FeNO may be additionally controlled by factors other than local 
airway inflammation.  Pointedly, we are the first to show that diurnal variability of 
FeNO persists following incremental ICS dosing. 
 
In terms of potential clinical relevance, the dose-response of FeNO to incremental 
ICS mirrored improvements in both asthma control and symptoms as measured by the 
ACQ and mini-AQLQ respectively.  Indeed the baseline ACQ score demonstrated 
‘borderline’ asthma control with the 95%CI lower bound >0.75, below which 
delineates good asthma control34.  The ACQ score improved significantly with both 
doses of ICS to mean scores that were below the 0.75 level (including upper 95%CI), 
while the mean change exceeded the minimum important difference of 0.5168.  
Similarly, significant improvements were seen in the mini-AQLQ symptom 
component and overall score with both ICS doses.  These are strong, clinically 
relevant signals for such a short study. 
Significant but clinically unimportant changes were seen in all measurements of 
pulmonary function (domiciliary and laboratory).  This is unsurprising given that 
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baseline lung function (spirometry; IOS) was relatively well preserved in these 
patients, and has reduced sensitivity to change over short time periods125. 
 
One limitation of this study was the short duration of ICS treatment, albeit this was a 
proof-of-concept study.  However, there was still a significant and clinically 
important signal from the primary outcome of domiciliary FeNO; along with 
clinically significant improvements in symptoms and asthma control. Moreover, 
previous data shows that with AHR, a plateau response occurs after two weeks of 
treatment with fluticasone225.  There will be bias in phenotype-driven analyses, but we 
designed this a priori, given the demands for ‘personalised’ treatment.  One of the 
strengths of the present study was the novel use of diurnal domiciliary FeNO to 
increase the signal-to-noise ratio, which may also have had a serendipitous effect on 
bolstering compliance.  Furthermore, we used additional inflammatory markers to 
validate this phenotype.  While presently the cost of domiciliary FeNO is prohibitive, 
it is possible that with developing technologies this cost will come down. 
 
In conclusion, we have demonstrated a significant dose-response relationship to ICS 
using diurnal domiciliary FeNO measurement in asthmatics with elevated FeNO as a 
common inflammatory phenotype.  These responses follow predictable exponential 
decay that is significantly greater with higher ICS dosing.  These findings translated 
into significant improvements in symptoms and asthma control in this selected 
phenotype despite the short study duration. Further studies are warranted in this 
specific asthma phenotype using longer-term outcome measures of asthma (e.g. 
exacerbations) following treatment based on monitoring domiciliary FeNO levels. 
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CHAPTER 4:   
DOES BODY MASS INDEX 
INFLUENCE 
RESPONSIVENESS TO 
INHALED CORTICOSTEROIDS 
IN PERSISTENT ASTHMA? 
 
 
 
Study Aims: 
1. To examine for any putative relationship between obesity and the dose 
response to inhaled hydrofluoroalkane budesonide on a variety of asthma 
outcome measures. 
2. To generate hypotheses for areas of further prospective evaluation with 
regard to inhaled corticosteroid dose response in overweight and obese 
individuals. 
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ABSTRACT 
 
Background 
While the relationship between asthma and obesity has been extensively explored, the 
effect of body mass index (BMI) on the dose response relationship to inhaled 
corticosteroids (ICS) has received little attention. 
 
Objective 
To assess the dose response of inhaled budesonide on outcome measures of asthma 
between overweight and normal weight persistent asthmatics. 
 
Methods 
72 mild-moderate persistent asthmatics from a post hoc analysis of previously 
reported trial data were divided into two groups: overweight, BMI≥25kg/m2; normal 
weight, BMI<25kg/m2.  Each group received 4 weeks treatment with inhaled 
(hydrofluoroalkane) budesonide 200µg/day then 800µg/day with ICS washout pre-
treatment.  Outcome measures included FEV1, Fractional exhaled nitric oxide 
(FeNO), Methacholine PC20, total daily asthma symptom score, and overnight urinary 
cortisol/creatinine ratio were performed at baseline and after each dose. 
 
Results 
There were significantly greater improvements in the normal weight group for both 
FeNO and symptom responses at 0-200µg and 0-800µg ICS doses (as change from 
baseline), compared to the overweight group:  FeNO 0-200µg, p=0.002; 0-800µg, 
p=0.045; Symptoms 0-200µg, p=0.002; 0-800µg, p=0.013.  There was also a trend 
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towards attenuated cortisol suppression in overweight subjects at 0-800ug (p=0.06), 
but there was no significant difference at either dose in FEV1 and methacholine PC20 
between weight groups. 
 
Conclusion 
Overweight persistent asthmatics may have attenuated symptom and FeNO dose 
responses to inhaled budesonide compared to normal weight asthmatics, with no 
differences in FEV1 or methacholine PC20 between groups.  Attenuated cortisol 
suppression in the overweight group may be the clue to this difference, alluding to 
reduced peripheral lung deposition or absorption in overweight asthmatics. 
 
Ethics reference:  08/S1402/14 
EudraCT number:  2008-001027-59 
ClinicalTrials.gov reference:  NCT00667992 
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INTRODUCTION 
 
It is widely accepted that the prevalence of both asthma228 and obesity229,230 are 
increasing.  Obesity has also been proposed as a risk factor for a higher prevalence of 
asthma178.  It follows, that increasing numbers of asthmatics will be overweight, 
necessitating a greater knowledge of any association, in particular in response to 
asthma medication.  Many studies have explored the relationship between asthma and 
obesity.  In general, these have suggested:  that obesity makes one more likely to 
develop asthma178; obesity is related to worsening asthma control231; clinical measures 
of asthma (e.g. airway hyper-responsiveness [AHR], fractional exhaled nitric oxide 
[FeNO]) are affected by obesity232-234; and treatment of overweight asthmatics with 
standard regimens may be attenuated235.  What is clear is that any relationship 
between asthma and obesity is complex and unlikely to be fully explained by one 
particular theory. 
 
Despite the interest in this area, no direct attention has been given to the clinical effect 
of obesity on asthmatics’ response to incremental doses of inhaled corticosteroids 
(ICS), the mainstay of asthma control treatment.  Sutherland et al studied in vitro 
responses to glucocorticoids in overweight/obese asthmatics236.  They found markers 
of dexamethasone response (including tumour necrosis factor [TNF]-α) were blunted 
- alluding to reduced clinical efficacy of glucocorticoid therapy.  There have also been 
post hoc analyses of clinical trials data examining this.  Peters-Golden et al studied 
the effect of body mass index (BMI) on percentage of asthma control days (ACD) 
between three groups of asthmatic patients receiving different asthma control 
medications at static doses (Montelukast 10mg/day, Beclomethasone 400µg/day, or 
Placebo)237.  They found normal BMI asthmatics had a higher percentage of ACD 
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than overweight/obese asthmatics.  The effect of beclomethasone on ACD was 
blunted with increasing BMI, whereas the montelukast effect remained constant 
across the BMI range.  Curiously, the effect of placebo on ACD also decreased with 
increasing BMI making the authors question how much of the beclomethasone 
response could be related to placebo effect.  There were no significant differences 
between BMI groups, by treatment for forced expiratory volume in 1 second (FEV1) 
in this study.  Boulet and Franssen studied response to inhaled fluticasone 
(200µg/day) as either a single agent or in combination with salmeterol and whether 
these were altered by BMI in 1242 currently steroid naïve asthmatics235.  For both 
treatments they found the odds of achieving asthma control (including symptoms, 
rescue medication, morning peak flow, emergency visits and exacerbations) were 
significantly lower in obese patients, particularly with a BMI≥40kg/m2.  In summary, 
therefore, previous studies have examined the ‘all or nothing’ effect of ICS at a fixed 
dose on asthma outcomes in overweight/obese asthmatics, rather than true dose-
response to ICS in a stepwise manner. 
 
One also needs to consider the potential differential effects of drug pharmacokinetics 
and pharmacodynamics between obese and normal weight individuals.  In general 
more lipophilic drugs have a larger volume of distribution in the obese, potentially 
reducing their peak effect but because they are then slowly released from the systemic 
tissues, can be present much longer.  However, given that most ICS moieties deliver 
their effects at a local level in the lungs, any systemic absorption of ICS is likely to be 
low, unless the drug is very lipophilic or by using very high doses of ICS49.  For 
budesonide (Table 1), its inhaled bioavailability is 15-30% with oral bioavailability 
around 11% (much higher than for example fluticasone at 1% oral bioavailability).  
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Budesonide is 88% protein bound, where again other ICSs are closer to 99%.  It also 
has a short half-life of elimination and faster lung clearance than most ICS.  It is, 
however, much less lipophilic than fluticasone.  These properties may therefore mean 
that budesonide is more widely distributed systemically in the obese asthmatic, than 
their normal weight counterparts. 
 
In this study we wished to examine the putative relationship between obesity and dose 
response to inhaled hydrofluoroalkane (HFA) budesonide through a variety of 
outcome measures – FEV1 (airway calibre), FeNO (airway inflammation), 
methacholine bronchial challenge (AHR), and asthma symptom scores.  We have 
taken advantage of previously reported clinical trials data that demonstrated 
equivalence between the dose response to both HFA and CFC budesonide in 
persistent asthmatics, to enable direct comparisons of dose response to ICS with BMI.  
We recognise that this method of study can only generate hypotheses for further 
investigation; nonetheless we believe it is an important and clinically relevant 
question. 
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METHODS 
 
We performed a post hoc analysis of the HFA-budesonide data from a previously 
reported double-blind randomised controlled crossover trial, which compared HFA 
and chlorofluorocarbon (CFC) formulations of inhaled budesonide at doses of 200ug 
and 800ug/day (as compared to ICS-free baseline) in persistent asthmatics2.  The trial 
demonstrated no difference in response to HFA-budesonide given first or second in 
randomised sequence order, and importantly, no difference in baseline values after 
each washout period.  We elected not to include data from the CFC-budesonide arm, 
because this would have resulted in using values from the same patient twice for each 
outcome measure, thus potentially biasing the results. Moreover, as CFC-budesonide 
is no longer available, the HFA-budesonide data is more relevant to current 
prescribing practice. 
 
The reference trial was a single-centre, randomised, crossover study of HFA and CFC 
budesonide pressurised metered dose inhaler (pMDI) formulations.  The institutional 
review board approved the study and all participants gave informed consent.  Eligible 
participants aged 18–65years had a diagnosis of stable, persistent asthma receiving 
≤1000µg beclomethasone dipropionate or equivalent.  Eligible patients entered a step-
down phase, during which second-line controllers were withdrawn, i.e. long-acting 
beta2-agonists, theophyllines, cromones and leukotriene inhibitors.  Patients then had 
their usual ICS dose tapered in a manner similar to previously published studies from 
this department238.  They then entered a 1-week pre-treatment (ICS-free) washout 
period.  A methacholine provocative concentration causing a 20% decrease in FEV1 
(PC20) of ≤4mg/ml and FEV1≥60% predicted after step-down was required for entry 
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to randomisation.  Subjects not meeting the entry requirements at the end of this phase 
were given a further 1–2 weeks of washout. 
 
The reference trial consisted of two randomised treatment periods.  Patients first 
received a low-dose (200µg/day) of budesonide, either via CFC or HFA pMDI, for 2 
weeks, followed by 2 weeks of medium-dose (800µg/day) budesonide of the same 
formulation.  Participants then crossed over treatment arms to the remaining 
budesonide formulation using the same dosing regimen; effectively acting as their 
own control.  Treatment periods were separated by a 1–2 week ICS-free washout 
period.  Subjects were required to be within one doubling dilution of baseline 
methacholine PC20 at the end of washout. 
 
During all study visits, participants underwent pulmonary function testing, exhaled 
tidal nitric oxide measurement and methacholine challenge.  Methacholine challenge 
was performed using the five-breath dosimeter technique in accordance with 
American Thoracic Society (ATS) recommendations20.  The PC20 was calculated 
using log-linear interpolation of the dose–response curve20.  Exhaled tidal nitric oxide 
was measured in line with ATS recommendations using a NIOX analyser (NIOX® 
Nitric Oxide Monitoring System, Aerocrine AB, Solna, Sweden).  Subjects were 
asked to rate their asthma symptoms twice daily; daytime scores recorded each 
evening, and night-time scores on waking.  The following rating scales were used:  
0=no asthma symptoms; 1=mild symptoms (easily tolerated); 2=moderate symptoms 
(interferes with normal activities/sleep); and 3=severe (prevents normal activities/ 
sleep).  Overnight (22.00–08.00h) urine was collected for cortisol and creatinine at 
baseline and the night prior to study visits.  Urinary cortisol was measured using a 
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commercial radioimmunoassay kit (DiaSorin Ltd, Wokingham, Berks, UK).  The 
intra-assay coefficient of variation=4%, with inter-assay coefficient of variation=8%.  
Urinary creatinine was measured on a Cobas-Bio auto analyser (Roche Products, 
Welwyn Garden City, Herts., UK). The intra-assay and inter-assay coefficients of 
variation were 4.6% and 3.0%, respectively.  Skin prick testing to a battery of 
common aeroallergens (Merck, UK) was performed at baseline. 
 
Statistical Analysis 
Data were assessed for normality using Kolmogorov-Smirnov tests along with visual 
inspection of data on histograms and Q-Q plots.  Non-Gaussian data were 
logarithmically transformed to achieve normality prior to analysis or analysed using 
non-parametric tests if normality could not be achieved with transformation.  Results 
data from log transformed values after analysis were then anti-logged and presented 
either as geometric means (for absolute values), geometric mean fold differences or 
percentage changes (for within and between group differences).  A multivariate 
analysis of variance (MANOVA) was performed to assess for any cumulative Type-I 
errors inherent with multiple T-tests as well as interactions between the different 
outcome variables with significance set at p<0.05 (two-tailed).  Pearson’s and 
Spearman’s correlations were performed on significant outcome variables from the 
between group T-tests or Mann-Whitney-U tests respectively, with BMI as a 
continuous (rather than categorical) variable.   Differences of within group means 
compared to respective baselines were assessed using paired Student’s T-tests (2-
tailed) or related-samples Wilcoxon Signed Ranks tests.  Differences between group 
means were assessed using independent Student’s T-tests (2-tailed) or independent-
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samples Mann-Whitney-U tests.  All significance levels were set at p<0.05.  
Statistical analyses were performed using SPSS version 18.0. 
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RESULTS 
 
A total of 72 patients (95% white Scottish) were identified combining the two HFA-
budesonide arms.  Two independent groups were subsequently identified based on 
their BMI; an overweight group with BMI≥25kg/m2 (mean 30.0kg/m2, range 25.1–
40.5kg/m2) and a normal weight (normal) group with BMI<25kg/m2 (mean 
22.9kg/m2, range 18.9–24.9kg/m2).  The baseline demographics for these two groups 
are presented in Table 5.  Of note, the overweight group were significantly older by 
approximately 9 years, with the normal group having a significantly higher baseline 
FeNO by approximately 13 parts per billion.  Subsequent Pearson’s correlation, 
however, demonstrated no significant effect of age (p=0.30) or baseline FeNO 
(p=0.24) with BMI as a continuous variable.  There were no significant differences 
between remaining baseline values. 
 
Table 5.  Baseline demographics. 
Group Overweight BMI≥25 (n=45) 
Normal Weight 
BMI<25 (n=27) p-value 
Sex (M:F) 21:24 8:19 0.15 
Age (years) 42.8 (39.0-46.6) 34.3 (28.6-39.9) 0.01 
Weight (kg) 86.4 (82.9-90.0) 64.15 (60.9-67.4) <0.001 
Height (cm) 169.8 (167.3-172.2) 167.0 (163.6-170.5) 0.20 
Body Mass Index, BMI (kg/m2) 30.0 (28.9-31.1) 22.9 (22.4-23.4) <0.001 
Atopic status, ≥ 1 positive skin prick (%) 93.3 96.3 0.60 
FEV1 (L) 2.83 (2.66-3.01) 2.83 (2.54 -3.13) 0.99 
FEV1 (% predicted) 82.1% (78.4-85.8) 81.7% (78-85.3) 0.87 
FeNO (ppb)* 29.7 (24.1-36.6) 43.2 (33.5-55.7) 0.03 
Methacholine PC20 (mg/ml)* 0.80 (0.6-1.07) 0.61 (0.43-0.87) 0.27 
Total daily symptom score (0-3) 0.94 (0.73-1.16) 0.98 (0.73-1.23) 0.81 
Cortisol/Creatinine Ratio (nmol/mmol)* 3.38 (2.72-4.21) 3.72 (2.8-4.95) 0.60 
 
Data presented as arithmetic mean (95% confidence intervals) unless stated.  *Geometric 
mean (95% confidence interval).  FEV1= Forced expiratory volume in 1 second.  FeNO= 
Fractional exhaled nitric oxide.  PC20= Provocation concentration (methacholine) causing 
20% fall in FEV1 from baseline.  Significance level p<0.05.  ppb= parts per billion. 
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Significant differences were observed between overweight and normal groups for 
both FeNO and total daily asthma symptom scores.  For FeNO (Table 6), there was a 
significantly greater reduction for 0-200µg and 0-800µg budesonide in the normal 
group than in the overweight group (Figure 10, Plot D), albeit the normal group 
started from a higher baseline.  Most of the reduction in FeNO was between 0-200µg 
of budesonide.  A similar pattern was seen with symptoms (Table 7), with 
significantly greater improvement in symptoms in the normal group for 0-200µg and 
0-800µg of budesonide (Figure 10, Plot B).  Again most symptom improvement was 
between 0-200µg. 
 
Table 6.  Fractional exhaled nitric oxide (FeNO). 
 
 
 
 
 
 
 Overweight Normal Weight Difference 
 Mean (95%CI) P Mean (95%CI) P Mean (95%CI) P 
Baseline 29.7 (24.1, 36.6)* 43.2 (33.5, 55.7)* 0.69 (0.49, 0.96) 0.03 
0-200µg 0.74 (0.67, 0.82) <0.001 0.56 (0.48, 0.65) <0.001 1.32 (1.11, 1.57) 0.002 
0-800µg 0.63 (0.54, 0.74) <0.001 0.48 (0.40, 0.58) <0.001 1.30 (1.01, 1.67) 0.045 
200-800µg 0.85 (0.76, 0.95) 0.005 0.87 (0.74, 1.01) 0.08 0.98 (0.81, 1.18) 0.83 
 
Data presented as geometric means (parts per billion)* for baseline values and geometric 
mean fold differences (95% confidence intervals) from baseline vs. 200µg (0-200µg), 
baseline vs. 800µg (0-800µg), 200µg vs. 800µg (200-800µg), and between groups of ICS.  
For each variable p-values (P) are shown for both within group responses and for between 
group differences in response.   Significance level p<0.05.  ICS= Inhaled corticosteroid 
(HFA-budesonide). 
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Table 7.  Total daily asthma symptom scores. 
 Overweight Normal Weight Difference 
 Mean (95%CI) P Mean (95%CI) P Mean (95%CI) P 
Baseline 0.94 (0.73, 1.16)* 0.98 (0.73, 1.23)* -0.04 (-0.39, 0.31) 0.78 
0-200µg -0.10 (-0.29, 0.09) 0.11 -0.53 (-0.70,  -0.35) <0.001 0.43 (0.14, 0.71) .002 
0-800µg -0.29 (-0.53, -0.06) 0.002 -0.69 (-0.90,  -0.48) <0.001 0.40 (0.04, 0.75) 0.01 
200-800µg -0.20 (-0.41, 0.01) 0.007 -0.16 (-0.31,  -0.02) 0.009 -0.03 (-0.33, 0.27) 0.98 
 
Data are presented as arithmetic means* for baseline values and arithmetic mean changes 
(95% confidence intervals) from baseline vs. 200µg (0-200µg), baseline vs. 800µg (0-800µg), 
200µg vs. 800µg (200-800µg), and between groups of ICS doses.  For each variable p-values 
(P) are shown for both within group responses and also for the between group differences in 
response.  Significance level p<0.05.  ICS= Inhaled corticosteroid (HFA-budesonide). 
 
 
 
Figure 10.  Between group differences by body mass index for 0-200µg and 0-
800µg daily inhaled HFA budesonide dose increments. 
A) Mean change in FEV1 from baseline.  B) Mean reduction in total daily symptoms scores 
from baseline.  C) Mean doubling dilution (DD) difference in methacholine PC20 from 
baseline.  D) Mean percentage reduction in fractional exhaled nitric oxide (FeNO) from 
baseline.  All means have 95% confidence interval error bars.    *Denotes significant within 
group change from baseline (p<0.05).  Overweight group = closed circles and thick error bars.  
Normal weight group = open squares and thin error bars.  ns = no significant difference. 
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Despite significant findings for FeNO and symptoms, there were no significant 
differences between overweight and normal groups for methacholine PC20 (Table 8; 
Figure 10, Plot C) although there were significant dose responses within both groups 
for this measure.  There was a non-significant trend towards attenuated cortisol 
suppression in overweight subjects at 0-800ug budesonide (p=0.06) (Table 9).  FEV1 
response (Table 10; Figure 10 Plot A) showed no significant differences between 
weight groups for change from baseline (0-200µg or 0-800µg), however, there was a 
significant difference between 200-800µg. 
 
Table 8.  Methacholine bronchial challenge. 
 Overweight Normal Weight Difference 
 Mean (95%CI) P Mean (95%CI) P Mean (95%CI) P 
Baseline 0.80 (0.60, 1.07)*   0.61 (0.43, 0.87)*   1.30 (0.81, 2.09) 0.27 
0-200µg 0.66 (0.33, 0.99) <0.001 0.62 (0.26, 0.99) 0.003 0.04 (-0.48, 0.56) 0.88 
0-800µg 1.16 (0.73, 1.59) <0.001 1.11 (0.67, 1.56) <0.001 0.05 (-0.62, 0.71) 0.89 
200-800µg 0.50 (0.13, 0.87) 0.01 0.49 (0.06, 0.92) 0.03 0.01 (-0.59, 0.60) 0.98 
 
Data are presented as geometric means* for baseline values (mg/ml) and mean doubling 
dilution differences (95% confidence intervals) in methacholine PC20 from baseline vs. 200µg 
(0-200µg ICS), baseline vs. 800µg (0-800µg ICS), 200µg vs. 800µg (200-800µg ICS), and 
between groups.  For each variable p-values (P) are shown for both within group responses 
and also for the between group differences in response.  Significance level p<0.05.  ICS= 
Inhaled corticosteroid (HFA-budesonide). 
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Table 9.  Overnight urinary cortisol/creatinine ratio (OUCC). 
 Overweight Normal Weight Difference 
 Mean (95%CI) P Mean (95%CI) P Mean (95%CI) P 
Baseline 3.38 (2.72, 4.21)*  3.72 (2.80, 4.95)*  0.91 (0.63, 1.31) 0.60 
0-200µg 1.02 (0.80, 1.31) 0.86 0.87 (0.63, 1.19) 0.40 1.17 (0.78, 1.76) 0.43 
0-800µg 0.78 (0.63, 0.97) 0.03 0.53 (0.38, 0.75) 0.001 1.46 (0.98, 2.17) 0.06 
200-800µg 0.76 (0.59, 0.99) 0.048 0.61 (0.39, 0.96) 0.04 1.24 (0.76, 2.03) 0.38 
 
Data presented as geometric means (nmol/mmol)* for baseline values and geometric mean fold 
differences (95% confidence intervals) from baseline vs. 200µg (0-200µg ICS), baseline vs. 
800µg (0-800µg ICS), 200µg vs. 800µg (200-800µg ICS), and between groups.  For each 
variable p-values (P) are shown for both within group responses and also for the between 
group differences in response.  Significance level p<0.05.  ICS= Inhaled corticosteroid (HFA-
budesonide). 
 
 
Table 10.  Forced expiratory volume in 1 second (FEV1). 
 Overweight Normal Weight Difference 
 Mean (95%CI) P Mean (95%CI) P Mean (95%CI) P 
Baseline 2.83 (2.66, 3.01)*   2.83 (2.54, 3.13)*   0.00 (-0.33, 0.32) 0.99 
0-200µg 0.09 (0.03, 0.15) 0.004 0.03 (-0.04, 0.10) 0.40 0.06 (-0.04, 0.15) 0.22 
0-800µg 0.07 (0.03, 0.11) 0.003 0.14 (0.07, 0.22) 0.001 -0.08 (-0.16, 0.01) 0.07 
200-800µg -0.02 (-0.06, 0.02) 0.37 0.11 (0.05, 0.18) 0.003 -0.13 (-0.21, -0.05) 0.001 
 
Data are presented as arithmetic means* for baseline values and arithmetic mean differences 
(95% confidence intervals) for baseline vs. 200µg (0-200µg ICS), baseline vs. 800µg (0-
800µg ICS), 200µg vs. 800µg (200-800µg ICS) and between groups.  For each variable p-
values (P) are shown for both within group responses and also for the between group 
differences in response.  Significance level p<0.05.  ICS= Inhaled corticosteroid (HFA-
budesonide). 
 
 
MANOVA comparisons of outcome variables demonstrated no significant 
interactions and confirmed there was an overall effect of BMI.  Moreover there was 
no confounding effect of cumulative type 1 error from multiple T testing.  Regression 
analyses of both FeNO and symptom responses at 0-200µg budesonide against BMI 
as a continuous variable show significant correlation and confirm the original between 
group findings.  These are presented in Figure 11. 
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Figure 11.  Regression analyses of change in Log FeNO (left) and symptom 
scores (right) for all patients between 0-200µg daily inhaled HFA budesonide 
against body mass index (BMI). 
Interrupted lines represent 95% confidence intervals for the regression line of identity (solid 
line).  r = correlation coefficient.  P-value for the slope is also shown. 
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DISCUSSION 
 
We have compared data on stepwise dose-response to ICS between normal weight 
and overweight persistent asthmatics.  Based on previous work suggesting reduced 
responsiveness to ICS in overweight asthmatics at fixed doses, we used a variety of 
asthma outcome measures to assess for differences between weight groups.  
Unsurprisingly, the overweight group in our study were older than the normal group 
despite a non-significant correlation with BMI (continuous variable).  This trend has 
been reported in previous studies examining obesity and asthma231,237. 
 
We found significantly greater improvement in total daily asthma symptom scores in 
the normal group, at both 0-200µg and 0-800µg ICS, compared to the overweight 
group.  Most improvement was demonstrated between 0-200µg ICS.  The lack of 
difference between groups in FEV1 at either dose level may simply reflect that our 
patient cohort had relatively preserved baselines, with FEV1 %predicted for normal 
and overweight groups 81.7% and 82.1% respectively, leaving little room for further 
improvement.  In this regard it is well documented that in response to dose titration 
with ICS, effects on exacerbations are rather removed from pulmonary function13,14.  
Both baseline symptoms and FEV1 were similar between groups, so cannot account 
for the disconnect we found between these outcome measures. 
 
Altered lung mechanics have previously been theorised to explain lack of 
improvement in symptoms in overweight asthmatics, i.e., an independent reason 
rather than asthma causing symptoms.  Indeed, excess adipose tissue, particularly in 
very obese patients, could reduce spirometric indices through external restriction, but 
we did not demonstrate this in our study.  It has been previously shown that 
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overweight patients have a reduced functional residual capacity compared to normal 
weight patients leading to reduced airway calibre and increased airway resistance239.  
Increased elastic load on the airways has also been suggested, and found to be an 
independent predictor of dyspnoea during bronchial challenge240.  The overweight 
group in our study had a mean BMI=30kg/m2, which is not exceptionally high, with a 
difference of 7kg/m2 between groups, hence it would be difficult to believe 
mechanical factors alone could explain the differences seen in symptoms.  Indeed, a 
small change in FEV1 (from the same baselines) was seen in both groups confirming 
that lung mechanics is probably not the major factor to explain the disconnect 
between FEV1 and symptoms.  It could be that symptoms are more closely related to 
airway inflammation and small airways function rather than large airway calibre, 
suggested by the connection we found between symptom and FeNO responses. 
 
We also found a significantly greater reduction in FeNO in the normal weight group.  
This was again seen at both 0-200µg and 0-800µg, with most improvement again at 0-
200µg.  The normal group had a significantly higher baseline FeNO than the 
overweight group.  This dose response difference could, therefore, be explained by a 
greater ‘regression to the mean’ in the normal group.  However, the baseline FeNO 
difference was only significant when BMI was a categorical rather than a continuous 
variable.  Previously it has been suggested that overweight asthmatics have a higher 
baseline FeNO232  - the opposite to our cohort.  FeNO is recognised as a surrogate 
measure of airway inflammation in asthma, reflecting airway eosinophilia241.  The 
difference between weight groups on FeNO response was in contrast to the lack of 
any difference between groups in methacholine AHR.  One might assume that AHR 
and FeNO should be highly correlated – i.e. the more inflammation in the airways, the 
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more ‘twitchy’ they should become to stimuli, hence response to ICS might be 
mirrored in both.   Nonetheless, methacholine PC20 showed a shift from baseline 
within each group, which was significant even at the lower dose. There are conflicting 
findings for this assumption of correlation from previous studies directly comparing 
FeNO and methacholine221,242.  Indeed, methacholine acts directly on airway smooth 
muscle, which may explain the disconnect between methacholine and FeNO in our 
study.  One might speculate that ‘indirect’ challenges such as adenosine 
monophosphate (AMP), or perhaps mannitol, may have shown more correlation with 
FeNO response as these have effect through inflammatory mediators, then 
subsequently on airway smooth muscle.  Alternatively, because methacholine acts on 
the central large airways, in contrast to FeNO, which reflects ‘whole lung’ 
inflammation, it alludes to the possibility of reduced peripheral lung deposition or 
absorption of ICS in overweight asthmatics.  Further methods to examine this theory 
could include impulse oscillometry as a measure of peripheral airways function, or 
perhaps radiolabelled ICS peripheral lung deposition imaging studies between normal 
and overweight asthmatics.  
 
It is postulated that obesity confers a ‘pro-inflammatory’ state by enhancing adipose 
tissue immune function via immune mediators including TNF-α, interleukin-6, leptin, 
adiponectin and resistin243,244.  Moreover, there is a theory that this triggers up-
regulation of pulmonary inflammatory mechanisms increasing levels of FeNO232.  
Unfortunately we did not measure any other inflammatory markers such as induced 
sputum eosinophils or extracellular cationic protein (ECP) to see if ICS response 
might also be blunted, like FeNO, in the overweight group.  Another study has 
suggested that there may be reduced airway inflammation in overweight subjects as 
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assessed by eosinophil levels, also remarking that lesser control may be related to 
other external factors such as gastro-oesophageal reflux and sleep disordered 
breathing245.  Our study suggests that it is not FeNO level per se that is important in 
overweight asthmatics, but that it may be a less sensitive outcome response to ICS 
compared to the normal group. 
 
Our findings suggest that following ICS dose increments, both asthma symptoms and 
FeNO may improve more in normal compared to overweight asthmatics, with no 
difference in FEV1 and methacholine response seen between groups.  It may be that 
symptoms and FeNO are more subtle measures of improvement in the normal group 
with the lack of response in the overweight group supporting the theory of reduced 
peripheral lung deposition/absorption of ICS in overweight patients.  We measured 
overnight urinary cortisol/creatinine ratio to reflect adrenal suppression in response to 
ICS, which correlates with systemic steroid absorption from the lung.  Pointedly 
within both groups there was significant suppression at 0-800ug, along with a non-
significant trend to attenuated adrenal suppression in the overweight group at 0-800µg 
with a 32% difference in cortisol response between groups (p=0.06).  This in turn 
suggests reduced corticosteroid absorption in the overweight group and again the 
possibility of reduced peripheral lung deposition/absorption upstream.  We did not 
however measure budesonide kinetics, so we cannot exclude the alternative 
explanation that the overweight group may have had reduced peripheral 
glucocorticoid responsiveness resulting in attenuated cortisol suppression.  Indeed, the 
distribution of body fat may play a role here too where a prior study found that men 
with abdominal obesity showed less inhibition of serum cortisol by dexamethasone, 
particularly at lower concentrations, while in the normal weight control subjects, 
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cortisol secretion was inhibited in an apparent dose-response manner246.  However, 
we have no data on distribution of body fat in this study.  Inhaled budesonide has a 
relatively smaller volume of distribution than other more lipophilic inhaled 
corticosteroids such as fluticasone247, making it an ideal inhaled steroid to reduce 
confounding between weight groups.  Obesity has also been shown to alter response 
to glucocorticoids through MAP-kinase signalling pathways236, however, Sutherland 
et al concedes that overall glucocorticoid insensitivity is likely to be complex, 
reflecting the multiple steps in glucocorticoid action. 
 
One hypothesis we have generated from this study is that dose response to ICS may 
be blunted with regard to FeNO and symptoms in overweight asthmatics, particularly 
at lower doses.  Peters-Golden demonstrated a markedly greater response of obese 
asthmatics to the leukotriene receptor antagonist montelukast as compared to ICS, 
ICS/LABA combination and placebo237.  This is supported by the finding that 
leukotriene receptors are up-regulated by leptin, an adipocyte-derived hormone whose 
serum levels parallel total body fat mass248,249.  It is worth considering that LTRAs 
could be added to ICS at an earlier stage in the stepwise therapy of overweight 
asthmatics, or indeed these patients may find greater benefit in terms of peripheral 
small airways disease using extra-fine particle ICS devices. 
 
In conclusion, we hypothesise that overweight persistent asthmatics may have 
attenuated symptom and FeNO responses to stepwise ICS increments compared to 
normal weight asthmatic counterparts.  Interestingly, we found no difference between 
weight groups in either FEV1 or methacholine responses at either dose.  There was a 
trend to attenuated cortisol suppression in overweight subjects, suggesting the 
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possibility of reduced bioavailability in this group.  Further prospective studies are 
warranted to explore these findings, in particular whether there is reduced peripheral 
lung deposition/absorption of ICS in overweight asthmatics. 
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CHAPTER 5:   
ADDING PROPRANOLOL TO 
LOW DOSE INHALED 
CORTICOSTEROID VERSUS 
HIGHER INHALED 
CORTICOSTEROID DOSING 
ALONE IN MILD-MODERATE 
PERSISTENT ASTHMA 
 
Study aims: 
1. To examine whether the inverse beta-2 receptor agonist propranolol (a 
non-cardioselective beta-blocker) provided any corticosteroid-sparing 
activity on histamine-induced airway hyperresponsiveness in persistent 
asthma. 
2. To examine whether adding propranolol to low dose inhaled corticosteroid 
provided any additional anti-inflammatory effects in persistent asthma, 
compared to higher inhaled corticosteroid dosing. 
3. To examine clinical safety outcomes when using propranolol in persistent 
asthmatics, in particular, effects on pulmonary function.  
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ABSTRACT 
 
Background 
The murine asthma model shows that switching off airway beta-2 receptors with an 
inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing 
activity. 
 
Objective 
We assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, 
added to low dose inhaled corticosteroid (ICS) versus higher dose ICS. 
 
Methods 
A randomized, double-blind, placebo-controlled, crossover trial in mild-moderate 
persistent asthmatics was performed. After a run-in (2weeks) on hydrofluoroalkane-
beclometasone dipropionate (HFA-BDP) 100µg/day, patients received randomised 
treatments (4weeks) with propranolol 80mg/day plus HFA-BDP 100µg/day; versus 
placebo plus HFA-BDP 400µg/day. Propranolol was up-titrated to 80mg/day over 
initial 2weeks. Tiotropium was co-administered until 5days before each histamine 
challenge (the primary outcome). 
 
Results 
16 patients completed the study, mean age 38yr; FEV1 86.4%; histamine PC20 
1.39mg/ml; ICS dose 406µg/day.  Histamine PC20 was unchanged by adding 
propranolol to HFA-BDP100 compared to baseline (HFA-BDP100): 0.17 doubling 
dilution (dd) difference (95%CI -0.58-0.92), but there was a significant improvement 
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with HFA-BDP400 compared to both baseline 1.05dd (95%CI 0.43-1.66), P=0.02; 
and propranolol + HFA-BDP100:0.88dd (95%CI 0.45-1.30), P=0.006.  Significant 
improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood 
eosinophils, serum eosinophilic cationic protein and asthma quality of life 
questionnaire symptoms, compared to propranolol + HFA-BDP100.  Salbutamol 
recovery post-challenge was partially blunted by propranolol (median prolongation 
5min, P=0.002). Domiciliary evening FEV1 also fell with propranolol +HFA-
BDP100: mean reduction from baseline 0.22L [95%CI 0.10-0.34L], P=0.012, while 
Asthma Control Questionnaire remained unchanged. 
 
Conclusion 
The inverse agonist propranolol produced no improvements when given with low 
dose ICS, while further significant improvements in airway hyper-responsiveness and 
inflammation were demonstrated with higher dose ICS.  Thus propranolol does not 
confer corticosteroid-sparing activity in persistent asthma. 
 
Ethics Reference:  11/ES/0031 
EudraCT number:  2011-002512-89 
MHRA reference:  21726/0278/001-0001 
ClinicalTrials.gov reference:  NCT01544634 
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INTRODUCTION 
 
Current asthma treatment advocates a step-wise approach, with inhaled corticosteroids 
(ICS) the main anti-inflammatory controller therapy and long-acting beta-2 agonists 
(LABA) the preferred second-line bronchodilator add-on therapy11.  However, despite 
optimizing ICS/LABA, many patients remain poorly controlled250.  Inevitably some 
patients require higher ICS dosing, highlighting the unmet need for new ICS-sparing 
strategies. 
 
One would not expect any novel asthma therapy to come in the guise of a drug long-
considered hazardous in asthmatics due to the risk of profound acute 
bronchoconstriction251; nevertheless beta-blockers have been the subject of recent 
interest and study in this regard.  Murine asthma models demonstrated improvements 
in airway hyper-responsiveness (AHR)252, up-regulation of beta-2 adrenoceptors 
(B2ADRs)252,253, and a reduction in airway inflammation following chronic beta-
blockade with nadolol254.  Moreover, in humans, open-label chronic nadolol therapy 
in steroid-naïve asthmatics255,256 resulted in significantly improved AHR, achieving a 
1.8 doubling dilution (dd) increase in methacholine PC20 (provocative concentration 
causing 20% FEV1 fall), almost twice the minimum important difference257. 
 
Regarding the pivotal safety issue of using beta-blockers in asthma, there was no 
adverse signal from a meta-analysis of chronic beta-blocker studies in patients with 
reactive airways disease for FEV1, symptoms or reliever use258.  Prospective open-
label studies by Hanania et al256 and Short et al259 have shown that the response to 
high-dose salbutamol rescue was only partially blunted post-bronchial challenge in 
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asthmatics receiving either chronic nadolol or single-dose propranolol respectively, 
with only minor FEV1 reductions. 
 
We recently published data showing no additional therapeutic benefit of chronic 
propranolol versus placebo when added to medium-dose ICS on AHR to either 
histamine or methacholine4.  This was surprising given the marked effect seen in ICS-
naïve patients using nadolol; however, this could perhaps be explained by the fact that 
ICS themselves act through both up-regulation of airway B2ADRs89 as well as being 
first-line anti-inflammatory treatment for asthma, therefore, leaving no room for 
further improvement. 
 
The next logical question, therefore, is whether there may be any corticosteroid-
sparing effect of chronic beta-blockade on AHR and other inflammatory outcomes in 
asthma.  This hypothesis is supported by data showing steroid-sparing properties of 
nadolol using the mouse asthma model260. In this study we wished to examine 
whether chronic propranolol treatment added to low dose ICS, was non-inferior to 
increasing the dose of ICS alone on the primary outcome of histamine AHR in 
persistent asthmatics; i.e. specifically testing for a corticosteroid-sparing effect. 
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METHODS 
 
Patients 
Stable, histamine responsive (PC20<8mg/ml) persistent asthmatics receiving 
≤1000µg/day of ICS (beclometasone dipropionate equivalent), (CONSORT diagram 
Figure 12).  The main exclusion criteria were: uncontrolled asthma symptoms; 
FEV1<60% predicted; resting systolic blood pressure (BP) <110mmHg; resting heart 
rate (HR) <60bpm; any degree of heart block assessed by electrocardiogram; current 
use of negatively chronotropic medication; asthma exacerbation requiring oral steroid 
use in previous 6 months; and pregnancy. 
 
 
Figure 12.  CONSORT diagram of patient recruitment. 
 
!
Assessed for eligibility (n=52) 
Excluded  (n=32) 
♦!!!Not meeting inclusion criteria (n=27) 
♦!!!Declined to participate (n=2) 
♦!!!Other reasons (n=3) 
Discontinued intervention (Withdrawn) (n=4) 
- No reason given by participant (n=1) 
- Low blood pressure (n=1) 
- Unable to attend all visits (n=2) 
Analysed  (n=16) 
♦!No exclusions!
!
Randomized (n=20) 
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Design 
Single-centre, randomized, double-blind, placebo-controlled, crossover study.  
Following a two-week run-in with hydrofluoroalkane-beclometasone dipropionate 
(HFA-BDP, Qvar® Easibreathe, TEVA Pharmaceuticals, Horsham, USA) 100µg/day, 
ex-valve dose (80µg ex-actuator), patients were randomized to either:  A) HFA-BDP 
100µg/day plus propranolol sequentially up-titrated from 10mg bid (one week), to 
20mg bid (one week), then 80mg (sustained release) od (two weeks); B) HFA-BDP 
400µg/day, ex-valve dose (320µg ex-actuator), plus matched placebo for four weeks 
(Figure 13).  Participants commenced tiotropium 18µg od (Spiriva® Handihaler, 
Boehringer Ingelheim Ltd, Berks, UK) at the beginning of run-in and both treatments, 
to mitigate against potential bronchoconstriction upon initial propranolol exposure261; 
then discontinued five days prior to each histamine challenge. 
 
 
 
Figure 13.  Study flow diagram. 
Screening visit (S). Tiotropium stopped 5 days (5d) prior to histamine challenges at main 
study visits 1, 3 and 5 (V1, V3, V5).  Patients randomized (*) at V1.  Cross over (†) to 
remaining treatment arm.  Safety visits at 2 weeks into treatment periods (V2, V4).  Study 
complete at end of V5. 
 
 
Patients were monitored in our department for two hours following administration of 
the first dose of propranolol (or placebo) at visits one and three; with safety 
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measurements (HR, BP, FEV1) assessed prior to up-titration to 80mg propranolol (or 
placebo) at visits two and four.  At the end of the first randomised treatment arm, 
patients were directly crossed over to the remaining treatment arm. 
 
Alongside initial ICS step-down, patients withheld any concomitant LABA or other 
third-line asthma therapy including antihistamines for 1 week prior to run-in and for 
the duration of the study. 
 
The primary outcome was histamine PC20 comparing post run-in baseline with 
completed treatment periods.  Secondary outcome measures were: spirometry; 
impulse oscillometry (IOS); exhaled nitric oxide (FeNO); blood eosinophils; serum 
eosinophilic cationic protein (ECP); overnight urinary cortisol/creatinine ratio 
(OUCC); pre/post-histamine challenge measurements (HR, BP, serum potassium, 
FEV1); domiciliary FEV1; Asthma Quality of Life (AQLQ) and Asthma Control 
Questionnaires (ACQ). 
 
St Mary’s Pharmaceutical Unit, Cardiff, Wales, UK performed blinding and 
randomisation of investigational medicinal products. 
 
Measurements 
Histamine was dispensed via nebulized solution (Tayside Pharmaceuticals, Dundee, 
UK), and the challenge was performed in accordance with standard guidelines. A 
dosimeter (Markos-Mefar, Bovezzo (BS), Italy) was used with doubling 
concentrations of histamine from 0.3125mg/ml-40mg/ml. The PC20 was then 
calculated by computer assisted log linear interpolation of the dose response.  
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Nebulized albuterol (5mg) was used to recover patients immediately post challenge.  
FEV1 was measured every 5mins for 30mins post challenge or until it returned to 
within 5% of baseline.  If FEV1 had not recovered by 15mins, nebulized ipratropium 
bromide (500µg) was additionally administered.  HR and serum potassium were 
measured pre-challenge and 15mins post albuterol administration.  All HR and BP 
measurements were recorded in triplicate.  Exhaled tidal nitric oxide was measured in 
line with ATS recommendations22 using a NIOX analyzer (NIOX® Nitric Oxide 
Monitoring System, Aerocrine AB, Solna, Sweden) prior to other pulmonary function 
measures. Impulse oscillometry (Masterscreen IOS, Höchberg, Germany) was 
performed in accordance with manufacturer’s guidelines.  Spirometry was performed 
using a SuperSpiro (Carefusion, Basingstoke, UK) according to ATS guidelines123.  
Domiciliary FEV1 was performed in triplicate both morning and evening using a 
handheld PiKO monitor (n-Spire Health, Longmont, CO, USA) according to 
manufacturer’s instructions.  Peripheral blood eosinophils were measured using the 
Sysmex XE2100 Hematology autoanalyser.  Serum ECP was measured in duplicate 
using a UniCAP system (Phadia, Milton Keynes, UK) - coefficient of variation 3%.  
Overnight urine was collected between 22.00h and 08.00h.  Urinary free cortisol was 
measured using a commercial radioimmunoassay kit (DiaSorin Ltd., Wokingham, 
Berkshire, UK).  The intraassay coefficient of variation (Cv) was 21%, with the 
interassay Cv 13%.  Urinary creatinine was measured using the RATE technique on a 
Cobas-Bio auto analyzer (Roche Products, Welwyn Garden City, UK) with an 
interassay Cv of 4.3%.  Skin prick testing was performed using standard allergen 
extracts (Diagenics Ltd, Milton Keynes, UK). 
 
 
129 
	 	
Statistical Analyses 
All data were assessed for normality of distribution.  Non-normally distributed 
variables were logarithmically transformed or analyzed non-parametrically. The null 
hypothesis was that compared to post run-in baseline on HFA-BDP 100µg/day, 
adding propranolol 80mg/day confers no change to Histamine PC20, whereas 
increasing the dose of HFA-BDP alone (400µg/day) causes a significant improvement 
(positive control).  To detect a minimal important difference of 1dd in histamine PC20 
between randomized treatments, assuming a within-subject standard deviation of 
1.3dd, required 16 participants to achieve 80% power with an alpha-error of 0.05 
(two-tailed) using a crossover design (matched subjects).  Analysis was performed 
using repeated measures analysis of variance, factoring treatment and sequence 
effects, followed by Bonferroni correction for all pairwise comparisons (P<0.05, two-
tailed).  All analyses were performed using IBM SPSS v20 (San Diego, CA, USA). 
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RESULTS 
 
Participants 
16 completed per protocol (Table 11, Figure 12).  Mean FEV1 was 86.4% predicted 
(95%CI: 80.9, 91.9) and the geometric mean histamine PC20 was 1.39mg/ml (95%CI: 
0.93, 2.07) at screening.  There were no significant adverse events. 
 
Table 11.  Demographics. 
Variable N=16 
Age (yr) 38 (31, 44) 
Gender (M:F) 6:10 
BMI (kg/m2) 26.9 (24.6, 29.2) 
Atopy (>1 SPT positive; n) 14 
SPT positivity* 2.5 (1, 4) 
BDP ICS (µg/day) 406 (243, 569) 
LABA (all combined with ICS; n) 7 
Antihistamine / LTRA (n) 2 / 2 
FEV1 (% predicted) 86.4 (80.9, 91.9) 
FEF25-75 (% predicted) 53.6 (46.5, 60.7) 
R5 (% predicted) 151 (126, 181) 
R5-R20 (kPa/L/sec) 0.13 (0.07, 0.19) 
FeNO (ppb)† 40 (29, 55) 
Histamine PC20 (mg/ml)† 1.39 (0.93, 2.07) 
Systolic BP (mmHg) 131 (122, 140) 
Diastolic BP (mmHg) 79 (73, 84) 
HR (bpm) 73 (68, 78) 
 
Data presented as mean (95% confidence intervals [CI]) or absolute values unless stated.  
*Median (interquartile range).  †Geometric mean (95%CI).  BMI = body mass index.  SPT = 
skin prick test to allergen.  BDP ICS = beclometasone dipropionate equivalent inhaled 
corticosteroid dose.  LABA = long-acting beta-2 agonist.  LTRA = leukotriene receptor 
antagonist.  FEV1 = forced expiratory volume in 1s.  FEF25-75 = forced expiratory flow 
between 25-75% of forced vital capacity.  R5 = resistance at 5Hz (total airway resistance) 
from impulse oscillometry.  R5-R20 = resistance between 5Hz and 20Hz (peripheral airway 
resistance).  FeNO = fractional exhaled tidal nitric oxide.  PC20 = provocative concentration 
(of histamine) causing 20% fall in FEV1.  BP = blood pressure.  HR = heart rate.  Ppb = parts 
per billion.  Bpm = beats per minute. 
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Airway hyper-responsiveness 
The primary outcome, histamine PC20, showed no significant difference adding 
propranolol to low-dose HFA-BDP 100µg/day versus post run-in baseline on HFA-
BDP 100µg/day alone (Table 12, Figure 14a): mean difference 0.17dd (95%CI: -0.58, 
0.92).  There was, however, a significant improvement in PC20 with higher dose HFA-
BDP 400µg/day and placebo versus both baseline, 1.05dd (95%CI: 0.43, 1.66), 
P=0.02, and propranolol, 0.88dd (95%CI: 0.45, 1.30), P=0.006 (Figure 15). 
 
 
Figure 14.  Airway hyper-responsiveness, symptoms, blood eosinophils and 
serum ECP. 
Data presented as arithmetic means (unless stated) with 95% confidence interval (CI) error 
bars for baseline on hydrofluoroalkane beclometasone dipropionate (HFA) 100µg/day 
(circle), HFA 400µg/day plus placebo (square), and propranolol 80mg/day plus HFA 
100µg/day (triangle).  (A) Histamine PC20 (primary outcome).  Geometric means (95%CI).  
(B) Asthma Quality of Life Questionnaire (AQLQ) symptom component.  (C) Blood 
eosinophils.  (D) Serum eosinophilic cationic protein (ECP).  Geometric means (95%CI). 
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Table 12.  Airway hyper-responsiveness; local and systemic inflammation; 
pulmonary function; adrenal function; asthma control; and cardiovascular 
outcomes. 
Variable Baseline 
HFA-BDP 100 (†) 
HFA-BDP 400 + 
Placebo (‡) 
HFA-BDP 100 + 
Propranolol (§) 
P-value 
(ANOVA) 
Histamine PC20 (mg/ml)* 1.31 (0.66, 2.63) 2.71 (1.87, 3.95)†,§ 1.48 (1.00, 2.19) 0.007 
     
FeNO (ppb)* 29 (21, 41) 19 (15, 25)† 25 (18, 35) 0.01 
Eosinophils (x109/L) 0.29 (0.22, 0.35) 0.19 (0.16, 0.22)†,§ 0.31 (0.24, 0.39) 0.001 
ECP (µg/L)* 22.3 (15.8, 31.4) 15.3 (10.5, 22.4) § 23.3 (17.1, 31.8) 0.006 
OUCC (nmol/mmol)* 5.14 (3.92, 6.75) 3.85 (2.71, 5.46) 3.73 (2.65, 5.27) 0.22 
     
FEV1 (% Pred) 91.6 (86.6, 96.7) 91.4 (87.1, 95.6) 88.9 (84.9, 92.9) 0.21 
FEF25-75 (% Pred) 60.3 (50.6, 69.9) 58.8 (50.3, 67.3) 54.6 (47.6, 61.7) 0.055 
     
R5 (% Pred)* 135 (111, 165) 144 (123, 169) 152 (130, 178) 0.22 
R5-R20 (kPa/L/s)* 0.06 (0.03, 0.12) 0.08 (0.05, 0.13) 0.10 (0.06, 0.16) 0.21 
     
ACQ score 0.57 (0.30, 0.84) 0.49 (0.29, 0.69) 0.65 (0.36, 0.94) 0.41 
AQLQ symptoms 6.19 (5.87, 6.51) 6.51 (6.30, 6.72)†,§ 6.21 (5.89, 6.54) 0.004 
AQLQ overall 6.16 (5.88, 6.44) 6.41 (6.15, 6.67) 6.20 (5.92, 6.49) 0.053 
     
Supine HR (bpm) 75.3 (70.5, 80.0) 76.1 (71.7, 80.5) 65.7 (62.2, 69.3)†,‡ <0.001 
Supine Systolic BP (mmHg) 127 (119, 135) 127 (118, 135) 119 (112, 126)†,‡ 0.01 
Supine Diastolic BP (mmHg) 79 (73, 85) 79 (73, 85) 71 (66, 77)†,‡ <0.001 
 
All data presented as mean values (95% confidence intervals [CI]) unless stated.  *Geometric 
mean (95%CI).  Overall significance with repeated measures analysis of variance (ANOVA).  
Significant (P<0.05) pairwise comparisons using Bonferroni correction are displayed as †, ‡ 
or § in superscript where the value is significantly different to respective named columns.  
HFA-BDP = hydrofluoroalkane beclometasone dipropionate.  PC20 = provocative 
concentration causing 20% fall in FEV1.  FeNO = fractional exhaled tidal nitric oxide.  Ppb = 
parts per billion.  ECP = serum eosinophilic cationic protein.  OUCC = overnight urinary 
cortisol/creatinine ratio.  FEV1 = forced expiratory volume in 1s.  FEF25-75 = forced expiratory 
flow between 25-75% of forced vital capacity.  R5 = resistance at 5Hz.  R5-R20 = difference 
between resistance at 5Hz to 20Hz.  ACQ = Asthma Control Questionnaire.  AQLQ = mini 
Asthma Quality of Life Questionnaire.  %Pred = percentage of predicted.  HR = heart rate.  
Bpm = beats per minute.  BP = blood pressure. 
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Figure 15.  Histamine PC20 doubling dilution differences. 
Scatter plots of individual histamine doubling dilution differences between all comparisons of 
baseline and both treatments with mean and 95% confidence interval error bars.  Horizontal 
interrupted line indicates unity.  *P<0.05 between treatments.  Base = baseline measurements 
post run-in on hydrofluoroalkane beclometasone dipropionate (HFA) 100µg/day.  HFA400 = 
400µg/day plus placebo.  Prop = propranolol plus HFA 100µg/day. 
 
 
Cardiovascular effects and salbutamol recovery 
Propranolol produced significant effects on other outcomes: 80mg/day caused 
significant reductions from baseline in both supine HR by approximately 10bpm, 
P<0.001 and supine BP after chronic dosing (Table 12).  Furthermore, recovery time 
to within 5% of baseline FEV1 post- salbutamol was significantly blunted by 
propranolol, compared to both baseline and placebo (median prolongation 5min), 
P=0.002 (Table 13, Figure 16a), as was post-recovery FEV1 - mean reduction 6.4% 
(95%CI: 3.7, 9.1%) from baseline, P=0.001 (Table 13, Figure 16d).  Three patients on 
propranolol required ipratropium bromide 15mins post-salbutamol to fully recover 
post-challenge, compared with no patients following baseline or placebo challenges, 
P=0.05.  All active propranolol patients had recovered by 25mins post-salbutamol.  
There was no salbutamol-induced fall in serum potassium post-challenge with 
propranolol, compared to significant reductions after baseline, P<0.001, and placebo, 
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P=0.002, challenges (Table 13, Figure 16c).  Similar significant blunting of response 
was seen in post-challenge HR and BP measurements with propranolol (Table 13, 
Figure 16b), compared to baseline and placebo. 
 
 
Table 13.  Salbutamol recovery outcomes post-histamine challenge. 
Variable Baseline 
HFA-BDP 100 (†) 
HFA-BDP 400 + 
Placebo (‡) 
HFA-BDP 100 + 
Propranolol 
P-value 
(ANOVA) 
FEV1(% Pred) 
 
92.8 (88.4, 97.1) 91.7 (87.9, 95.5) 86.4 (82.3, 90.4)†,‡ 0.001 
Time to >95% base 
FEV1 (min)* 
5 (5, 5) 5 (5, 10) 12.5 (5, 15) 0.002§ 
IB given at 15min 
(n)** 
0 0 3 0.05†† 
Supine HR(bpm) 
 
93.3 (87.0, 99.5) 96.0 (92.1, 99.9) 65 (60, 71)†,‡ <0.001 
Supine Systolic BP 
(mmHg) 
135 (128, 143) 136 (129, 143) 122 (114, 129)†,‡ <0.001 
Potassium (mmol/L) 3.6 (3.4, 3.8) 3.6 (3.4, 3.8) 4.3 (4.1, 4.4)†,‡ <0.001 
 
FEV1 and IB data are following recovery to within 5% of baseline FEV1 monitored at 5min 
intervals. HR, BP and Potassium were measured at 15min post nebulized salbutamol 5mg.  
All data presented as mean values (95% confidence intervals [CI]) unless stated. *Median 
(Interquartile range). **Absolute number of cases.  Overall significance with repeated 
measures ANOVA unless stated.  Significant (P<0.05) pairwise comparisons using 
Bonferroni correction are displayed as † or ‡ in superscript where the value is significantly 
different to respective named columns.  §Related samples Friedman's two-way ANOVA. 
††Related samples Cochran's Q test. HFA-BDP = Hydrofluoroalkane beclometasone 
dipropionate. FEV1 = forced expiratory volume in 1s. IB = ipratropium bromide. HR = heart 
rate. Bpm = beats per minute. BP = blood pressure. 
  
135 
	 	
 
Figure 16.  FEV1 recovery post-salbutamol; heart rate, serum potassium, and 
FEV1 pre and post-salbutamol. 
Arithmetic means (unless stated) with 95%CI: baseline HFA100µg/day (circle), 
HFA400µg/day plus placebo (square), and propranolol 80mg/day plus HFA100µg/day 
(triangle).  (A) Cumulative recovered patients >95% baseline FEV1.  Data: absolute values.  
Vertical line: ipratropium administration.  *P=0.02 propranolol versus baseline/placebo.  (B) 
Heart rate.  L/S=lying/standing.  Vertical lines: pre/post-challenge. *P<0.001 propranolol 
versus baseline/placebo.  (C) Potassium.  Lines join pre/post-challenge (*P<0.05).  (D) FEV1.  
Lines join pre/post-challenge (*P<0.05). 
 
 
Inflammation 
We also assessed local and systemic inflammatory outcomes – FeNO, blood 
eosinophilia and serum ECP - finding no significant difference in any outcome with 
propranolol compared to baseline.  However, there were significant reductions with 
high dose ICS plus placebo versus baseline for both FeNO (Table 12), P=0.02, and 
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eosinophil levels, P=0.03 (Table 12, Figure 14c).  Serum ECP was significantly lower 
with high dose ICS plus placebo versus propranolol, P=0.01 (Table 12, Figure 14d). 
 
Symptoms and asthma control 
Propranolol did not cause any significant change in AQLQ or ACQ over baseline 
values (Table 12).  High dose ICS did lead to significant improvements in AQLQ 
symptom component score versus both baseline and propranolol, but less than the 
minimal important difference of 0.5 (Table 12, Figure 14b). 
 
Airway caliber 
There was a significant reduction in domiciliary evening FEV1 with propranolol 
versus both baseline and placebo - mean 0.22L (95%CI: 0.10, 0.34) from baseline, 
P=0.012. This was only evident with the highest propranolol dose (80mg/day) and not 
with 40mg/day during week 2 of up-titration (Table 14).  There was no significant fall 
in domiciliary morning FEV1 with either propranolol dose (Table 14).  Visit-based 
spirometry and IOS measures, including total airway resistance at 5Hz (R5), did not 
significantly change with either randomized treatment versus baseline (Table 12). 
 
Adrenal function 
We found no significant systemic suppression of adrenal function, using OUCC, with 
either treatment versus baseline (Table 12). 
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Table 14.  Domiciliary FEV1 at mid-point and end of treatments. 
Variable Baseline 
HFA-BDP 100 (a) 
HFA-BDP 400 + 
Placebo (b) 
HFA-BDP 100 + 
Propranolol (c) 
P-value 
(ANOVA) 
Propranolol 40mg     
Morning FEV1 (L) 2.96 (2.60, 3.33) 2.99 (2.67, 3.30) 2.91 (2.58, 3.24) 0.32 
Evening FEV1 (L) 2.98 (2.62, 3.34) 2.95 (2.65, 3.26) 2.90 (2.57, 3.22) 0.19 
     
Propranolol 80mg     
Morning FEV1 (L) 2.96 (2.60, 3.33) 2.95 (2.65, 3.26) 2.84 (2.53, 3.15) 0.08 
Evening FEV1 (L) 2.98 (2.62, 3.34) 2.92 (2.60, 3.24) 2.76 (2.46, 3.06)a,b 0.002 
     
Domiciliary data presented as 7-day rolling mean (95%CI) values over week 2 of run-in as 
well as week 2 (propranolol 40mg/day or placebo) and week 4 (propranolol 80mg/day or 
placebo) of both treatment periods. Overall significance with repeated measures analysis of 
variance (ANOVA).  Significant (P<0.05) pairwise comparisons using Bonferroni correction 
are displayed as a, b or c in superscript where the value is significantly different to respective 
named columns. FEV1 = forced expiratory volume in 1s.  HFA-BDP = hydrofluoroalkane 
beclometasone dipropionate. 
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DISCUSSION 
 
The results of the present study demonstrated that adding propranolol to low dose ICS 
in persistent asthma did not significantly change histamine AHR, whilst increasing the 
dose of ICS conferred a significant further improvement.  In other words, propranolol 
did not demonstrate any corticosteroid-sparing effect on AHR, a hallmark of the 
underlying asthmatic disease process.  Moreover, we found significant room for 
further improvement with the higher ICS dose for local and systemic inflammatory 
outcomes, namely FeNO, blood eosinophils and serum ECP, while adding 
propranolol to low dose ICS did not significantly impact on these. 
 
The novel counterintuitive theory that beta-blockade might be effective in the 
treatment of asthma came through beta-adrenoceptor basic science and murine models 
of asthma.  Inverse agonist activity occurs at the B2ADR in the presence of certain 
beta-blockers including propranolol and nadolol, essentially ‘switching off’ the 
receptor by reducing basal constitutional activity262,263 with the potential, therefore, to 
up-regulate other B2ADRs.  However other data would tend to negate the role of 
inverse agonism, whereby epinephrine depletion in the mouse model resulted in 
inhibition of allergen-induced asthma61.  Other theories have postulated that certain 
beta-blockers such as nadolol and timolol might confer anti-asthmatic properties 
unrelated to their inverse agonism, such as inhibition of pro-inflammatory signaling 
pathways involving beta-arrestin and extracellular signal regulated kinases 
(ERK)263,264.  Indeed, adrenaline depleted mice again demonstrated that any anti-
inflammatory effect might be ligand specific, where the asthma phenotype developed 
in the presence of propranolol but not nadolol in these mice; and in the wild type mice 
propranolol did not prevent the occurrence of asthma, where nadolol was 
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preventative265.  However the putative role of such in vitro anti-inflammatory activity 
in human asthmatics remains to be proven in placebo-controlled trials. 
 
Open-label studies in mild steroid-naïve asthmatics showed that nadolol resulted in a 
4.7% fall in pre-challenge FEV1, with a preserved bronchodilator response to high 
dose salbutamol post-challenge255,256.  This preserved salbutamol response might be 
explained by previous data from human peripheral blood lymphocytes which have 
shown that marked B2ADR up-regulation occurs within 2 days of chronic exposure to 
propranolol, with a fully restored isoproterenol-induced cyclic-AMP response after 2 
weeks266.  In our previous study4 and in the current report we have shown partial 
blunting of salbutamol recovery post-challenge with propranolol versus placebo.  
Pointedly, the partially preserved bronchodilator response to salbutamol post-
challenge in the presence of propranolol occurred despite complete attenuation of 
systemic B2ADRs in the form of salbutamol-induced hypokalemic and chronotropic 
responses, in turn suggesting much higher local than systemic receptor occupancy by 
inhaled salbutamol.  Presumably it might be possible to completely overcome airway 
B2ADR occupancy by propranolol if one was to give much higher nebulized doses of 
salbutamol than the 5mg used in the present study.  We were cautious about doing this 
because of the possibility of causing greater B2ADR mediated systemic adverse 
effects in the placebo arm. 
 
Studies have consistently shown a dose response to ICS for AHR in asthma267.  This 
was integral to our study design by including a positive control arm with high dose 
ICS, both to demonstrate any room for further improvement over low dose ICS and 
therefore any putative steroid-sparing effect of propranolol on AHR, as well as to 
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confirm that we had adequate power to detect any clinically important change in the 
primary outcome of histamine AHR.  It is clear, therefore, from this study that there is 
no effect of chronic propranolol on AHR in persistent asthma as the histamine PC20 
values were similar both pre- and post-propranolol, while taking the same 100µg dose 
of HFA-BDP.  This adds to our previous data, where we found no additional effect of 
chronic propranolol over and above medium dose ICS at a BDP equivalent dose of 
440µg/day4, by answering the question of whether there might have been no 
additional room for improvement in AHR at this dose. 
 
Dose-dependent ICS effects have also been demonstrated on other inflammatory 
outcomes.  There is a significant dose response on FeNO with incremental ICS1,159, 
albeit most improvement occurs with low dose ICS.  Nevertheless, we did 
demonstrate significant improvements in FeNO, blood eosinophilia and serum ECP 
with the increased dose of ICS, but not with propranolol, suggesting there is no 
additional anti-inflammatory effect with chronic beta-blockade in the presence of low 
dose ICS.  Furthermore, given that we found no difference between randomized 
treatments in regard to urinary cortisol levels, these effects on systemic allergic 
biomarkers (eosinophils and ECP) are more likely to be due to topical effects on the 
airway of higher dose HFA-BDP rather than any increased systemic activity. 
We believe it noteworthy that chronic propranolol did not result in any significant 
worsening of AHR, FeNO, eosinophils, ECP, symptoms (AQLQ) or overall asthma 
control (ACQ); with only a minor reduction in domiciliary evening FEV1.  Indeed this 
was with a usual 80mg dose of sustained-release propranolol sufficient to cause a 
10bpm mean reduction in supine HR as well as a significant reduction in resting BP.   
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On the basis of the screening FEV1 (mean 86.4%), ICS dose (406ug/day), AHR (mean 
PC20 1.39mg/ml), and FeNO levels (mean 40ppb), our cohort would be classified as 
having persistent asthma; one would therefore have expected them to fare worse when 
given propranolol especially while only taking low dose ICS. This preservation of 
outcomes on propranolol may perhaps be due to using a gradual dose ramp255 of 
propranolol over several weeks, as well as co-prescribing the long-acting muscarinic 
antagonist tiotropium in order to avert any potential catastrophic fall in FEV1 upon 
first exposure to beta-blockade261.  However, it may also simply be that the presence 
of ICS even at low dose is intrinsically bronchoprotective against propranolol. 
 
In keeping with previous studies that found significant reductions in FEV1 
(approximately 5%) with chronic beta-blockade255,259, we also demonstrated a 
significant reduction in evening domiciliary FEV1 with propranolol amounting to 
0.22L (i.e. a 7.4% fall).  Furthermore, we did not demonstrate any significant 
improvement with high dose ICS on airway caliber measurements, presumably 
because these were relatively preserved at baseline.  There was a small improvement 
in the AQLQ symptom score with high dose ICS, but this was less than the minimum 
important difference of 0.535.  Moreover there was no change in ACQ throughout the 
study, with mean scores indicating well-controlled asthma from the outset. 
 
We believe the strengths of our study are in its prospective, randomized, placebo-
controlled design, particularly with regard to including a positive control arm (high 
dose ICS), which proved effective in demonstrating potential room for further 
improvement in the primary outcome measure of histamine AHR.  Furthermore, we 
have shown that this study design has robust safety attributes in utilizing a gradual 
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dose ramp for propranolol, and providing protection with concomitant long-acting 
muscarinic antagonist therapy during this up-titration period. 
 
One of the main limitations of our study may also be related to our focus on safety as 
evidenced by initial clinical stability (as seen by ACQ score) and relatively well 
preserved pulmonary function on study entry, thus leaving relatively little room for 
improvement in these outcomes upon chronic propranolol exposure.  Another 
limitation may be due to small patient numbers, although the study was powered on 
the primary outcome of histamine AHR in terms of being able to detect a difference 
of one doubling dilution.  It could also be reasonably argued that we should have 
employed nadolol as the beta-blocker of choice as used in the previous studies of 
nadolol in steroid naïve asthmatics.  However, due to the available dosage of nadolol 
in the UK, the cost of formulating specific doses of nadolol at great expense, as well 
as the fact that the prevailing theory at the time of writing this study protocol was that 
of inverse agonism (which both nadolol and propranolol display), we deemed it 
plausible that propranolol would be a suitable substitute for nadolol. 
 
In conclusion, adding propranolol to low dose ICS in persistent asthma provides no 
corticosteroid-sparing effect on histamine AHR and other inflammatory outcomes, 
compared to the significant improvements conferred by using a higher ICS dose.  
Salbutamol recovery post-histamine challenge was partially blunted and there was a 
small but significant fall in evening FEV1 when adding propranolol to low dose ICS, 
but no deterioration in ACQ or AQLQ.  One would not therefore advocate 
propranolol as a corticosteroid-sparing agent in persistent asthma.  However, clinical 
equipoise might still be challenged as propranolol could perhaps be given at these 
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doses to asthmatic patients for its usual indications provided our strict safety criteria 
are adhered to in carefully selected patients controlled on ICS. 
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CHAPTER 6:   
RELATIONSHIPS OF MANNITOL 
CHALLENGE TO METHACHOLINE 
CHALLENGE AND 
INFLAMMATORY MARKERS IN 
PERSISTENT ASTHMATICS 
RECEIVING INHALED 
CORTICOSTEROIDS. 
 
Study Aims: 
1. To examine the relationships of putative categorical cut-off values for 
mannitol airway hyperresponsiveness (AHR) severity against previously 
described severity cut-off values for methacholine AHR, and severity of 
airway inflammation (as measured by fractional exhaled nitric oxide, 
FeNO), in persistent asthmatics, receiving inhaled corticosteroid therapy. 
2. To examine the relationships of mannitol AHR, methacholine AHR and 
FeNO as continuous variables, to confirm or refute any relationships found 
as categorical variables. 
3. To examine the relationship between mannitol AHR and a further 
surrogate marker of allergic inflammation, namely salivary eosinophilic 
cationic protein.  
145 
	 	
ABSTRACT 
 
Background 
Mannitol is a novel osmotic indirect bronchial challenge agent used to aid asthma 
diagnosis and management, and is thought to reflect underlying inflammatory 
processes in asthma. 
 
Objective 
To evaluate relationships between mannitol AHR and other measures of airway 
inflammation as well as direct-acting methacholine challenge in persistent asthmatics 
receiving inhaled corticosteroids. 
 
Methods 
We analysed screening data of mild to moderate persistent asthmatics, all receiving 
ICS, who had mannitol and/or methacholine challenges, FeNO and salivary ECP 
performed as part of the same screen.  Mannitol AHR was grouped by PD10: mild 
(315-635mg); moderate (75-315mg); severe (0-75mg).  FeNO groups: low (<25ppb); 
medium (25-50ppb); high (>50ppb).  Methacholine PC20 groups: mild (2-8mg/ml); 
moderate (0.5-2mg/ml); severe (0-0.5mg/ml). 
 
Results 
Mannitol PD10 groups were significantly different overall for FeNO (p=0.023): 43% 
higher in the severe vs. mild group.  There was a significant overall difference for 
methacholine PC20 (p=0.006): a 2.1 doubling dilution difference between severe vs. 
mild mannitol groups.  FeNO groups were significantly different overall for mannitol 
146 
	 	
PD10 (p=0.01) and methacholine PC20 (p=0.029).  Methacholine PC20 groups were 
significantly different overall for mannitol PD10 (p<0.001) and FeNO (p=0.005).  No 
significant differences were found across any groups for: salivary ECP, FEV1%, or 
ICS dose.  Mannitol PD10, methacholine PC20 and FeNO as continuous variables all 
correlated with each other. 
 
Conclusions 
Mannitol challenge reflects both underlying inflammation using FeNO and direct 
AHR using methacholine.  Thus mannitol may be a useful screening tool for the 
assessment of asthmatic patients receiving inhaled corticosteroids. 
 
Ethics reference:  NFB/FB/192/03 
ClinicalTrials.gov reference:  NCT01216579 
  
147 
	 	
INTRODUCTION 
 
Mannitol is a novel ‘indirect’ bronchial challenge agent used as an aid to the diagnosis 
and management of asthma132,209,268.  The two main hallmarks of asthma are airway 
inflammation and airway hyper-responsiveness to a variety of stimuli.  Mannitol is an 
osmotic agent that causes a dehydrating effect on the airway epithelium leading to 
release of inflammatory mediators from inflammatory cells in the bronchial mucosa, 
ultimately leading to airway smooth muscle contraction and airway narrowing269.  
Similar indirect challenge agents include adenosine monophosphate (AMP) and 
hypertonic saline.  These are in contrast to ‘direct’ bronchial challenge agents such as 
histamine and methacholine20 used to detect airway hyper-responsiveness, which 
when inhaled, act directly on airway smooth muscle receptors to cause airway 
narrowing, i.e. identifying smooth muscle sensitivity to the exogenous agent. 
 
The use of mannitol as a bronchial challenge agent has increased in recent years both 
because of its ease of administration as well as the relation this challenge bears to 
exercise induced bronchoconstriction270 and to a lesser degree clinical asthma271.  
Mannitol does not require extensive equipment, nor is it time consuming to perform 
the challenge; rather a simple spirometer and a trained staff member who can instruct 
in the use of the dry powder inhaler that is used to administer the mannitol in standard 
incremental doses are all that are required. In addition, there is increasing evidence to 
suggest that achieving control of asthma through monitoring airway inflammation and 
adjusting treatment based on this6, rather than just simple spirometry and symptoms, 
may provide an ‘early warning system’ or ‘inflammometer’ before asthma symptoms 
worsen or exacerbations14 occur. 
 
148 
	 	
Previous studies have demonstrated relationships of mannitol challenge with other 
bronchial challenge tests and markers of airway inflammation.  Unsurprisingly 
mannitol correlates well with other ‘indirect’ challenges including AMP, hypertonic 
saline, exercise and eucapnic hyperpnoea217,272,273.  Mannitol also correlates well with 
histamine challenge274 and methacholine challenge275.  There have been differing 
reports on the relationship between mannitol and FeNO dependent on whether or not 
patients are receiving inhaled corticosteroids (ICS), i.e. the relationship seems more 
robust when ICS are not used274,276.  The theory that mannitol more closely reflects 
airway inflammation is also supported by its strong correlation not only with FeNO 
but also with sputum eosinophils in steroid naïve patients as compared to 
methacholine which did not correlate with eosinophils in the same study131. 
 
Mannitol has been recently shown to have a sensitivity and specificity similar to 
methacholine challenge for the diagnosis of asthma275 along with a similar negative 
predictive value to fractional exhaled nitric oxide (FeNO) levels using a FeNO cut-off 
of <36ppb to exclude asthma in a steroid naïve group275. 
 
As a clinician it is clearly useful to be able to quickly and easily quantify the degree 
of severity of a test and how this corresponds to the underlying condition in question, 
particularly a test that is becoming more widely used.  There are no standardised 
guidelines on severity grading of mannitol challenge as there are for methacholine20, 
and more recently for FeNO212, from the American Thoracic Society.  Therefore, our 
objective was to further explore the relationships of mannitol AHR with other markers 
of inflammation in asthma, as well as methacholine challenge, by using cut-off values 
to help describe AHR to mannitol as mild, moderate or severe in addition to how 
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these groups relate to previously reported cut-off values for both FeNO212 and 
methacholine challenge277.  We also examined the relationship between these 
mannitol grades and salivary eosinophilic cationic protein (ECP) as a further 
surrogate marker of allergic inflammation in persistent asthma. 
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METHODS 
 
We performed analysis of data from patients who attended the Asthma and Allergy 
Research Group for screening prior to a clinical trial6 who had a diagnosis of mild to 
moderate persistent asthma, all of whom were regularly taking inhaled corticosteroids, 
and had either or both mannitol and methacholine challenges performed within a 1 
week period.  Each individual had given their consent for their information to be held 
in our database and used for research purposes.  Tayside Medical Research Ethics 
Committee granted ethical approval. 
 
Patients either had a mannitol or methacholine challenge performed at screen along 
with spirometry, exhaled tidal nitric oxide levels, skin prick testing, salivary ECP 
quantification, and demographic data including: age, gender, smoking status and ICS 
dose.  Patients who had both challenges performed as part of their screening process 
had the second challenge within 1 week of the initial visit because this could not be 
performed at the same time as the initial challenge.  Patients were required to have a 
baseline forced expiratory volume in 1s (FEV1) ≥60% predicted to ensure safety 
during both bronchial challenge tests as per our departmental policy. 
 
Groups were generated based on AHR to mannitol PD10 (cumulative provocative dose 
required to produce a 10% fall in FEV1) with cut-off values in line with specific dose 
increments (mild: 315-635mg; moderate: 75-315mg; severe: 0-75mg); and to 
methacholine provocative concentration of methacholine required to cause a 20% fall 
in FEV1 (PC20) (mild: 2-8mg/ml; moderate: 0.5-2mg/ml; severe: 0-0.5mg/ml) – these 
are related to a previous study we performed using these cut-off values277 and are 
closely related to but not exactly the same as the ATS severity levels20.  We also 
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grouped FeNO as per the recent ATS guidelines (low: <25ppb; medium: 25-50ppb; 
high: >50ppb)212.  The lower limit of each group comprised exact numbers; the exact 
number for the upper limit belonged to the next highest group. 
 
We used mannitol PD10 rather than PD15 (which is the standard measurement in 
diagnosis for steroid-naïve patients) for several reasons.  PD10 provided a greater 
number of responsive patients (i.e. below 635mg) in order that we could more 
accurately assess correlations between the different measurements.  Moreover, these 
were patients already on inhaled corticosteroids; therefore, we believed there would 
be a greater signal using PD10 over PD15 for these patients – indeed in the STAMINA 
study6 mannitol PD10 was used a priori as the experimental method of ICS dose 
titration showing benefits on exacerbations and other outcomes.  To validate this 
method, we have performed a correlation between mannitol PD10 to PD15 (for those 
patients who reached this) in this cohort. 
 
Study measurements 
Mannitol challenge was performed217 with a dry powder inhaler (Aridol Pharmaxis 
Ltd, Sydney, Australia) using increments up to a maximum cumulative dose of 
635mg.  The PD10 was calculated by interpolation of the log-linear dose-response 
curve.  Results from patients who did not respond to mannitol by failing to reach a 
PD10 at the highest cumulative dose, i.e. censored at >635mg, were imputed to 
1270mg (double the maximum dose) for statistical purposes.  A SuperSpiro 
spirometer (Micro Medical Ltd., Chatham, Kent, UK) was used to perform spirometry 
in accordance with European Respiratory Society (ERS) guidelines216. Methacholine 
was dispensed via a nebulised solution of methacholine (Tayside Pharmaceuticals, 
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Dundee, UK), and the challenge was performed in accordance with American 
Thoracic Society (ATS) guidelines20. A Mefar dosimeter was used with doubling 
concentrations from 0.03 to 32 mg/ml. The PC20 was then calculated.  FeNO was 
performed using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, 
Sweden) at 50 ml/s in accordance with the published guidelines22. Skin prick testing 
with eight common aeroallergens (Merck, Middlesex, UK) was performed.  Salivary 
eosinophilic cationic protein (ECP) was quantified in duplicate using an enzyme 
linked immunoassay technique (UniCAP; Sweden Diagnostics UK Ltd, Milton 
Keynes, UK) with an intra-assay co-efficient of variation of 3.3% and inter-assay co-
efficient of variation of 4%. 
 
Statistical analysis 
All data were checked for normality of distribution prior to analysis.  Any non-
Gaussian data were logarithmically transformed to achieve normality prior to 
analysis.  Any data that could not achieve a normal distribution with transformation 
were analysed using the equivalent non-parametric statistical tests.  Primary analysis 
was based on comparisons of the categories for severity of mannitol AHR, as well as 
methacholine AHR and FeNO groups, against outcome variables using an overall 
ANOVA for multiple means comparisons (or independent samples Kruskal-Wallis 
test for non-parametric outcome variables).  Confirmatory analyses were performed 
using Pearson’s and Spearman’s correlations (parametric and non-parametric 
variables respectively) for mannitol PD10, methacholine PC20, and FeNO all as 
continuous variables, with each other, as well as salivary ECP, smoking status, 
inhaled corticosteroid dose, age, gender, and number of positive skin prick tests.  
SPSS version 18.0 (SPSS Inc., Chicago, IL) was used for all analyses.  
153 
	 	
RESULTS 
 
143 patients with a physician diagnosis of persistent asthma were identified for this 
study from our records.  134 patients had a mannitol challenge of which 123 patients 
(92%) had a positive response with a mannitol PD10≤635mg.  111 patients had a 
methacholine challenge performed of which 99 patients (89%) responded positively 
with a PC20≤8mg/ml.  100 patients had both mannitol and methacholine challenges 
performed of which 87% were positive to both at the levels described above.  Mean 
age was 53.7years, 51% were female.  79% of patients with skin prick tests were 
positive.  Patients had well preserved lung function with mean FEV1 85.7% predicted.  
Mean ICS dose as BDP equivalent was 345µg/day (95% CI: 310, 379).  All 
demographic variables can be seen in Table 15. 
 
Table 15.  Baseline demographics. 
Variable N=143 
Age (years) 53.7 (51.3, 56.1) 
Gender (Female %) 51.0 
Smoking Status (yes, no, %) 3.5, 96.5 
FEV1 (L) 2.5 (2.39, 2.61) 
FEV1 (% predicted) 85.7 (83.1, 88.3) 
ICS Dose (µg/day) 345 (310, 379) 
Mannitol PD10* (mg, n=134) 137.6 (108.2, 175.0) 
FeNO* (ppb) 26.2 (22.6, 30.5) 
Meth PC20* (mg/ml, n=111) 1.19 (0.8, 1.78) 
ECP* (µg/L) 14.4 (11.5, 17.9) 
 
Data presented as arithmetic mean with 95% confidence intervals unless stated.  *Geometric 
mean with 95% confidence intervals. FEV1=forced expiratory volume in 1 second.  
ICS=inhaled corticosteroid as beclometasone dipropionate equivalent dose.  
PD10=provocative dose of mannitol causing 10% fall in FEV1.  FeNO=fractional exhaled 
nitric oxide.  ppb=parts per billion.  Meth PC20 =methacholine provocative concentration 
causing 20% fall in FEV1.  ECP=Salivary eosinophilic cationic protein. 
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Categorical Analysis by Mannitol AHR 
There were significant overall differences between mannitol PD10 groups for FeNO 
levels (p=0.023) with FeNO rising across the 3 groups from ‘mild’ through to ‘severe’ 
mannitol AHR (Table 16, Figure 17).  FeNO levels were 43.5% (95% CI: 14.9, 62.5) 
higher in the severe mannitol AHR group than in the mild group.  There were also 
significant differences across mannitol groups for methacholine PC20 (p=0.006) with 
greater AHR to methacholine demonstrated from mild through to severe mannitol 
AHR (Table 16, Figure 17) – there was a 2.09 (95% CI: 0.58, 3.60) doubling dilution 
reduction in methacholine PC20 between mild and severe mannitol groups.  There 
were no significant differences between mannitol AHR groups for: salivary ECP 
(Table 16, Figure 17); number of positive skin prick tests; FEV1 %predicted (Table 
16, Figure 17); or ICS dose (Table 16). 
 
Table 16.  Mannitol groups. 
Mannitol PD10 (mg) Mild 
(315-635) 
Moderate 
(75-315) 
Severe 
(0-75) 
P-value 
FeNO (ppb) 20.4 (15.5, 27.0) 24.7 (19.0, 32.2) 36.1 (26.7, 48.8)** 0.023† 
Meth PC20 (mg/ml) 1.98 (1.15, 3.41) 1.20 (0.79,1.83) 0.47 (0.20, 1.06)*** 0.006† 
ECP (µg/L) 12.5 (7.8, 19.9) 14.8 (10.1, 21.8) 14.1 (9.0, 22.1) 0.842† 
FEV1* (% predicted) 88.7 (83.3, 94.2) 84.1 (79.5, 88.7) 83.9 (78.7, 89.0) 0.350† 
ICS dose* (µg/day) 382 (305, 461) 333 (280, 386) 355 (282, 428) 0.495‡ 
 
Data presented as geometric mean with 95% confidence intervals in parenthesis unless stated.  
*Arithmetic mean (95% confidence intervals). FEV1=forced expiratory volume in 1 second.  
ICS=inhaled corticosteroid as beclometasone dipropionate equivalent dose.  
PD10=provocative dose of mannitol causing 10% fall in FEV1.  FeNO=fractional exhaled 
nitric oxide.  ppb=parts per billion.  Meth PC20 =methacholine provocative concentration 
causing 20% fall in FEV1.  ECP=Eosinophilic cationic protein.  †Means comparison with 
overall analysis of variance (ANOVA).  ‡Comparison of distributions with independent 
samples Kruskal-Wallis test.  **p<0.05 pairwise comparison (after Bonferroni correction) to 
mild group.  ***p<0.01 pairwise comparison (after Bonferroni correction) to mild group.  
Significance set at p<0.05 for all analyses. 
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Figure 17.  Mannitol PD10 airway hyper-responsiveness groups. 
Versus: FeNO (top left); Methacholine PC20 (top right); Forced Expiratory Volume in 1 
second (FEV1) as % of predicted (bottom left); and salivary ECP (bottom right).  Data 
presented as geometric means with 95% confidence error bars for FeNO, Meth PC20 and ECP.  
FEV1 data presented as arithmetic means with 95% confidence error bars.  *ANOVA 
comparisons with significance at p<0.05.  PD10=provocative dose (of mannitol) causing 10% 
fall in FEV1.  FeNO=fractional exhaled nitric oxide.  Meth PC20=provocative concentration 
(of methacholine) causing 20% fall in FEV1.  ECP=Eosinophilic cationic protein.  ppb=parts 
per billion. 
 
 
Categorical Analysis by Exhaled Nitric Oxide 
There were significant overall differences between FeNO groups for mannitol PD10 
(p=0.01) with a reduction in mannitol AHR as FeNO levels reduced (Table 17, Figure 
18).  There was a 1.14 (95% CI: 0.31, 1.97) doubling dose increase in mannitol PD10 
between highest FeNO (>50ppb) and lowest FeNO (<25ppb) groups.  Also there were 
significant differences across FeNO groups for methacholine PC20 (p=0.029) with a 
2.08 (95% CI: 0.60, 3.55) doubling dilution increase in PC20 between highest 
(>50ppb) and lowest (<25ppb) FeNO groups (Table 17, Figure 18).  There were no 
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significant differences between FeNO groups for: salivary ECP (Table 17, Figure 18); 
number of positive skin prick tests; FEV1 %predicted (Table 17, Figure 18); or ICS 
dose (Table 17). 
 
Table 17.  Fractional exhaled nitric oxide groups. 
FeNO Grade (ppb) Severe 
>50 
Moderate 
25-50 
Mild 
<25 
p-value 
Mannitol PD10 (mg) 80 (49, 131) 199 (122, 324)** 177 (126, 248)** 0.01† 
Meth PC20 (mg/ml) 0.49 (0.27, 0.89) 1.23 (0.47, 3.25) 2.09 (1.08, 4.03)** 0.029† 
ECP (µg/L) 12.3 (7.4, 20.5) 12.7 (7.6, 21.2) 21.0 (15.0, 29.4) 0.106† 
FEV1* (% predicted) 86.5 (80.7, 92.3) 85.0 (78.6, 91.5) 86.3 (82.6, 90.1) 0.922† 
ICS dose* (µg/day) 299 (242, 356) 355 (283, 426) 367 (311, 423) 0.392‡ 
 
Data presented as geometric means (95% confidence intervals) unless stated.  *Arithmetic 
mean (95% confidence intervals).  FEV1=forced expiratory volume in 1 second.  ICS=inhaled 
corticosteroid as beclometasone dipropionate equivalent dose.  PD10=provocative dose of 
mannitol causing 10% fall in FEV1.  FeNO=fractional exhaled nitric oxide.  ppb=parts per 
billion.  Meth PC20 =methacholine provocative concentration causing 20% fall in FEV1.  
ECP=Eosinophilic cationic protein.  †Means comparison with overall analysis of variance 
(ANOVA).  ‡Comparison of distributions with independent samples Kruskal-Wallis test.  
**p<0.05 pairwise comparison (Bonferroni correction) to severe group.  Significance set at 
p<0.05 for all analyses. 
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Figure 18.  FeNO airway inflammation groups. 
Versus: Mannitol PD10 (top left); Methacholine PC20 (top right); Forced Expiratory Volume in 
1 second (FEV1) as % of predicted (bottom left); and salivary ECP (bottom right).  Data 
presented as geometric means with 95% confidence error bars for Mannitol PD10, Meth PC20 
and ECP.  FEV1 data presented as arithmetic means with 95% confidence error bars.  
*ANOVA comparisons with significance at p<0.05.  PD10=provocative dose (of mannitol) 
causing 10% fall in FEV1.  FeNO=fractional exhaled nitric oxide.  Meth PC20=provocative 
concentration (of methacholine) causing 20% fall in FEV1.  ECP=Eosinophilic cationic 
protein.  ppb=parts per billion. 
 
 
Categorical Analysis by Methacholine AHR 
There were significant overall differences between methacholine AHR groups for 
mannitol PD10 (p<0.001) with mannitol AHR reducing as methacholine AHR reduced 
(Table 18, Figure 19).  There was a 2.07 (95% CI: 1.19, 2.95) doubling dose increase 
in mannitol PD10 between severe (<0.5mg/ml) through to mild (2-8mg/ml) 
methacholine AHR groups.  There was also a significant difference across 
methacholine AHR groups for FeNO levels (p=0.005) with FeNO reducing as 
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methacholine AHR reduced with a 51.6% (95% CI: 23.4, 69.4) reduction in FeNO 
levels between severe and mild methacholine AHR groups (Table 18, Figure 19).  
There were no significant differences between methacholine AHR groups for: salivary 
ECP (Table 18, Figure 19); number of positive skin prick tests; FEV1 %predicted 
(Table 18, Figure 19); or ICS dose (Table 18). 
 
Table 18.  Methacholine groups. 
Meth PC20 Grade 
(mg/ml) 
Severe 
<0.5 
Moderate 
0.5-2 
Mild 
>2-8 
P-value 
Mannitol PD10 (mg) 57 (35, 92) 147 (89, 242)** 239 (161, 354)*** <0.001† 
FeNO (ppb) 38.7 (28.5, 52.4) 25.1 (19.1, 32.9) 18.7 (13.2, 26.6)*** 0.005† 
ECP (µg/L) 13.0 (8.3, 20.3) 19.3 (11.6, 32.3) 12.1 (7.1, 20.8) 0.354† 
FEV1* (% predicted) 87.1 (82.2, 92.0) 86.4 (81.6, 91.1) 89.5 (83.9, 95.2) 0.677† 
ICS dose* (µg/day) 314 (246, 382) 312 (266, 358) 390 (301, 479) 0.152‡ 
 
Data presented as geometric means (95% confidence intervals) unless stated.  *Arithmetic 
mean (95% confidence intervals). FEV1=forced expiratory volume in 1 second.  ICS=inhaled 
corticosteroid as beclometasone dipropionate equivalent dose.  PD10=provocative dose of 
mannitol causing 10% fall in FEV1.  FeNO=fractional exhaled nitric oxide.  ppb=parts per 
billion.  Meth PC20 =methacholine provocative concentration causing 20% fall in FEV1.  
ECP=Eosinophilic cationic protein.  †Means comparison with overall analysis of variance 
(ANOVA).  ‡Comparison of distributions with independent samples Kruskal-Wallis test.  
**p<0.05 pairwise comparison (Bonferroni correction) to severe group.  ***p<0.01 pairwise 
comparison (Bonferroni correction) to severe group.  Significance set at p<0.05 for all 
analyses. 
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Figure 19.  Methacholine PC20 airway hyper-responsiveness groups. 
Versus: Mannitol PD10 (top left); FeNO (top right); Forced Expiratory Volume in 1 second 
(FEV1) as % of predicted (bottom left); and salivary ECP (bottom right).  Data presented as 
geometric means with 95% confidence error bars for Mannitol PD10, FeNO and ECP.  FEV1 
data presented as arithmetic means with 95% confidence error bars.  *ANOVA comparisons 
with significance at p<0.05.  PD10=provocative dose (of mannitol) causing 10% fall in FEV1.  
FeNO=fractional exhaled nitric oxide.  Meth PC20=provocative concentration (of 
methacholine) causing 20% fall in FEV1.  ECP=Eosinophilic cationic protein.  ppb=parts per 
billion. 
 
 
Continuous Data Analysis 
Modest significant correlations were found between mannitol PD10 as a continuous 
variable versus FeNO (r=-0.209, p=0.025), (Figure 20a) and versus methacholine 
PC20 (r=0.463, p=<0.001), (Figure 20b).  There were also significant correlations 
between methacholine PC20 versus FeNO (r=-0.367, p<0.001) and methacholine PC20 
versus ICS dose (r=0.282, p=0.005).  Salivary ECP also correlated with number of 
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skin prick tests (r=0.389, p=0.003).  There were no other significant correlations of 
mannitol PD10, FeNO or methacholine PC20 with any remaining variables. 
 
Figure 20.  Correlations between (a) Mannitol PD10 vs. FeNO and (b) Mannitol 
PD10 vs. Methacholine PC20. 
Analysis with Pearson’s test following logarithmic transformation of all variables.  Solid line 
represents line of identity with interrupted lines 95% confidence intervals. 
 
There was a very strong correlation between mannitol PD10 and mannitol PD15 (in 
those patients who also demonstrated this greater degree of mannitol AHR, i.e. 
provocative dose of mannitol causing 15 % fall in FEV1), Figure 21. 
 
Figure 21.  Correlation between mannitol PD10 and PD15 in subgroup with both 
values. 
Analysis with Pearson’s test following logarithmic transformation of both variables.  Solid 
line represents line of identity with interrupted lines 95% confidence interval. r = correlation 
coefficient.  R2 = goodness of fit of line of identity.  Significance set at p<0.05. 
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DISCUSSION 
 
This study has sought to categorise the response to mannitol bronchial challenge in 
relation to other measures of allergic inflammation, and to direct AHR measurement 
using standard methacholine challenge in patients taking ICS for persistent asthma. 
 
We have found that mannitol AHR grouped by PD10, showed significant relationships 
with both FeNO levels and methacholine PC20.  The corollary was also true - in that 
previously described groupings for FeNO212 and methacholine PC20277 were both 
significantly related to mannitol PD10 in our cohort.  These significant correlations 
also remained when all three measures (mannitol PD10, FeNO and methacholine PC20) 
were analysed as continuous variables.  This clearly demonstrates that mannitol 
bronchial challenge is related to both classical hallmarks of clinical asthma, i.e. 
airway inflammation (FeNO) and AHR (methacholine).  Furthermore, the magnitudes 
of differences between our mild and severe mannitol groups for these outcome 
variables were clinically relevant - a 2.1 doubling dilution difference for methacholine 
PC20, and a 43% difference in FeNO.  Pointedly such differences were seen despite 
patients taking concomitant ICS therapy, suggesting that patients may not need to stop 
their ICS prior to mannitol challenge. 
 
Despite finding a significant relationship between our mannitol AHR groups and 
FeNO, which is a non-specific measure of whole lung inflammation, there were no 
such relationships between our mannitol groups with salivary ECP, also used to 
reflect the allergic inflammatory process in asthma.  One explanation for the 
disconnect between mannitol and salivary ECP could be current inhaled corticosteroid 
use.  It may be that salivary ECP is much more responsive to low doses of ICS than 
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FeNO, meaning that ECP reaches a much earlier plateau in response than other 
markers.  This theory is supported by the absolute values for salivary ECP in our 
cohort, which were rather low compared to other studies that used this as a biomarker 
of asthma278,279.  It may also be that salivary ECP does not correlate with ECP in 
sputum from the airways280. 
 
It has previously been shown that FeNO bears a stronger correlation to mannitol than 
it does to methacholine131 in steroid naïve asthmatics.  Whilst we have demonstrated a 
correlation between FeNO and mannitol, the correlation between FeNO and 
methacholine is stronger in the present study, which may be due to FeNO suppression 
with ICS.  However, despite the expectation that ICS would suppress FeNO even at 
relatively low doses221, it seems that FeNO still provides a signal of airway 
inflammation on ICS, albeit this is attenuated.  We have previously reported a 
relationship between methacholine and FeNO in a population of asthmatics with 
different demographics277 than reported here, and reassuringly the results are similar 
in this regard. 
 
Our study also confirms that measurement of airway calibre (as pulmonary function) 
in mild to moderate asthmatics is not useful in determining degree of severity of the 
underlying airway inflammation and hyper-responsiveness, with no correlation found 
between FEV1 (% predicted) or any of mannitol AHR, FeNO, or methacholine AHR.  
The main reason for this is that FEV1 tends to be well preserved in mild to moderate 
asthmatics as we have once again demonstrated in our cohort. 
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Previous studies have shown that mannitol AHR correlates both with FeNO and 
methacholine131,275.  Indeed mannitol is almost equivalent in terms of its sensitivity 
and specificity for diagnosing asthma as methacholine275.  Given the relationships we 
have also found, one wonders if mannitol should be the initial screening investigation 
of choice, particularly since current standard screening employs spirometry, yet 
mannitol challenge is a simple and relatively inexpensive challenge test that clearly 
bears more relation to the hallmarks of asthma than spirometry for mild to moderate 
patients.  Previously, mannitol PD15 has been the standard used as the diagnostic cut-
off for this challenge.  However, not only have we demonstrated a strong significant 
correlation between mannitol PD10 and PD15 (in the subgroup of patients who reached 
this), it is possible that ‘stratifying’ asthmatic patients already on ICS may be more 
accurately performed with PD10. 
 
The strengths of this study are the prospectively collected, ‘real life’, screening data 
of mild to moderate asthmatics on doses of ICS that accurately reflect community 
prescribing practices.  The size of our cohort was moderately large, presenting us with 
a good cross-section of asthmatic patients.  There were very few current smokers 
(3.4%) making confounding of our findings from this source unlikely.  A limitation of 
this study could be our reliance on patient reporting about compliance to their ICS 
therapy prior to screening.  In addition to this we had no joint mannitol/methacholine 
screening data on patients who were not taking ICS, which would have been helpful 
given that mannitol challenge could be considered a de novo diagnostic test.  
However, what we have shown confirms that mannitol challenge is important when it 
comes to monitoring disease control given its relation to the hallmarks of asthma, 
once it has been diagnosed.  Finally, other easier to measure biomarkers of underlying 
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inflammation may be equally or more useful in stratifying asthma.  For example 
serum high sensitivity C-reactive protein has been shown to correlate well with both 
FeNO and serum ECP in steroid naïve asthmatics, and it is also present in much 
higher levels in unstable asthma281.  However, this test was not part of our battery of 
screening tests at the time of collecting this data. 
 
In conclusion, we have identified categories of mannitol AHR which are correlated to 
airway inflammation as measured by FeNO as well as to direct AHR using 
methacholine challenge in mild to moderate persistent asthmatics currently taking 
inhaled corticosteroids.  This might provide a useful guide to gauge the degree of both 
airway inflammation and airway hyper-responsiveness in persistent asthmatics.  We 
also found that mannitol AHR is not associated with salivary ECP or to airway calibre 
in mild to moderate asthmatics.  These findings help to add weight to the argument 
that mannitol challenge is related to local airway allergic inflammation and hyper-
responsiveness in persistent asthma.  However, further prospective studies using these 
categories for mannitol AHR (as PD10) compared to other outcome measures of 
asthma are warranted, such as exacerbations or asthma control, including those 
patients on higher doses of inhaled corticosteroids. 
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CHAPTER 7:   
INHALED 
CORTICOSTEROID 
DOSE RESPONSE IN 
ASTHMA: SHOULD WE 
MEASURE 
INFLAMMATION? 
 
 
Study aims: 
1. To compare dose response relationships of ICS between measures of 
pulmonary function, symptoms and inflammation in persistent asthmatics. 
2. To compare these ICS dose response relationships using common dose 
ramps of ICS. 
3. To identify where ICS dose titration provides the greatest impact for a 
given individual’s treatment in order to achieve optimal asthma control. 
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ABSTRACT 
 
Background 
Inhaled corticosteroid (ICS) titration in asthma is primarily based on symptoms and 
pulmonary function.  ICS may not be increased on this basis despite residual airway 
inflammation. 
 
Objective 
To compare the dose-response relationships of ICS on measures of pulmonary 
function, symptoms and inflammation in persistent asthmatics. 
 
Methods 
We performed a pooled post-hoc analysis of 121 patients with mild-moderate asthma, 
from four randomised controlled trials that incorporated an ICS dose ramp.  Dose 
ramps were: 0-200µg/day, 0-800µg/day, 200-800µg/day (beclomethasone 
equivalents).  Outcome measures included: spirometry, fractional exhaled nitric oxide 
(FeNO), airway hyper-responsiveness (AHR), symptoms, serum eosinophilic cationic 
protein (ECP), and blood eosinophils (Eos). 
 
Results 
We found a plateau beyond a small improvement at 0-200µg for forced expiratory 
volume in 1s (FEV1, %predicted): 0-200µg, 3.3% (95%CI: 2.0,4.7) vs. 200-800µg, 
0.3% (95%CI: -0.8,1.4), P=0.001.  A similar plateau was seen for symptom 
improvement beyond 0-200µg.  Inflammatory and AHR outcomes showed further 
room for improvement beyond low dose ICS. There was dose related suppression 
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(P<0.0001) for FeNO: ICS free, 40.4ppb (95%CI: 34.7,46.9); 200µg, 26.8ppb (95%CI 
23.4,30.2); 800µg, 20.8ppb (95%CI: 18.8,23.1).   ECP was significantly reduced with 
both higher dose ramps.  Eos also improved across all three dose ramps, with dose 
separation between ICS free, 370cells/µL (95%CI: 280,450), vs. 800µg, 250cells/µL 
(95%CI: 200,300), P=0.03.  AHR improved with all three dose ramps, with greater 
improvement at lower doses for indirect versus direct challenges. 
 
Conclusion 
ICS dose-response extends beyond low dose for inflammation and AHR, but not 
symptoms or spirometry.  Further study is required to identify whether this correlates 
with sub-optimal longitudinal asthma control. 
 
Ethics references:  NFB/FB/192/0311, 09/S0501/5223, 11/ES/003125, 08/S1402/1424 
ClinicalTrials.gov references:  NCT00667992, NCT00995657, NCT01216579, 
NCT01544634. 
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INTRODUCTION 
 
Asthma is a heterogeneous chronic inflammatory disease of global importance16, 
which places a significant burden both on individual patients and on health care 
services, where many patients remain inadequately treated30,31 with an ongoing 
attendant mortality25.  The concept of achieving ‘total asthma control’10 is important 
for reducing the future risk of exacerbations28,29,46.  It is therefore imperative that we 
have robust procedures for accurate diagnosis, measurement of severity, prediction of 
future risk, along with appropriate personalised treatments to achieve this goal.  
Nevertheless, present guidelines for the identification and treatment of asthma merely 
include symptoms and lung function measurements10,11.  The Royal College of 
Physicians’ recent National Review of Asthma Deaths report25 found that only 39% of 
patients who died were actually labelled as having ‘severe’ asthma according to 
current guidelines, with the remainder therefore labelled as ‘mild’ or ‘moderate’, 
suggesting we may not be accurately identifying those at greatest risk. 
 
Measurement of inflammatory outcomes has significantly improved the management 
of asthma, evolving personalised treatment.  Studies have consistently shown that 
titrating steroid therapy against inflammation improves outcomes such as 
exacerbation rates6,14,15. Green et al demonstrated this by titrating steroid treatment 
against sputum eosinophil counts, resulting in significantly fewer severe 
exacerbations compared to standard guideline driven treatment14. 
 
Price et al demonstrated retrospectively, in a primary care cohort, that those with 
higher blood eosinophil counts fared worse in terms of experiencing more severe 
exacerbations and poorer asthma control77.  Moreover, eosinophilic inflammation may 
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be masked when using a long-acting beta-2 agonist (LABA) as a steroid-sparing 
agent282,283.  Sputum and blood eosinophilia in asthma have both been separately 
shown to predict loss of asthma control and increased exacerbation rates46,76,151.  This 
is also true of fractional exhaled nitric oxide (FeNO) levels155 and airway hyper-
responsiveness (AHR)46, the latter being largely driven by airway inflammation131. It 
is therefore logical that one might wish to control inflammation over and above 
simply controlling symptoms and lung function – much like controlling asymptomatic 
hypertension to prevent subsequent cardiovascular sequelae.  This is relevant given 
lung function and lack of symptoms may be deemed normal despite the possibility of 
an ongoing underlying inflammatory process39. 
 
We performed a post-hoc pooled analysis of data from four previously published 
randomised controlled trials (RCTs) where inhaled corticosteroid (ICS) dose titration 
was used in a prospective manner.  Outcome measurements included symptoms, lung 
function, inflammation and AHR.  We then analysed the dose-response relationship to 
ICS for these outcomes to identify where incremental ICS dosing provides the 
greatest impact, and thus likely to be most informative when titrating a given 
individual’s treatment to achieve optimal asthma control. 
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METHODS 
 
Patients 
Male and female mild-moderate persistent asthmatics aged 18-65 years receiving 
≤1000µg/day ICS, i.e. expressed as a reference dose of large particle beclomethasone 
dipropionate (BDP) equivalent dose, were recruited to each of four RCTs1,2,5,6.  For 
example, large particle HFA-fluticasone 200ug or small particle HFA-
beclomethasone 200ug would be equivalent to large particle HFA-BDP 400ug.  Their 
post-run-in baseline measurements are presented in Table 19.  Further detailed 
inclusion and exclusion criteria can be found in each of the reported trials. 
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Table 19.  Baselines post run-in. 
Study 
Baselines 
All 
n=121 
FP 
(ICS Free) 
n=21 
Bud 
(ICS free) 
n=72 
HFA-BDP 
(200µg BDP) 
n=16 
CIC 
(200µg BDP) 
n=12 
Age (yr) 39.8 
(37.2,42.4) 
36.8 39.6 37.8 48.7 
Sex (M:F) 44:77 6:15 29:43 6:10 3:9 
FEV1 (% pred) 85.1 
(82.9,87.3) 
88.5 82 90.3 89 
FEF25-75 (% 
Pred) 
65.7 
(61.5,69.8) 
53.5 70.4 60.3 - 
FEV1/FVC 
ratio (%) 
75.2 
(73.7,76.7) 
71.2 75.6 74.6 80.5 
FeNO (ppb)* 37.3 
(32.3,42.6) 
72.4 34.7 29.1 25.4 
(n=10) 
AHR* - 102mg 
(57,183) 
Mann PD15 
0.72 mg/ml 
(0.58,0.90) 
Meth PC20 
1.31mg/ml 
(0.64,2.69) 
Hist PC20 
59mg 
(15,233) 
Mann PD10 
ECP (µg/L)* 
(n=47) 
20.5 
(15.9,26.3) 
18.6 - 22.4 21.9 
Eos (cells/µL) 
(n=37) 
330 
(280,390) 
370 - 290 - 
Symptom 
Score 
- 5.8 
(5.4,6.2) 
0.96¶ 
(0.79,1.12) 
6.2 
(5.9,6.5) 
6.1 
(5.6,6.5) 
Screening ICS 
(BDP, µg/day) 
420 
(361,479) 
440 414 406 436 
 
Baselines post run-in at the given beclomethasone dipropionate (BDP) equivalent doses for: 
large-particle hydrofluoroalkane (HFA)-fluticasone propionate (FP), large-particle HFA-
budesonide (Bud), small-particle HFA-beclomethasone (HFA-BDP), and small-particle HFA-
ciclesonide (CIC).  Overall means (95%CI), leftmost column.  Arithmetic means (95%CI), 
unless stated.  *Geometric mean (95%CI).  Symptom scores are the symptom component of 
the mini-AQLQ, except Bud. ¶Total Symptom Score: 0-no symptoms; 1-mild; 2-moderate; 
and 3-severe. 
 
 
Study Design 
We performed a post-hoc analysis using data from 4 RCTs1,2,5,6, each comprising a 
component where ICS dose ramp effects were examined on a variety of outcomes 
including: spirometry, FeNO, AHR including both indirect (mannitol) and direct 
(methacholine, histamine) challenges, asthma symptoms, serum eosinophilic cationic 
protein (ECP), and blood eosinophil count (Eos).  Briefly, one study used large 
particle hydrofluoroalkane (HFA)-fluticasone propionate (FP) using FeNO as the 
primary outcome1: with an ICS-free run-in, followed by either 200µg or 800ug BDP 
172 
	 	
equivalent.  A second study titrated small particle HFA-ciclesonide against mannitol 
AHR versus titration using standard British Thoracic Society (BTS) guidelines6: 
patients were selected from both arms of this study where there was an appropriate 
dose ramp (i.e. BDP equivalent 200-800µg/day).  A third study used methacholine 
AHR as the primary outcome comparing large particle (HFA) and chlorofluorocarbon 
(CFC) formulations of budesonide2: within the HFA arm there was an ICS free 
washout followed by 200µg/day or 800ug/day BDP equivalent.  The fourth study 
examined whether propranolol was useful as an ICS sparing agent5, with histamine 
AHR the primary outcome: the control arm was effectively a dose ramp between 
small particle HFA-beclomethasone at BDP equivalent doses of 200µg/day or 
800ug/day. 
 
Measurements 
Extended detail of measurements can be found in each parent study.  Briefly, 
spirometry was measured using a SuperSpiro spirometer (Micro Medical Ltd.) 
according to American Thoracic Society (ATS) guidelines123.  Exhaled tidal nitric 
oxide was measured according to ATS recommendations22 using a NIOX analyser 
(NIOX® Nitric Oxide Monitoring System, Aerocrine AB) prior to other pulmonary 
function measures.  Mannitol challenge was performed as previously described217 
with a dry powder inhaler (Aridol; Pharmaxis Ltd) using cumulative dose increments 
up to 635 mg.  Histamine for bronchial challenge was dispensed via nebulized 
solution with doubling concentrations of histamine from 0.3125mg/ml to 40mg/ml.  
Methacholine challenge was performed using the five-breath dosimeter technique in 
accordance within ATS recommendations20. Peripheral blood eosinophils were 
measured using the Sysmex XE2100 Hematology auto-analyser. Serum ECP was 
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measured in duplicate using a UniCAP system (Phadia) with a coefficient of variation 
of 3%.  For symptoms, 3 studies1,5,6 included the mini-Asthma Quality of Life 
Questionnaire (AQLQ, symptom component), where a mean score of 7 indicates no 
symptoms, and <7 indicates progressively worse symptoms.  In the fourth study2, the 
following rating scales were used: 0, no asthma symptoms; 1, mild symptoms (easily 
tolerable); 2, moderate symptoms (interferes with normal activities/sleep); and 3, 
severe (prevents normal activities/ sleep).  The total asthma symptom score was a 
mean of both morning and evening symptom scores.  
 
Statistical Analysis 
All data were initially assessed for normality of distribution, with non-Gaussian 
distributions logarithmically transformed to enable parametric analyses.  For the 
primary analyses, examining for any change within a given outcome measure 
following an ICS dose ramp, arithmetic means of the difference within each ICS dose 
ramp were calculated for outcomes with the same parametric measure across all 4 
studies.  Geometric mean fold differences were calculated for changes in outcomes 
that were either non-parametric, or with different measurements between the studies 
in order to standardize any changes (e.g. bronchial challenges).  Analyses of variance 
(ANOVA) with Bonferroni correction were also used to compare the differences 
between dose ramp responses, and each individual dose mean.  Statistical significance 
for all comparisons was set at P<0.05.  IBM SPSS version 22 was used for the 
statistical analyses.  
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RESULTS 
 
We included 121 evaluable participants from the parent studies (Table 19).  
Ciclesonide patients were approximately 10 years older.  Patients had generally 
preserved pulmonary function, overall mean FEV1 85.1% predicted, and had mild 
symptoms.  FeNO was higher in the Fluticasone group due to the inclusion criteria of 
that study.  Despite the different bronchial challenges, their figures all indicated a 
moderate-severe degree of AHR.  Patients had been receiving similar ICS doses prior 
to study inclusion, mean 420µg/day BDP equivalent. 
 
For pulmonary function, there were small but statistically significant changes seen 
within the 0-200µg dose ramp for both FEV1 and FEF25-75 (Table 20, Figure 22), with 
a 3.3% (95%CI 2.0,4.7) rise in FEV1 (P<0.0001), and 4.6% (95%CI 2.4,6.9) rise in 
FEF25-75 (P<0.0001).  However, there was a plateau in response at 200-800µg for both 
these measures.  There were also statistically significant within-group improvements 
for symptom scores (Figure 22) at all dose ramps, but with less improvement within 
the 200-800ug dose ramp: along with a significant difference (P=0.01) when 
comparing responses between 0-800µg vs. 200-800µg, i.e. again indicating a plateau 
in response. 
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Table 20.  Pulmonary function and inflammatory outcomes. 
ICS BDP 
(µg/day) 
ICS Free 
(a) 
200ug 
(b) 
800ug 
(c) 
P-value 
(ANOVA) 
 
Pulmonary Function 
FEV1 (% pred) 83.4 
(81.0,85.9) 
87.6§ 
(85.4,89.9) 
87.9§ 
(86.0,89.9) 
0.01 
FEF25-75 (% pred) 66.6 
(62.0,71.2) 
69.6 
(65.7,73.5) 
70.0 
(66.1,73.8) 
0.47 
 
Inflammatory Outcomes 
FeNO (ppb)* 40.4 
(34.7,46.9) 
26.8♯ 
(23.4,30.2) 
20.8♯¶ 
(18.8,23.1) 
<0.0001 
ECP (µg/L)* 18.7 
(12.1,28.8) 
20.2 
(15.3,26.5) 
13.2 (9.9,17.4) 0.08 
Eos (cells/µL) 370 (280,450) 300 (240,350) 250§ (200,300) 0.04 
 
Data presented as arithmetic means (95% confidence intervals) unless otherwise stated. 
*Geometric mean (95% CI).  §P<0.05 vs. (a).  ¶ P=0.01 vs. (b). ♯P<0.001 vs. (a). 
 
 
 
Figure 22.  Dose responses for FEV1 and symptom scores. 
(a) mean percentage changes (95%CI error bars) for FEV1 as %predicted.  (b) change in 
symptom scores as geometric mean fold differences (GMFDs, 95% CI error bars); scores <1 
indicate improvement.  Asterisk denotes significant within-group change, P<0.05.  Remaining 
P-values compare responses between groups.  Where there is no p-value for comparison 
indicates non-significance. 
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For inflammation, significant improvements in FeNO were seen across all ICS dose 
ramps (Table 20, Figure 23a), with clear evidence of dose separation (Table 20).  
Improvements were more pronounced in the subgroup with baseline values of 
FeNO≥25ppb (Figure 23b), and significantly different compared to the subgroup with 
baseline values of FeNO<25ppb.  Serum ECP did not improve with the low dose 
ramp 0-200µg (Table 20, Figure 23c), rather requiring the higher ICS dose to achieve 
significant within-group improvements between 0-800µg (P=0.002) and 200-800µg 
(P=0.0002); again the dose ramp responses were significantly different between 0-
200µg and 200-800µg (P<0.05).  Finally there were significant within group 
improvements for blood Eos across all dose ramps (Table 20, Figure 23d), where Eos 
also continued to fall significantly as the ICS dose increased: 370cells/µL (95%CI 
280,450) at 0µg, to 250cells/µL (95%CI 200,300) at 800µg, P=0.03. 
  
177 
	 	
 
Figure 23.  Dose responses for inflammatory outcomes. 
Within-group changes (GMFDs, 95%CI) unless stated; scores <1 represent a reduction.  (a) 
FeNO.  (b) FeNO comparing baseline FeNO≥25ppb (squares) vs. FeNO<25ppb (circles).  (c) 
Serum ECP.  (d) Blood eosinophils, arithmetic mean (95%CI).  Asterisk denotes significant 
within-group difference, P<0.05.  Remaining P-values indicate significant between group 
differences; or significant differences between baseline FeNO groups within each ramp (b), 
P<0.05. 
 
 
Significant within group changes were seen across all dose ramps for AHR (Figure 
24a).  The greatest improvement was in the 0-800µg group at 1.35 doubling dilutions 
(DD) (95%CI 1.06,1.63), P<0.0001, with further significant improvement in the 200-
800µg group amounting to 0.7DD (95%CI 0.43,0.96), P<0.0001.  Significantly 
greater improvements were seen when AHR was separated into indirect (mannitol) 
versus direct challenges (histamine, methacholine), particularly at the lower dose 
ramp 0-200µg, 1.64DD (95%CI 0.94,2.35) indirect vs. 0.65DD (95%CI 0.40,0.89) 
direct, P=0.015 (Figure 24b). 
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Figure 24.  Dose responses in airway hyper-responsiveness (AHR). 
Within-group changes expressed as doubling dilution differences (DDD).  Scores >0 indicate 
improvement. (a) combined bronchial challenges.  (b) direct (circles) vs. indirect (squares) 
challenges.  Asterisk denotes significant within group change, P<0.05.  Remaining P-values 
indicate significant between group differences (a), or significant differences between 
challenge groups within each ramp (b), P<0.05. 
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DISCUSSION 
 
In the present study we have demonstrated that incremental ICS dosing in persistent 
asthma leads to small improvements in both pulmonary function and symptoms, 
which then reaches a plateau above low doses.  We have also found that the same ICS 
dose ramps reveal further room for improvement in both inflammatory outcomes and 
AHR, when using higher ICS doses up to 800µg/day (beclomethasone equivalent). 
 
The BTS guidelines describe the goal of total (or optimal) asthma control as 
comprising no symptoms day or night, normal lung function and no exacerbations10.  
Unfortunately, it has been shown that patients are not good at recognizing when their 
asthma is not controlled30.  Furthermore, lingering underlying inflammation may be 
present39, and until this is treated, symptoms may take many months to become 
completely normal40.  We have shown here that patients who have only mild 
pulmonary function and symptom impairment respond optimally to low doses of ICS 
for these outcomes.  Pointedly, however, the 3.3% rise in FEV1 for 0-200µg equated 
to a mean of 98ml (95%CI 57,140), which is less than the putative minimal clinically 
important difference (MCID) of 230ml in asthma126.  Moreover, for symptoms, the 
geometric mean fold difference of 0.94 (95%CI 0.90,0.98) in the 200-800µg group 
equates to around a 6% improvement.  For the mini-AQLQ, for example, 6% 
represents a change of around 0.4, where the MCID is 0.5166.  Although the low dose 
plateau of symptoms and lung function have been well documented41,44,127,225, we still 
largely base our asthma management on these two outcomes, in addition to reliever 
use, particularly for mild to moderate persistent asthma; thus potentially limiting 
further appropriate ICS escalation. 
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We have demonstrated room for further improvement in markers of inflammation 
(FeNO, serum ECP and blood Eos) and AHR with higher doses of ICS, despite the 
plateau in symptoms and lung function.  The presence of ongoing airway 
inflammation in asthma has been shown to predict not only future exacerbations152,155, 
but also loss of asthma control151 upon reduction or removal of ICS treatment.  
Furthermore, this has been demonstrated using a variety of inflammatory outcomes 
including sputum Eos151,152, blood Eos77, FeNO155 and AHR6,13.  Moreover, targeted 
ICS therapy towards inflammatory outcomes has been shown to reduce the rate of 
exacerbations14, or reduce the overall steroid dose required for total control15.  We 
have found that while most improvement in FeNO occurs with low dose ICS, there is 
still a further dose response to higher ICS doses, particularly in patients who exhibit a 
high baseline FeNO≥25ppb.  This dose response has been shown previously, and 
indeed when ICS is stopped there is a rebound rise in FeNO once again159, which 
alludes to a possible need for persistent over intermittent ICS therapy, or indeed non-
adherence to ICS therapy158. 
 
We saw a similar pattern of response to that of inflammatory outcomes with AHR to a 
variety of bronchial challenges, both direct and indirect.  Indirect challenges are more 
closely related to the inflammatory pathway as they invoke the inflammatory response 
in the airway to cause bronchoconstriction131.  This is perhaps the reason we found a 
greater magnitude of response for AHR to indirect than direct challenges, in keeping 
with previous studies284,285.  Targeting ICS therapy using mannitol challenge AHR has 
been shown to reduce exacerbations over and above standard guideline driven 
therapy6, in line with that for sputum eosinophils14.  However, AHR can be driven by 
other mechanisms such as airway smooth muscle hyperplasia, and airway closure 
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itself286, and is therefore an area requiring further study with regards to personalised 
asthma treatment135. 
 
There is therefore a growing body of evidence suggesting that we need to include 
inflammatory measurements routinely to best manage patients with asthma.  This is 
problematic, not least by the cumbersome nature of inflammatory and challenge 
measurements that are difficult to perform in a community setting, albeit measuring 
blood eosinophils might be part of the solution77.  Cowan et al. have suggested a panel 
of inflammatory biomarkers to better enable prediction of ICS responsiveness in 
asthma162, but delivery of such a test remains the most difficult hurdle.  Even simply 
using the asthma control questionnaire33 itself seems to be a good predictor of future 
risk29. 
 
We believe the strengths of this study are in the cross-section of patients with mild to 
moderate disease that we commonly see in the clinic; who additionally use a variety 
of ICS.  Furthermore we believe it has been helpful to study a wide variety of 
outcome measures, none of which have taken priority in the study design.  The 
limitations of this study are in its post-hoc nature, with relatively low numbers and 
our ability to only examine low to moderate, albeit commonly used, doses of small 
and large particle HFA-ICS. 
 
In conclusion, we have demonstrated further room for improvement in markers of 
inflammation and AHR, despite a plateau in the dose response to ICS for both asthma 
symptoms and pulmonary function, with small and large particle ICS HFA-
formulations and doses.  This points to an unmet need of uncontrolled underlying 
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inflammation in certain asthmatic patients, which may be a precursor to future loss of 
control. 
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CHAPTER 8: 
PROSPECTIVE FOLLOW-UP 
OF NOVEL MARKERS OF 
BONE TURNOVER IN 
PERSISTENT ASTHMATICS 
EXPOSED TO LOW AND HIGH 
DOSES OF INHALED 
CICLESONIDE OVER 12 
MONTHS 
 
Study aims: 
1. To identify any systemic adverse effects on sensitive markers of bone 
turnover comparing low and high doses of inhaled ciclesonide over 12 
months in persistent asthmatics. 
2. To examine for any effects on adrenal suppression between these 
ciclesonide doses over 12 months. 
3. To confirm the safety of using a strategy of ICS dose titration based on 
inflammatory airway hyper-responsiveness rather than standard 
guideline-driven ICS dose titration, where this results in overall higher 
ICS dosing.  
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ABSTRACT 
 
Background 
In asthmatic patients receiving long-term inhaled corticosteroid therapy, there are 
concerns regarding the potential for developing systemic adverse effects on bone 
metabolism, possibly even in the absence of adrenal suppression. 
 
Objective 
To investigate whether exposure to inhaled ciclesonide at high verses low doses over 
one year causes any significant systemic adverse effect on sensitive biomarkers of 
bone turnover in asthmatic patients. 
 
Methods 
We performed a post hoc analysis of stored samples in a subgroup of patients from a 
prospective, randomised parallel group primary care trial with one year follow-up.  
164 mild-moderate persistent asthmatics aged 18-65years with evidence of airway 
hyper-responsiveness using mannitol bronchial challenge were enrolled into the 
original study.  Of the 119 completed patients per protocol, 100 participants had bone 
marker samples available for analysis.  Ciclesonide was titrated to control persistent 
asthma against either mannitol bronchial challenge (AHR strategy) or a control group 
(based on symptoms, reliever use and pulmonary function) over one year.  Markers of 
bone formation (PINP, PIIINP), resorption (ICTP, CTx) and adrenal suppression 
(overnight urinary cortisol/creatinine: OUCC) at 0 and 12 months were measured. 
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Results 
Mean ciclesonide doses after 12 months were: AHR=507µg/day (n=50); controls=202 
µg/day (n=50), p<0.00001.  There were no significant differences between AHR and 
control groups at either baseline or after 12 months in PINP, PIIINP, ICTP or CTx; 
ratios of bone turnover as PINP/ ICTP; PIIINP/CTx; or OUCC. 
 
Conclusion 
Higher doses of inhaled ciclesonide do not adversely affect sensitive markers of bone 
turnover in persistent asthmatics over 12 months. 
 
Ethics reference:  NFB/FB/192/03 
ClinicalTrials.gov reference:  NCT01216579 
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INTRODUCTION 
 
Inhaled corticosteroids (ICS) are the mainstay of anti-inflammatory therapy in 
persistent asthma, even in mild disease.  During acute exacerbations of asthma, short 
courses of oral corticosteroid are given for up to two weeks, and in more severe 
patients long-term use of oral corticosteroids may be required.  The use of oral 
corticosteroids have previously led to a rational concern about what may happen to 
asthmatic patients with regard to systemic adverse effects such as suppression of their 
hypothalamic-pituitary-adrenal (HPA) axis, as well as causing detrimental effects on 
bone metabolism in terms of the potential to develop osteoporosis with increased 
fracture risk.  Indeed, the question of inhaled corticosteroid side effects seems to be 
increasingly enquired about by well-informed patients during asthma clinic 
consultations. 
 
It is widely known that systemic corticosteroids, particularly given orally, cause 
suppression of markers of bone formation117,118,287, thus altering the balance between 
bone formation and resorption, leading to an overall reduction in bone mineral density 
and increased fracture risk.  Indeed glucocorticoid induced osteoporosis is the most 
common cause of secondary osteoporosis288.  However, the influence of inhaled 
corticosteroids on bone metabolism is more complex.  The degree of systemic 
bioactivity varies depending on the individual; the dose administered; the 
pharmacokinetics; and the amount of drug reaching the lung.  In general ICS do not 
cause much problem systemically given at low to medium doses.  However, higher 
doses of certain types of ICS, particularly those that are lipophilic with a large volume 
of distribution such as fluticasone propionate, can lead to significant HPA axis 
suppression49.  For example in a dose ranging study in persistent asthmatics, 440ug 
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twice daily of inhaled fluticasone was bioequivalent to 8.5mg of oral prednisolone in 
terms of their propensity for causing adrenal suppression.  Current guidelines on 
corticosteroid-induced osteoporosis delineate a value of 7.5mg prednisolone daily, 
above which the risk of osteoporotic fracture increases, and bone protection should be 
considered289.  Severe asthmatics demonstrate significant peripheral small airways 
obstruction, which can serendipitously be protective against the systemic effects of 
high doses of ICS by reducing bioavailability from the distal lung, thus reducing 
systemic absorption as compared to mild to moderate asthmatics290.  It has also been 
demonstrated that high doses of beclometasone dipropionate both increases markers 
of bone resorption and reduces bone formation as compared to equivalent doses of 
budesonide119. 
 
Ciclesonide is a relatively new and novel ICS with several significant 
pharmacological properties.  It has been dubbed a ‘designer’ third generation ICS291 
because it is a pro-drug with low glucocorticoid receptor activity that is subsequently 
converted to an active form locally in the lungs that exhibits high glucocorticoid 
receptor activity292.  This firstly, has benefits in terms of the pro-drug producing less 
oropharyngeal candidiasis or laryngeal dysphonia.  The active form, des-isobutyryl-
ciclesonide (des-CIC) demonstrates significant absorption from the lungs where it is 
delivered with a high fine particle dose, being an extra-fine aerosol.  However, 
because des-CIC has a very high plasma protein-binding affinity at around 99%, the 
systemic availability of free active compound is minimal.  This has been shown to be 
effective in producing minimal HPA axis suppression as compared to equivalent 
therapeutic doses of fluticasone293-295 creating an enticingly high therapeutic index for 
this particular drug.  The unanswered question, however, is whether there remains a 
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deleterious effect on bone turnover, in spite of minimal HPA axis suppression with 
ciclesonide? 
 
In this study we have analysed sensitive serum markers of bone turnover (formation 
and resorption) as a novel method of investigating any putative systemic adverse 
effects of inhaled ciclesonide, comparing low and high doses given over one year to 
patients with mild to moderate persistent asthma.  These samples were prospectively 
collected during a recently published study6 (the STAMINA trial, ClinicalTrials.gov 
Identifier: NCT01216579), stored and subsequently analysed after publication once 
funding became available.  To summarise, the STAMINA study compared two 
separate strategies for titrating ICS dose (as ciclesonide) to achieve asthma control in 
parallel groups of patients.  One was a control group using a standard strategy based 
on adjusting ICS dose against symptoms, pulmonary function and reliever use, 
according to conventional British Thoracic Society Guidelines.  The other group had 
their ICS dose adjusted against airway hyper-responsiveness (AHR) using mannitol 
bronchial challenge as a surrogate for airway inflammation.  It demonstrated that the 
AHR group were exposed to a significantly higher dose of inhaled ciclesonide to 
achieve superior asthma stability as compared to the control group over the course of 
one year.  Hence this created the ideal environment in which to investigate possible 
differences in systemic exposure between high and low dose ciclesonide on long-term 
bone turnover and HPA axis.  Nevertheless, ciclesonide was originally chosen for this 
community-based study because of its high therapeutic index, and lower likelihood of 
adverse effects (both local and systemic) at higher doses. 
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METHODS 
 
The methods employed in the reference study have been described previously6 but we 
have reiterated the key details and measurements specific to this study with the 
addition of methods of bone marker analysis. 
 
Patients 
164 mild to moderate persistent asthmatics aged 18-65years were initially enrolled 
from primary care practices within Tayside.  Forced Expiratory Volume in 1 second 
(FEV1) was required to be >60% of predicted normal to ensure the safety of bronchial 
challenge testing in a community setting.  Patients had to demonstrate AHR following 
mannitol challenge with a provocative dose causing a 10% drop in FEV1 (PD10) 
≤635mg at the end of a step down period where patients’ usual ICS was weaned to the 
lowest stabilising dose then converted to an equivalent dose of ciclesonide (Alvesco, 
Nycomed. Konstanz, Germany); the ICS to be used throughout the remainder of the 
study.  All patients had to have been receiving ICS for at least 1 year prior to the 
study and patients were excluded if they had used oral corticosteroids within 3 months 
of study commencement, had a prior diagnosis of osteopenia/osteoporosis or were 
receiving any anti-resorptive therapy.  All patients gave written informed consent 
prior to the study.  The study was reviewed and approved by the Tayside Committee 
on Medical Research Ethics. 
 
Study Design 
The study was a prospective, randomised parallel group trial with 1-year follow-up.  
Comparison was made between an AHR strategy to reduce mannitol AHR to a 
PD10≥635mg by serially incrementing the ciclesonide dose every 2 months according 
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to a predefined dosing regimen, with a control strategy based on the British Thoracic 
Society guidelines for asthma management.  Venous blood samples for markers of 
bone turnover were taken at baseline (end of ICS step down) and at the final 12-
month visit along with overnight 10-hour urinary cortisol (corrected for creatinine) at 
the same time points. 
 
Measurements 
Standardised spirometry was performed to measure FEV1 using MicroMedical 
SuperSpiro (Carefusion, Basingstoke, UK)216.  Mannitol challenge was measured as 
described previously with dry powder mannitol challenge (Aridol Pharmaxis Ltd, 
Sydney, Australia), to determine the PD10 217.  Assessment of suppression of 
endogenous cortisol through systemic absorption of ICS was made by quantifying 
overnight 10hour urinary free cortisol corrected for creatinine (OUCC), this has been 
shown to be as sensitive as an integrated 24hour serum or urine profile296.  
Furthermore, OUCC was found to be more sensitive at detecting adrenocortical 
suppression in response to high dose ICS than low dose ACTH stimulated cortisol297.  
Assessment of bone formation was made using serum amino-terminal propeptides of 
type I and III collagen – PINP and PIIINP respectively.  Bone resorption was assessed 
using serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen 
(ICTP), and type I collagen cross-linked C-telopeptide (CTx).  Approximations of 
bone turnover were made using PINP/ICTP and PIIINP/CTx ratios. 
 
All assays were performed in duplicate in a blinded fashion in the same laboratory.  
Urinary free cortisol was measured using a commercial radioimmunoassay kit 
(DiaSorin Ltd, Wokingham, Berkshire, UK).  The intra-assay coefficient of variation 
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(Cv) was 21% with the inter-assay Cv 13%.  This assay has no cross-reactivity with 
ciclesonide or des-CIC.  Urinary creatinine was measured using the RATE technique 
on a Cobas-Bio auto analyser (Roche Products, Welwyn Garden City, UK) with an 
inter-assay Cv of 4.3%.   PINP, PIIINP and ICTP were measured using commercial 
radioimmunoassay kits (Oxford Biosystems, UK) with inter/intra-assay Cvs 1.6% / 
6.0%, 4.6% / 7.9%, and 9.3% / 5.4% respectively.  CTx was measured using an 
ELISA assay (Immunodiagnostics, UK) with inter/intra-assay Cvs 24% / 21%. 
 
Statistical analysis 
Data were initially checked for normality prior to analysis, with non-Gaussian data 
logarithmically transformed to achieve normality.  Post hoc calculations demonstrated 
that our sample size (50 patients per independent group) provided 81% power (two-
tailed) to detect a minimal important difference of 30% in the CTx bone resorption 
marker between groups with a SD = 52% and α-error 0.05.  Comparisons within and 
between groups for baseline and 12 month values and between baseline and 12 
months were made using Student’s t-test for paired and independent groups 
respectively (two-tailed), with significance set at p<0.05.  The between group 
comparisons (i.e. AHR vs. Control) were considered as being of primary interest and 
the within group (i.e. baseline vs. 12 months in either AHR or Control) as secondary.  
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RESULTS 
 
119 patients completed the reference study.  Of these, 100 patients had suitable blood 
samples stored for analysis of bone markers after the trial.  This comprised 50 patients 
in each of the AHR and Control groups.  The baseline demographics for both groups 
can be seen in Table 21, demonstrating they were well matched with no significant 
differences at baseline between the two groups. 
 
Table 21.  Baseline Demographics. 
Baseline Variable Control (n=50) AHR (n=50) p-value 
Age (years) 54.4 (51.2, 57.5) 53.8 (50.6, 57.0) 0.79 
Gender (M:F) 28 : 22 27 : 23 0.84 
FEV1 (L) 2.60 (2.40, 2.79) 2.56 (2.38, 2.73) 0.78 
FEV1 (% predicted) 88.9 (84.5, 93.3) 85.8 (81.6, 90.0) 0.31 
Mannitol PD10 (mg)* 96.0 (64.6, 142.8) 107.4 (73.7, 156.6) 0.69 
PINP (µg/L)* 38.4 (33.9, 43.4) 39.0 (34.7, 43.9) 0.85 
PIIINP (µg/L)* 2.93 (2.66, 3.21) 3.07 (2.71, 3.47) 0.55 
ICTP (µg/L)* 2.54 (2.32, 2.78) 2.71 (2.42, 3.02) 0.39 
CTx (µg/L)* 0.16 (0.13, 0.20) 0.15 (0.12, 0.18) 0.68 
PINP/ICTP ratio* 15.1 (13.0, 17.5) 14.4 (12.5, 16.7) 0.66 
PIIINP/CTx ratio* 18.6 (14.5, 23.8) 20.3 (15.7, 26.3) 0.63 
OUCC (nmol/mmol)* 7.28 (5.91, 8.96) 7.44 (6.28, 8.81) 0.87 
CIC dose (µg/day) 138 155 0.33 
 
Data presented as arithmetic mean (95% confidence intervals) unless stated.  *Geometric mean (95% 
confidence interval).  AHR = Airway hyper-responsiveness.  FEV1 = Forced expiratory volume in 1 
second.  PD10 = Provocation dose (mannitol) causing 10% fall in FEV1.  Serum bone formation 
markers = PINP & PIIINP.  Serum bone resorption markers = ICTP & CTx.  OUCC = Overnight 
urinary cortisol/creatinine ratio.  CIC = Ciclesonide dose (ex-actuator). 
 
The final mean doses of ciclesonide (ex-actuator) after 12 months in each group were 
202µg/day for controls and 507µg/day for AHR group, p<0.00001.  This mirrors what 
was found in the reference study.  The ICS dose increments over the 12-month study 
period for each group are illustrated in Figure 25, where it can be seen that even after 
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just 2 months, the AHR patients were receiving significantly greater amounts of 
ciclesonide, with the gulf between doses continuing to widen over the course of the 
year. 
 
 
Figure 25.  Ciclesonide titration over 1 year. 
Incremental titration of ciclesonide (as ex-actuator dose) between groups at 2-month intervals over 1 
year.  Data presented as arithmetic means with 95% confidence interval error bars.  AHR = airway 
hyper-responsiveness. 
 
 
For the primary study comparison between the two groups, there were no significant 
differences after 12 months for markers of bone formation: PINP and PIIINP (Figure 
26a), nor for markers of bone resorption: ICTP and CTx (Figure 26b).  The bone 
turnover ratios PIIINP/CTx and PINP/ICTP at baseline and study end were also not 
significantly different between groups and are illustrated in Figure 26c and 26d 
respectively. 
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Figure 26.  Bone turnover markers and ratios at 1 year. 
Bone turnover markers at 12 months (a, b) and bone turnover ratios at 0 and 12 months (c, d) between 
groups.  Data presented as geometric means with 95% confidence interval error bars.  Bone formation 
markers (a) PINP & PIIINP = serum amino-terminal pro-peptides of type I and III collagen 
respectively.  Bone resorption markers (b):  ICTP = serum pyridinoline cross-linked carboxy-terminal 
telopeptide of type I collagen; CTx = type I collagen cross-linked C-telopeptide.  Bone turnover ratios:  
PIIINP/CTx (c) and PINP/ICTP (d).  AHR = Airway hyper-responsiveness. 
 
 
Figure 27 confirms that the lack of difference in OUCC found in the reference study 
between groups at baseline and study end is mirrored in this subgroup of patients, 
indicating no significant HPA axis suppression in either group.  This is further 
confirmed on Figure 28 showing all the actual OUCC values at baseline and 12 
months for both groups, compared to a threshold of 3nmol/mmol – above which 
adrenal function is considered to be normal226,227.  Reassuringly, the few patients 
below this threshold at baseline improved their adrenal function during the trial in 
both groups.  
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Figure 27.  OUCC between groups at baseline and 1 year. 
Data presented as geometric means with 95% confidence interval error bars.  OUCC = Overnight 
urinary cortisol/creatinine ratio.  AHR = Airway hyper-responsiveness. 
 
 
 
Figure 28.  Scatterplots for individual OUCC ratios. 
For both the Airway Hyperresponsiveness (AHR) and Control groups, absolute values are displayed for 
each individual at baseline and joined by a solid line to their respective values at 12 months. The 
interrupted line represents the cut-off value above which the overnight urinary cortisol/creatinine 
(OUCC) ratio is considered to be normal. 
 
Results for bone markers and bone turnover ratios at baseline and at 12 months within 
both groups can be seen in Table 22.
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Percentage changes from baseline for bone markers and ratios within each group are 
recorded in Table 23. 
 
Table 23.  Comparison of within group changes in bone markers/ratios over 1 
year. 
 
Variable Control (%) AHR (%) p-value 
PINP (µg/L) 10.6 (2.6, 17.9) 6.1 (-3.3, 14.8) 0.50 
PIIINP (µg/L) 6.6 (1.5, 11.4) 6.7 (-1.9, 14.6) 0.93 
ICTP (µg/L) 13.7 (7.1, 19.7) 10.8 (0.7, 19.8) 0.62 
CTx (µg/L) 9.0 (-13.6, 27.1) 14.8 (-3.1, 29.6) 0.66 
PINP/ICTP ratio -3.5 (-14.4, 6.3) -4.3 (-13.4, 5.3) 0.89 
PIIINP/CTx ratio -3.0 (-31.1, 19.0) -11.1 (-29.3, 10.6) 0.61 
 
Data are presented as percentage change from baseline (95% confidence interval).  Serum bone 
formation markers = PINP & PIIINP.  Serum bone resorption markers = ICTP & CTx. 
 
 
Whilst there were statistically significant increases over 12 months for PINP, PIIINP 
and ICTP within the control group, these did not reach the minimal important 
difference (~30%) to exclude biological variability, i.e. 10.6%, 6.6% and 13.7% 
respectively. There was also a statistically significant increase in ICTP (10.8%) in the 
AHR group without reaching the minimal important difference.  Moreover all 
differences as change from baseline for bone markers and ratios were not statistically 
different when comparing between the groups over the 12-month period. 
 
Individual within group percentage changes from baseline for bone formation (PINP) 
and resorption (ICTP) in both groups are represented using scatterplots with 
superimposed mean ± 95% confidence intervals and representative 30% minimum 
clinically important difference (MCID) cut-offs for both in Figure 29. 
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Figure 29.  Individual changes in markers of bone formation and resorption. 
Scatterplots of percentage changes for each patient between baseline and 12 months with superimposed 
mean ± 95% confidence intervals and representative -30% cut-off for bone formation and +30% cut-off 
for bone resorption (interrupted lines) as minimal clinically important differences. 
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DISCUSSION 
 
The results of the present study show that in patients exposed to ciclesonide over 12 
months, using a higher dose to achieve better asthma control has no adverse effects on 
sensitive biochemical markers of bone turnover or on adrenocortical function.  It has 
long been recognised that systemic corticosteroid therapy leads to a rapid reduction in 
bone formation markers, such as osteocalcin – a marker of osteoblast activity, leading 
to reduced bone mineralisation and ultimately bone loss117,118,298,299.  The role of 
markers of bone resorption has been less clear in this regard117,298,299 but seem more 
useful for monitoring anti-resorptive therapy such as the bisphosphonates300. 
 
More sensitive biomarkers of bone metabolism – the collagen peptides - have 
emerged in recent years.  These markers can be measured in the serum or urine, 
however, it has been demonstrated that markers in serum are more sensitive in terms 
of signal-to-noise ratio than their urinary counterparts with the added benefit that they 
do not require correction for the patient’s glomerular filtration rate300.  One example 
of this is the carboxy-terminal collagen crosslinks or CTx.  This crosslink peptide 
sequence of type I collagen is the part cleaved by osteoclasts during bone resorption, 
reflecting osteoclastic activity301.  CTx has been shown to more accurately track 
changes in levels of bone resorption after bisphosphonate therapy than other markers 
such as urinary N-telopeptide crosslinks302.  This is aided by its low coefficient of 
variability (15.1% over 3 months) and large changes in response to bisphosphonate 
therapy302.  Estimates of the MCID for CTx do vary, i.e. the degree of change that can 
exclude normal biological variability.  It has been suggested that for a coefficient of 
variation of 10%, a change of at least 25-30% must be observed for serum markers to 
consider significant evolution300.  Other papers have quoted 30.2%302 and as much as 
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55-60% for change in CTx to be clinically significant303.  Indeed, when it comes to 
predicting fracture risk, an elevated CTx is associated with an increased risk of 
osteoporotic fractures304,305.  A cut-off of 30% change has been suggested elsewhere, 
i.e. a >30% fall in CTx with bisphosphonate therapy reduced fracture risk306.  We 
have taken a 30% change as the MCID on which to base our post hoc power 
calculation.  In addition to CTx we have used other serum biomarkers to reflect both 
bone formation (PINP & PIIINP) and resorption (ICTP) in a novel way in persistent 
asthmatics receiving both high and low doses of the inhaled corticosteroid 
ciclesonide.  In one study, PINP was investigated as a marker of raloxifene therapy in 
post-menopausal women who had evidence of osteoporosis307.  PINP reductions were 
11% with placebo and 41% with raloxifene.  The reduction in the raloxifene group 
accounted for 28% of the total reduction in vertebral fracture risk.  This again 
suggests that a MCID in these markers is around 30-40%. 
 
There have been numerous studies demonstrating both short and long term effects of 
ICS on the HPA axis293,297,308,309, with some types of ICS more potent in their 
suppression of it as mentioned previously290.  This logically leads one to consider the 
consequent effect on bone turnover and potential for the development of osteoporosis.  
Some studies have indeed shown deleterious effects on markers of bone turnover and 
bone mineral density with ICS119, with some doubt cast on this by other longer term 
studies failing to demonstrate any effect on bone with high dose ICS with or without 
significant HPA axis suppression120,121, alluding to the possibility of a disconnect 
between the two.  We hypothesised that if such a disconnect is present, then it may be 
possible that one may have a normal HPA axis yet still suffer deleterious effects on 
bone turnover during long-term ciclesonide therapy. 
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Reassuringly, our study suggests that even with long-term treatment using a higher 
dose of inhaled ciclesonide - both sensitive markers of bone formation PINP and 
PIIINP, as well as of bone resorption ICTP and CTx, are no different between groups 
to any clinically significant degree at the end of a 1-year period.  This is also in accord 
with the lack of any deleterious effect on the HPA axis as measured by OUCC.  What 
is most relevant is the lack of any reduction in bone formation because this is where 
most effect is seen with oral systemic corticosteroid therapy, i.e. PINP and PIIIP 
levels remain approximately the same over the 12 month period in the higher ICS 
dose AHR group.  For PINP only 3 patients in the AHR group fell below the -30% 
MCID, at -32%, -37% and -41%, which is reassuring particularly as we had 
considered using a more conservative MCID of -40%.  There was one significant 
outlier below -30% in the control group for PINP, but all other patients remained 
above the line in this group.  In fact, bone formation markers increased overall in the 
control group, possibly suggesting an effect of higher ICS dose with the lack of 
increase in the AHR group, but as mentioned above, these increases did not meet our 
assumed MCIDs.  There were statistically significant increases in the ICTP resorption 
marker in both groups to an approximately equal degree, without meeting the MCID; 
but no significant increases in CTx which may confirm that these measure different 
aspects of bone resorption.  For ICTP, there were 12 patients in the AHR groups and 
13 patients in the control group where their change was greater than the 30% MCID.  
These numbers reduced to 7 for AHR and 3 for control when utilising a 40% cut-off.    
Reassuringly there were similar numbers of patients who had an increase above 30% 
in bone formation (PINP) – 11 patients in AHR group and 10 in the control group.  
We also approximated overall bone turnover with two ratios of bone formation to 
bone resorption – PINP/ICTP and PIIINP/CTx.  Once again these showed no 
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significant change over a year either within or between groups, further confirming the 
safe therapeutic profile of ciclesonide at higher doses. 
 
The most obvious limitation of this study is the lack of confirmatory evidence for our 
findings through formal measurement of each patient’s bone mineral density at 
beginning and end.  However, biomarkers of bone turnover have shown a strong 
correlation with radiological bone density measurements310,311.  Another potential 
drawback of this data is the fact that ciclesonide does not tend to cause much adrenal 
suppression in general, compared to fluticasone propionate, for example.  The 
strengths of this study include the prospective nature of data collection in a 
community setting, the long treatment period of a year, and the statistical power of the 
study with large patient numbers to detect significant changes in the bone markers.  
Even though this was a subgroup of the original study, our findings mirror what was 
found in that study in terms of lack of OUCC suppression, helped by the fact that we 
studied 84% of the original participants who had suitable blood samples for analysis. 
 
In conclusion, we have demonstrated that the higher doses of inhaled ciclesonide 
required to achieve superior asthma control through reducing levels of airway 
inflammation over a 1 year period do not adversely affect sensitive biomarkers of 
bone formation, resorption and their respective turnover ratios in persistent 
asthmatics, as compared to a lower dose of inhaled ciclesonide.  Moreover, this is in 
keeping with lack of HPA axis suppression in these patients, providing reassurance 
that inhaled ciclesonide has a safe systemic therapeutic profile even with the higher 
dosing required to achieve better asthma control.  
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CHAPTER 9:   
DISCUSSION AND 
CONCLUSIONS 
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DISCUSSION 
 
This body of work incorporates a variety of areas of study with the aim of furthering 
our understanding of how we might better individualise the mainstay of asthma 
controller therapy for patients, namely inhaled corticosteroids (ICS), by examining 
ICS dose responses to multiple asthma outcomes that delineate the disease.  This 
thesis therefore begins by exploring both intrinsic and extrinsic factors that may alter 
or help predict responsiveness to incremental ICS dosing.  The utility of 
pharmacological manipulation of the ICS dose response with an additional therapy is 
then examined for any steroid sparing effects in this regard, and to provide additional 
insight into the underlying pathophysiological mechanisms.  Further, the relationships 
between inflammatory and other asthma outcomes are examined both when patients 
are receiving static doses of ICS, as well as following incremental ICS dosing.  
Finally, potential systemic effects of this degree of ICS dose ramp are examined in a 
long-term study of sensitive markers of bone turnover where patients have had their 
ICS titrated against either standard care (BTS guidelines) or inflammation driven 
AHR. 
 
Current ICS titration strategies for the treatment of asthma are largely based on 
guidelines produced from professional groups such as the British Thoracic Society10.  
Whilst they incorporate an extensive overview of asthma management, when it comes 
to the detail of incremental ICS dosing, any titration is based on simple measures 
applicable in the community including symptoms, basic pulmonary function 
measurements, and beta-2 agonist reliever use.  This is certainly appropriate when we 
consider the asthmatic population as a whole, given that most will have mild to 
moderate disease where low doses of ICS can easily correct these parameters in most 
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cases.  However, this overarching plan can begin to unravel in several ways for 
individual patients.  Either the patient or physician may not strictly adhere to 
treatment guidelines, given that we know strict guideline adherence in a clinical trial 
improves asthma outcomes32.  There is also an ongoing attendant morbidity and 
mortality25 with asthma that is theoretically avoidable, and proves that this disease is 
being significantly undertreated in certain individuals for a variety of potential 
reasons.  Furthermore, patients are not good at recognizing when their disease might 
be uncontrolled30 and therefore don’t seek additional help.  Pointedly, it is impossible 
to know if there is any ongoing inflammation or airway hyper-responsiveness (the two 
main hallmarks of the asthmatic disease process) without specifically testing for them 
– which currently is prohibitive in a community setting.  However, given ongoing 
asthmatic inflammation and AHR are precursors of poor future asthma control and 
exacerbations46,152,155, it is logical that one would wish to know about them before 
completing any individual’s ICS treatment review.  It is this inability to completely 
quantify any future risk that leaves us in a precarious position.  Even well validated, 
yet relatively simple, measures of asthma control such as the asthma control 
questionnaire33 are still not well utilised for this purpose.  It is therefore imperative 
that we improve our understanding of incremental ICS dose responses, not only to 
usual measures of symptoms and pulmonary function, but also to measures of the 
underlying ongoing disease process, specifically inflammation and AHR. 
 
The first study in this thesis began with the evaluation of ICS dose response on FeNO 
levels.  This was a phenotype driven study, where asthmatic patients were selected on 
the basis of displaying high FeNO levels from the outset following ICS washout.  The 
reason for this study design was to observe how predictable their ICS dose response 
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might be, both in relation to FeNO, as well as on other clinically relevant measures of 
inflammation and asthma control.  Furthermore, whilst a dose response of FeNO to 
ICS had been observed previously159, we decided to examine this relationship using 
domiciliary FeNO measurements – a technique used before in children, but not in 
adults with asthma.  We believed this method of serial diurnal FeNO measurement 
would also improve the signal to noise ratio of this outcome measure. 
 
We learned a number of things about how domiciliary FeNO responds to ICS from 
this study.  Firstly, we observed significant improvements in both morning and 
evening FeNO levels with both low and high dose fluticasone, with significant dose 
separation between the two domiciliary response curves.  Furthermore the domiciliary 
measurement approach helped us to see that improvements in FeNO levels follow a 
one-phase exponential decay pattern, with 50% reduction in FeNO levels seen after 
only 2.9 or 2.3 days (for 100µg/day and 500µg/day FP doses respectively, which 
equate to approximately 200µg and 800-1000µg BDP equivalent doses).  A rapid rise 
in FeNO levels back to baseline levels also occurred during ICS-free washout periods 
of only 2 weeks.  FeNO is therefore very sensitive to the effects of ICS, even at low 
doses, confirming previous findings in this regard220.  It may, therefore, be useful as a 
rapidly responsive measure of compliance to ICS therapy.  Indeed, it has been shown 
as a useful measure of non-adherence to treatment in severe asthmatics158. 
 
The most clinically relevant finding from this study is the relationship of FeNO 
response to ICS leading to significant improvements in measures of asthma control 
and quality of life.  Not only were significant improvements seen over such a short 
period of time, 2 weeks, but these improvements were clinically relevant with mean 
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changes of >0.5 for both ACQ and AQLQ scores, the minimum clinically important 
difference for both these outcome measures33,166.  Indeed, ACQ improved to a score 
of <0.75 with both doses of FP indicating well-controlled asthma34.  In addition to the 
correlation of FeNO improvement with measures of asthma control and quality of life, 
the fall in FeNO with ICS was followed by improvements in other measures of 
asthmatic inflammation.  However, the same degree of dose separation was not seen 
equally between these other inflammatory outcome measures, suggesting a further 
level of complexity to the airway inflammation story.  That is, serum ECP required 
higher ICS dosing to be suppressed, whereas mannitol challenge and blood 
eosinophils improved initially with low dose ICS, but not significantly further with 
the higher ICS dose.  These findings could be due in part to the fact that the study was 
not powered on these as primary outcome measures, or that treatment for 2 weeks was 
simply too short a time period to observe any meaningful dose separation in these 
other outcomes.  However, the fact that we still observed meaningful improvements in 
asthma control, might mean that domiciliary FeNO measurement is more sensitive in 
this regard.  There were statistically significant improvements in FEV1 as well, but 
these did not meet the minimum clinically important difference for this outcome 
measure, perhaps due to patients having relatively preserved spirometry from the 
outset.  Future studies using domiciliary FeNO measurement should focus on longer-
term outcome measures such as exacerbations, as well as examining for any 
improvement in compliance to ICS therapy by perhaps using daily domiciliary FeNO 
measurement to help reinforce the need for this important treatment for individual 
patients. 
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Having examined the ICS dose response of FeNO as an intrinsic factor related to 
asthma control, the second study in this thesis examined the relationship of obesity to 
ICS dose response as an extrinsic factor that may influence this.  Previous studies had 
suggested both possible blunting of glucocorticoid responsiveness181 and indeed 
reduction in overall asthma control in obese compared to normal weight asthmatics180, 
when compared using static doses of steroid.  They did not however examine any 
dose response relationship.  This thesis’ study was a post-hoc analysis of data from a 
pharmacodynamic bioequivalence study comparing dose ramps between 200µg/day – 
800µg/day of both CFC and HFA-budesonide.  We elected to study the HFA-
budesonide arm as it was more clinically relevant to today’s practice now that CFC-
propelled inhalers are obsolete.  There was no particular primary outcome measure 
overarching the study, however, patients were selected on the basis of the presence of 
AHR to methacholine with a PC20<4mg/ml. 
 
Once separated into normal weight (BMI<25kg/m2) and overweight (BMI≥25kg/m2) 
groups, we found greater improvements in both FeNO and symptom responses to 
incremental ICS dosing in the normal weight group, where no differences were seen 
for either AHR to methacholine or FEV1 between BMI groups, despite significant 
overall improvements with ICS for both these outcomes.  As with the FeNO study, 
most improvement was seen with low dose ICS for both FeNO and symptoms.  
Whilst baseline FeNO levels were different between the BMI groups, i.e. higher in the 
normal weight group, baseline symptom scores were not different, yet followed a 
remarkably similar pattern of response to FeNO between BMI groups following 
incremental ICS dosing.  It might be, therefore, that FeNO is a more sensitive marker 
when it comes to following symptom improvement in persistent asthma, than AHR or 
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FEV1; albeit baseline lung function in this study was once again relatively preserved 
from the outset.  This putative further room for improvement in overweight 
asthmatics for FeNO and symptoms may also be important when it comes to 
exacerbation risk, given that pulmonary function is not such a good predictor in this 
regard as seen in previous studies using inflammation or AHR to guide steroid 
therapy in asthma6,13,14. 
 
These findings generate several hypotheses to try to explain the differences in 
outcome measures and ICS dose responses between the BMI groups.  Given that we 
have classified obesity as an extrinsic factor here, it raises the possibility that altered 
lung mechanics239,240 from increased chest wall restriction or increased elastic recoil 
might be the reason for lack of symptom improvement in the overweight group upon 
incremental ICS dosing.  To put it another way, perhaps the obesity itself is adding to 
the symptom burden, independent of any asthmatic symptoms, and so would not 
respond to ICS in the same manner.  Whilst an attractive proposition, we did not 
observe any spirometric restriction in the overweight compared to normal weight 
group.  Furthermore, the overweight group was certainly not morbidly obese, with a 
mean BMI of 30kg/m2.  It could be, therefore, that symptoms are more closely related 
to airway inflammation and small airways function rather than large airway calibre.  
We did not, however, specifically measure small airway function in this study.  
Another potential theory is that of reduced (distal) lung deposition of ICS particles in 
the overweight group, leading to reduced efficacy for FeNO and symptoms.  This is 
backed up by the fact that FeNO is a whole lung measurement (from both large and 
small airways); whereas FEV1 and AHR relate to central large airway responses in the 
main.  We also found a trend to greater cortisol suppression in the normal weight 
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group; again alluding to possible reduced systemic absorption (from reduced lung 
delivery) in the overweight group.  This could also be due to reduced glucocorticoid 
sensitivity181, but we did not have the kinetics data to confirm or refute this.  Future 
prospective studies to answer this question could be performed using imaging studies 
of lung deposition and small airway measurements, using both small (MMAD<2µm) 
and large particle (MMAD>2µm) ICS compared across a wider range of BMI. 
 
If FeNO and symptoms are less sensitive to ICS in overweight and obese asthmatics, 
then patients may require their ICS doses to be titrated further to gain the same 
response as in normal weight individuals.  This is relevant, given that control of 
inflammation can be more beneficial in preventing future exacerbation risk14,220, over 
and above simply normalizing symptoms or lung function.  Alternatively, it has been 
shown that the addition of other therapies such as leukotriene receptor antagonists 
might be more beneficial earlier in the asthma treatment ladder for overweight 
asthmatics, as their effects have been shown to be upregulated by leptin, which is 
more prevalent in obese asthmatics248,249.  It is ultimately important to remember, 
however, that achieving weight loss in these individuals will not only benefit their 
asthma182, but will also prevent many other co-morbid sequelae such as diabetes and 
cardiac disease. 
 
The third study presented in this thesis investigated the role of propranolol (a non-
cardioselective beta-blocker and inverse agonist at the beta-2 adrenoceptor, 
B2ADR262) as a novel, counterintuitive, corticosteroid-sparing agent in persistent 
asthma.  Previous murine and open-label human studies have shown that another 
B2ADR inverse agonist, nadolol, significantly improved AHR when patients were 
211 
	 	
steroid naïve252-256, as well as potentially acting as a steroid-sparing agent260.  In order 
to answer this question, we utilised a positive control arm of higher ICS dosing 
compared to low dose ICS plus propranolol, measuring the primary outcome of 
change in histamine AHR compared to low dose ICS alone between both treatment 
arms.  Furthermore, we wished to examine for any possible anti-inflammatory effects 
of propranolol as a secondary outcome, again with the benefit of the higher dose of 
ICS as a positive control.  Safety was clearly paramount in this study; indeed it 
required careful and detailed discussions with the local ethics committee in order for 
them to provide their approval, including conceding that we would put ‘risk of death’ 
in the participant information sheet!  We therefore monitored a variety of safety 
measures in domiciliary fashion throughout the study for each patient.  This was 
perhaps even more important given that patients enrolled in the study could be 
considered to have moderate severity of asthma, as evidenced by almost half being on 
combination ICS/LABA therapy pre-study, with a mean pre-study ICS dose of 
406µg/day (95% CI: 243, 569) for the whole group, yet still displaying moderately 
severe AHR to histamine with mean PC20 1.39mg/ml (95%CI: 0.93, 2.07) as well as 
moderately elevated FeNO levels 40ppb (95%CI: 29, 55). 
 
We found that the addition of propranolol to low dose ICS did not alter AHR to 
histamine, despite observing significant systemic effects of beta-blockade on heart 
rate and blood pressure measurements.  Moreover, the lack of any steroid-sparing 
activity of propranolol on histamine AHR was confirmed by the higher dose of ICS 
alone leading to further improvement in histamine AHR with a mean improvement of 
more than 1 doubling dilution difference over baseline, i.e. meeting the pre-specified 
power calculation.  In addition, propranolol did not improve any inflammatory 
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measures either, whereas the higher ICS dose significantly further improved all 
measured inflammatory outcomes including FeNO, blood eosinophils and serum 
ECP.  Small but significant improvements in symptoms were also seen in the positive 
control arm, but there were no improvements in measures of lung function despite the 
higher ICS dosing.  Reassuringly, we did not observe any clinically significant 
adverse pulmonary effects in the propranolol arm.  There was some mild blunting of 
salbutamol recovery post-histamine challenge, as well as a reduction in evening, but 
not morning, domiciliary FEV1.  Importantly, while asthma control (as measured by 
ACQ) did not improve significantly with higher dose ICS (from a well-controlled 
baseline), neither did it worsen upon chronic exposure to 80mg/day of sustained 
release propranolol. 
 
Inverse agonist activity occurs at the B2ADR in the presence of certain beta-blockers 
including propranolol and nadolol, essentially ‘switching off’ the receptor by reducing 
basal constitutional activity262,263 with the potential, therefore, to up-regulate other 
B2ADRs.  Indeed B2ADR upregulation was seen in a previous pharmacological study 
after only 2 days of propranolol exposure with a fully restored isoprenoterol-induced 
cyclic-AMP response at 2 weeks266.  We were therefore able to cover the first period 
of any potential dramatic worsening in bronchoconstriction with tiotropium (a long-
acting muscarinic antagonist, LAMA), both to allow time for the B2ADRs to 
upregulate, and to prevent unopposed acetylcholine-induced bronchoconstriction due 
to beta-2 receptor blockade with propranolol261.  Moreover, we utilised a gradual dose 
ramp of propranolol, in order to further prevent any associated initial worsening of 
airway bronchoconstriction.  We showed that both of these safety strategies were 
successful in our study. 
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However, with regard to the lack of improvement in AHR with the addition of 
propranolol to low dose ICS, it is possible that any clinically significant upregulation 
of B2ADRs had already been achieved with the low dose of ICS alone86-88, negating 
any effect the propranolol might have had.  Nevertheless, the higher ICS dose still 
achieved a greater improvement in histamine AHR, confirming that the 
pharmacological effects of ICS are much more wide-ranging than simply upregulating 
B2ADRs, e.g. through their effects on suppressing inflammation.  It is perhaps 
unsurprising that there was little improvement in both ACQ and lung function with 
higher dose ICS, given that patients started out with relatively normal baseline levels 
of both when receiving low dose ICS.  Nevertheless, it is more than a little worrying 
that we still observed significant consistent further improvements in both AHR and a 
variety of inflammatory markers with the higher ICS dose alone, that did not translate 
into observable improvements in either ACQ or lung function.  The reason for this 
concern is due to previous studies showing that uncontrolled AHR and airway 
inflammation both independently predict a greater risk of future adverse events such 
as exacerbations46,152,155, and this usually in the presence of preserved lung function, 
as in our study.  It is perhaps more concerning that ACQ didn’t change, and was even 
considered ‘well-controlled’ from the outset despite further room for improvement 
demonstrated for both AHR and inflammation upon higher ICS dosing.  I say this 
because ACQ has itself been shown to predict future risk29, and so its seeming 
normality here is perhaps falsely reassuring in this regard.  A more interesting, but 
probably more dangerous study, would be to assess for any steroid-sparing effect of 
inverse-agonist beta-blockers in more severe asthmatics, where higher ICS dosing 
alone does not always achieve total asthma control; but there are already well 
established and probably safer additional therapies, such as add-on LABA therapy, for 
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this purpose.  Ultimately, in this study of carefully monitored and well controlled 
persistent asthmatics, we have shown that propranolol can be given safely – which is 
an important message in terms of opening up this therapy to carefully selected 
asthmatics for its more usual indications, where previously non-cardioselective beta-
blockers would have been denied. 
 
The fourth study of this thesis examined the relationships between AHR to mannitol 
bronchial challenge, AHR to methacholine challenge, FeNO, salivary ECP and lung 
function as FEV1; in asthmatic subjects receiving their usual doses of ICS.  The 
reasons for exploring these were to increase the potential for wider utility of mannitol 
bronchial challenge testing by categorizing the severity of mannitol AHR into groups, 
and comparing these with established severity groupings for both methacholine 
AHR20 and FeNO212 in asthma.  Given that mannitol challenge is a simple test to 
administer209 (requiring only a spirometer and the ability to instruct the use of the dry 
powder inhaler delivery device), it is ideally suited to becoming established as a 
community, as well as a secondary care, method of additionally confirming or 
refuting the diagnosis of asthma268, tailoring ICS therapy on the basis of mannitol 
AHR6, or even predicting future risk of poor control and exacerbations – so called 
‘inflammometry’14.  Furthermore, mannitol bronchial challenge reflects both airway 
hyper-responsiveness and airway inflammation at the same time, because it is an 
indirect challenge that invokes the inflammatory pathway in the airway mucosa to 
cause bronchoconstriction269; whereas direct bronchial challenge tests including 
methacholine only measure airway smooth muscle sensitivity.  This means that it can 
measure both main hallmarks of the underlying asthmatic process simultaneously, 
potentially improving its diagnostic and monitoring efficiency further.  We used 
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mannitol PD10 AHR levels rather than the standard mannitol PD15 values, both 
because we believed that we would find more responsive patients using this lower 
threshold, and perhaps more importantly because they were already being treated with 
moderate doses of ICS, thus we additionally wanted to improve the signal-to-noise 
ratio of the test in this setting.  We showed that for those patients who were 
responsive at both PD10 and PD15 for mannitol, there was a very strong correlation 
between the two (r=0.93) confirming our proposition as valid. 
 
This study revealed that by grouping mannitol AHR into mild, moderate and severe 
responses based on mannitol PD10 levels, these positively correlated with severity 
levels for both methacholine AHR and FeNO.  Furthermore, when reciprocal 
correlations were examined using both methacholine and FeNO severity groups, the 
same correlations were observed for mannitol AHR.  Moreover, correlations between 
all three outcomes persisted when examined as continuous rather than categorical 
variables.  Indeed, clinically significant magnitudes of difference were identified 
between mild and severe mannitol AHR groupings for both methacholine PC20 and 
FeNO levels in these patients who were currently receiving ICS.  There were no 
significant correlations, however, between any of these outcome severity groupings 
and FEV1, salivary ECP or current ICS dose. 
 
These findings confirm that mannitol bronchial challenge is a clinically useful 
measurement of both AHR and airway inflammation jointly.  Indeed, mannitol AHR 
has previously been shown to have a similar sensitivity and specificity to 
methacholine challenge for diagnosing asthma131,275.  Mannitol additionally has been 
shown to have a similar negative predictive value for excluding the diagnosis of 
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asthma as a FeNO<36ppb275.  Also given its simplicity of administration, it could be a 
potentially invaluable tool for the diagnosis and ongoing management of asthmatic 
patients in a community setting; over and above the standard markers of symptoms 
and spirometry that are currently used for this purpose in primary care.  Pointedly, the 
ability to measure multiple disease hallmarks at once, might improve our ability to 
better predict future adverse events such as exacerbations, but this requires further 
prospective study to confirm this hypothesis.  It has again been shown here that FEV1 
does not reflect the underlying pathophysiological processes in asthma well, given the 
lack of correlation of this outcome with any of mannitol AHR, methacholine AHR or 
FeNO; albeit once again FEV1 was relatively preserved in this patient cohort.  
Moreover, there was no correlation between current ICS dose and any of the severity 
groupings for the three outcome measures, perhaps telling us that these individual 
patients’ underlying asthma severity had not been discriminated well enough to be 
translated into increasing ICS doses for patients with greater markers of asthma 
severity; or more simply perhaps that ICS compliance was not optimal.  We did not 
formally measure asthma control in this cohort, but this would have been useful, 
particularly in relation to the question of optimal ICS dosing in the face of disparate 
asthma severity as demonstrated with three separate outcome measures. 
 
The penultimate study presented in this thesis draws together the various strands of 
investigation in the previous studies by examining the dose responses of a variety of 
asthma outcome measures to a combination of commonly used ICS, utilizing similar 
dose ramps between 0, 200 and 800µg/day (BDP equivalent).  The premise of this 
pooled analysis was to determine whether there might be any further room for 
improvement in any outcome measure beyond low dose ICS, in particular whether 
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there was any difference between routine measures of ICS dose response (symptoms 
and pulmonary function) and measures of the underlying pathophysiological 
processes in asthma (inflammation and AHR). 
 
We found a plateau of the ICS dose response to both pulmonary function and 
symptoms beyond low dose therapy.  However, with the same ICS dose ramp, we 
uncovered further room for improvement in measures of asthmatic inflammation 
(FeNO, serum ECP and blood eosinophils) and AHR (to both direct and indirect 
bronchial challenges).  This disconnect, therefore, potentially challenges clinical 
equipoise, where mainly symptoms and pulmonary function are used to determine 
ICS response in both primary and secondary care10.  Indeed, this leads to the potential 
for inadequate ICS dose escalation in an individual who presents with preserved 
spirometry and no significant symptoms, but has unrecognized ongoing underlying 
airway inflammation and AHR.  Furthermore, given that patients do not always 
recognise when their asthma control is worsening30, additional objective 
measurements of these two underlying pathological processes may help to achieve 
optimal ICS dosing, in order to prevent future exacerbations or further loss of asthma 
control46,76,151. 
 
There is therefore a growing body of evidence that points to the logical conclusion 
that we, as a community of asthma physicians, need to decide how best to include 
measures of asthmatic inflammation and AHR for routine asthma evaluation, rather 
than whether they should be included; not least because at the present time these are 
the best determinants of future risk in asthma that we have, and that by targeting these 
outcomes therapeutically, reductions in asthma exacerbations have been 
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achieved6,13,14.  The simplest of these additional routine measurements might be blood 
eosinophil levels.  Indeed, it has been shown that higher levels of blood eosinophilia 
>400 cells/µL accounted for more severe exacerbations and poorer asthma control, 
than in those asthmatics whose blood eosinophils are lower than this77.  There was 
also a count-response relationship between blood eosinophil levels and asthma-related 
outcomes in that particular study.  As previously discussed in this thesis, FeNO levels 
may also be useful as an additional measure in this regard155; and although expensive 
at the present time, the technology for FeNO measurement might become cheaper and 
more straightforward to administer in the future.  AHR to mannitol bronchial 
challenge provides information about both hallmarks of asthma, namely inflammation 
and AHR simultaneously, and thus might provide a simple solution to increased 
community measurement of these outcomes6 in addition to pulmonary function 
measurement and asthma symptom evaluation.  Ultimately, it may be that we need a 
panel of tests162 that cover the spectrum of asthmatic disease pathophysiology, in 
order to adequately personalise ICS therapy for an individual asthmatic.  This has 
been partially achieved through the use of the asthma control questionnaire33 that 
combines multiple objective facets of asthma symptoms and daily experience with 
measurement of lung function.  Adding inflammatory/AHR measurements, perhaps 
with simple blood sampling for eosinophil levels to the ACQ for example, might be 
the first step in this process.  However, these hypotheses would need to be validated 
in further ICS titration studies using future asthma control and exacerbations as strong 
and clinically relevant outcome measures. 
 
The final study in this thesis rounds off the examination of the complete therapeutic 
profile of ICS dose response, by looking at the issue of safety when exposing patients 
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to higher doses of ICS in order to achieve optimal asthma control over a longer period 
of time.  In particular this study focused on the most worrying long-term adverse 
effect of steroid therapy, namely alteration of bone metabolism that may ultimately 
lead to osteoporosis and, therefore, increased fracture risk.  It is certainly clear that 
oral corticosteroids rapidly cause significant reductions in bone formation that lead to 
osteoporosis by tipping the balance of bone turnover to favour that of resorption with 
chronic steroid treatment117,287.  Previous studies of ICS have been conflicting in this 
regard, albeit we can be assured of the safety of low to moderate doses.  Indeed it is 
not until ICS doses are much higher (or more potent ICS are used such as fluticasone 
propionate), that biochemical effects on the HPA axis can be observed49,290.  
However, even when HPA axis effects are not seen, there may be a disconnect in 
regard to the potential for ongoing effects on bone turnover itself120,121.  We therefore 
examined this hypothesis using ciclesonide (CIC) as the ICS, where CIC was titrated 
against either standard BTS treatment guidelines or using an AHR strategy resulting 
in higher ICS dosing in the AHR arm after the 1 year study period (mean doses 
202µg/day vs. 507µg/day).  We performed a post hoc analysis of previously stored, 
sensitive serum biomarkers of both bone formation and resorption, and used the same 
to approximate any differences in overall bone turnover between the groups 
comparing low and high dose ICS prospectively over a 1 year period. 
 
We found no differences between the low (control) and high (AHR) dose ICS groups 
for either markers of bone formation (P1NP, P3NP), or bone resorption (1CTP, CTx) 
after the 1-year study period.  Furthermore, ratios of bone turnover as approximated 
by P1NP/1CTP and P3NP/CTx were also no different between the two ICS doses 
after 1 year of treatment.  These findings were additionally corroborated by observing 
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no deleterious impact on the patients’ HPA axes, as measured by overnight urinary 
cortisol/creatinine ratio in either treatment group at the end of the 12 months.  CIC is 
certainly well placed from the outset in this regard.  Its pharmacological profile is 
such that very little is systemically absorbed due to 99% of it being protein bound292.  
It is perhaps therefore unsurprising that we saw no significant effects on sensitive 
markers of bone turnover with this particular ICS.  Indeed, it may have been a 
different picture with a more systemically potent ICS such as fluticasone 
propionate295.  Nevertheless, CIC was clearly able to achieve more optimal control of 
asthmatic inflammation as measured by mannitol AHR in the parent study with the 
higher ICS dose. 
 
It is important to highlight the absence of any difference between ICS doses for the 
approximated ratios of bone turnover.  While the mean differences in standalone bone 
markers were not different, some individual patients had significant increases in bone 
resorption markers (1CTP).  It is difficult to be certain of the MCID for these markers, 
but it is considered to be around 30%.  With some individuals falling outside this 
threshold, it is reassuring that their overall bone turnover ratios remained unchanged. 
 
The major limitation of this study was a lack of confirmatory bone densitometry 
measurement at either end of the study period, particularly given the mean age of all 
patients being 54 years.  However, the serum biomarkers used here were more 
sensitive than bone densitometry, and have also been shown to strongly correlate with 
these radiological measurements310.  Indeed, the serum bone markers are also more 
sensitive and reliable than their urinary counterparts, with a lower Cv and without the 
need for correction with renal function.  The particular strengths of the study are both 
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the long study period of 1 year, as well as the prospective nature of bone marker 
measurement throughout the study. 
 
Overall, therefore, we can be assured that by embarking on a strategy of total asthma 
control using the higher doses of ICS required to dampen the underlying 
inflammatory process (as measured here using mannitol AHR), there is unlikely to be 
any significant detrimental long term effect on bone metabolism. 
 
To complete this discussion, it is important to identify future areas of research that 
should be considered on the basis of the findings from this thesis.  I believe the main 
finding that requires more work, is the identification of asthmatic patients who may 
have preserved symptoms and lung function, but ongoing underlying and 
unrecognised airway inflammation and AHR.  This is because the presence of both of 
these may lead to worsening asthma control or exacerbations in the future.  This 
therefore suggests that we need to be measuring multiple facets of asthma 
pathophysiology in order to best predict future outcome, and therefore the most 
appropriate treatment for an individual asthmatic.  One potential study might be to 
examine the utility of combining measures of asthma control along with another 
marker of inflammation and/or AHR to guide ICS therapy, and whether this might 
improve asthma control and future exacerbation rate better than either test alone.  
Even adding a more simple to measure biomarker such as blood eosinophils to routine 
review may prove useful.  Another spin-off outcome from this could be compliance to 
ICS therapy, whereby keeping tighter control of both a biomarker and for example 
ACQ together might help patients understand their need for ongoing ICS therapy 
despite lack of symptoms. 
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The incidences of obesity and asthma are both increasing, necessitating a better 
understanding of how ICS effects differ between overweight and normal weight 
asthmatics.  On the basis of this thesis’ findings, several areas of future study are 
warranted.  Firstly to examine whether it is indeed reduction in ICS delivery to the 
lung periphery through lung deposition imaging studies that is the main reason for 
reduced ICS efficacy in the obese asthma population.  In addition, studies of small 
peripheral airway function in obese versus normal weight asthmatics would be useful 
both on static doses of ICS as well as the effects of incremental ICS in this regard.  
Leading on from this would be a study of the utility of specifically selecting extra-fine 
particle ICS in obese subjects on outcomes such as asthma control compared to 
standard size particle ICS i.e. whether potential better delivery of ICS leads to better 
outcomes in these patients. 
 
One final area of potential future study relates to the use of beta-blockers in asthmatic 
subjects.  This would not be for the treatment of asthma per se, but to examine how 
best to increase their use in patients who might need them, for example, when they 
might suffer comorbid ischaemic heart disease where the benefits of beta-blockade 
are dramatic.  It is clear from this thesis that they are safe in carefully selected 
asthmatic patients controlled on ICS therapy.  This would initially require a case-
finding study for those patients with asthma who could/should be on beta-blockade 
for an alternative condition.  Further study into how best to commence beta-blocker 
treatment would be needed on a large scale in order to challenge clinical equipoise, 
where beta-blockers are shunned in asthma for safety reasons that may no longer 
apply provided patients are controlled on ICS therapy. 
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To draw this discussion to a close, I have included a proposed algorithm using the 
findings from this thesis in order to potentially improve asthma control with regard to 
ICS dosing alone (Figure 30). On the basis of asthma control as measured by ACQ, 
where an individual’s ICS treatment might not be altered on the basis of BTS/SIGN 
2014 asthma guidelines10, I have outlined serial measurements that could be employed 
in order of increasing complexity in order to attain total asthma control in a 
personalised manner.  This algorithm would clearly need further study and validation, 
but this may be used as a starting point for that process through future research 
projects.    
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Figure 30.  Proposed ICS dose titration algorithm. 
This algorithm is purely theoretical and only for ICS dosing as per this thesis, where ICS dose 
may not be changed on the basis of BTS/SIGN 2014 asthma guidelines.  It takes no account 
of other second line asthma therapies such as LABAs. 
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CONCLUSIONS 
 
1. This thesis demonstrated a significant dose-response relationship to ICS using 
diurnal domiciliary FeNO measurement in asthmatics with elevated FeNO as a 
common inflammatory phenotype.  These responses followed predictable 
exponential decay of FeNO that was significantly greater with higher ICS 
dosing.  These findings translated into significant improvements in symptoms 
and asthma control in this selected phenotype despite the short study duration. 
 
2. Overweight persistent asthmatics may have attenuated symptom and FeNO 
responses to stepwise ICS increments compared to normal weight asthmatic 
counterparts.  There was no difference, however, between weight groups for 
either FEV1 or methacholine responses at either dose.  There was a trend to 
attenuated cortisol suppression in overweight subjects, suggesting the 
possibility of reduced bioavailability of ICS as the reason for reduced 
symptom and FeNO responses in this group. 
 
3. Adding the beta-2 adrenoceptor inverse agonist propranolol to low dose ICS in 
persistent asthma provided no corticosteroid-sparing effect on histamine AHR 
and other inflammatory outcomes, compared to the significant improvements 
conferred by using a higher ICS dose.  Salbutamol recovery post-histamine 
challenge was partially blunted and there was a small but significant fall in 
evening FEV1 when adding propranolol to low dose ICS, but no deterioration 
in ACQ or AQLQ.  One would not therefore advocate propranolol as a 
corticosteroid-sparing agent in persistent asthma.  However, clinical equipoise 
might still be challenged as propranolol could perhaps be given at these doses 
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to asthmatic patients for its usual indications provided our strict safety criteria 
are adhered to in carefully selected patients controlled on ICS. 
 
4. This thesis identified categories of mannitol AHR which are correlated to 
airway inflammation as measured by FeNO as well as to direct AHR using 
methacholine challenge in mild to moderate persistent asthmatics currently 
taking inhaled corticosteroids.  This might provide a useful gauge of the 
degree of both airway inflammation and airway hyper-responsiveness in 
persistent asthmatics simultaneously.  We also found that mannitol AHR is not 
associated with salivary ECP or airway calibre in these asthmatic subjects.  
These findings add weight to the argument that mannitol challenge is related 
to both local airway allergic inflammation and hyper-responsiveness in 
persistent asthma. 
 
5. This thesis demonstrated further room for improvement in markers of 
inflammation and AHR, despite a plateau in the dose response to ICS for both 
asthma symptoms and pulmonary function, with both small and large particle 
ICS HFA-formulations and doses.  This points to an unmet need of 
uncontrolled underlying inflammation in certain asthmatic patients, which 
may be a precursor to future loss of asthma control. 
 
6. There were no significant differences in levels of sensitive markers of bone 
formation or resorption over 1 year, between groups using either low or high 
doses of ICS.  Furthermore, there was no difference in approximated ratios of 
bone turnover with the higher ICS dose.  These findings provide reassurance 
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that the higher ICS doses required to achieve control of asthmatic 
inflammation, over and above standard care, are safe with regard to the risk of 
steroid induced bone demineralisation. 
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APPENDIX II – ASTHMA QUESTIONNAIRES 
Asthma Control Questionnaire 
 
Please answer questions 1 – 6 
 
Circle the number of the response that best describes how you have been during the 
past week. 
 
 
 
1. On average, during the past week, 
how often were you woken by your 
asthma during the night? 
 
 
 
 
 
 
2. On average, during the past week, 
how bad were your asthma 
symptoms when you woke up in the 
morning? 
 
 
 
 
3. In general, during the past week, 
how limited were you in your 
activities because of your asthma? 
 
 
 
 
 
4. In general, during the past week, 
how much shortness of breath did 
you experience because of your 
asthma? 
0 Never 
1 Hardly ever 
2 A few times 
3 Several times 
4 Many times 
5 A great many times 
6 Unable to sleep because of 
asthma 
 
0 No symptoms 
1 Very mild symptoms 
2 Mild symptoms 
3 Moderate symptoms 
4 Quite severe symptoms 
5 Severe symptoms 
6 Very severe symptoms 
 
0 Not limited at all 
1 Very slightly limited 
2 Slightly limited 
3 Moderately limited 
4 Very limited 
5 Extremely limited 
6 Totally limited 
 
0 None 
1 A very little 
2 A little 
3 A moderate amount 
4 Quite a lot 
5 A great deal 
6 A very great deal 
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5. In general, during the past week, 
how much time did you wheeze? 
 
 
 
 
 
 
6. On average, during the past week, 
how many puffs/inhalations of short-
acting bronchodilator (e.g. 
Ventolin/Bricanyl) have you used 
each day? 
(If you are not sure how to answer 
this question, please ask for help) 
0 Never 
1 Hardly any of the time 
2 A little of the time 
3 A moderate amount of the time 
4 A lot of the time 
5 Most of the time 
6 All the time 
 
0 None 
1 1-2 puffs/inhalations most days 
2 3-4 puffs/inhalations most days 
3 5-8 puffs/inhalations most days 
4 9-12 puffs/inhalations most days 
5 13-16 puffs/inhalations most days 
6 More than 16 puffs/inhalations 
most days
 
 
To be completed by a member of the clinic staff
 
 
7. FEV1 pre-
bronchodilator:…………… 
 
 FEV1 
predicted:………………………….. 
 
 FEV1 
%predicted:……………………….. 
 (Record actual values on the dotted 
lines and score the FEV1 %predicted 
in the next column) 
 
 
0 >95% predicted 
1 95-90% 
2 89-80% 
3 79-70% 
4 69-60% 
5 59-50% 
6 <50% predicted 
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Mini Asthma Quality of Life Questionnaire 
 
Please complete all questions by circling the number that best describes how you have 
been during the last 2 weeks as a result of your asthma. 
 
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID 
YOU: 
 
  All of 
the time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
1 Feel short of 
breath as a 
result of your 
asthma? 
1 2 3 4 5 6 7 
2 Feel bothered 
by or have to 
avoid dust in 
the 
environment? 
1 2 3 4 5 6 7 
3 Feel frustrated 
as a result of 
your asthma? 
1 2 3 4 5 6 7 
4 Feel bothered 
by coughing? 
1 2 3 4 5 6 7 
5 Feel afraid of 
not having 
your asthma 
medication 
available? 
1 2 3 4 5 6 7 
6 Experience a 
feeling of 
chest tightness 
or chest 
heaviness? 
1 2 3 4 5 6 7 
7 Feel bothered 
by or have to 
avoid cigarette 
smoke in the 
environment? 
1 2 3 4 5 6 7 
8 Have 
difficulty 
getting a good 
night’s sleep 
as a result of 
your asthma? 
1 2 3 4 5 6 7 
9 Feel 
concerned 
about having 
asthma? 
1 2 3 4 5 6 7 
10 Experience a 
wheeze in 
your chest? 
1 2 3 4 5 6 7 
 
 
272 
	 	
IN GENERAL, HOW MUCH OF THE TIME DURING THE LAST 2 WEEKS DID 
YOU: 
 
  All of 
the time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little 
of the 
time 
Hardly 
any of 
the time 
None of 
the time 
11 Feel bothered 
by or have to 
avoid going 
outside 
because of 
weather or air 
pollution? 
1 2 3 4 5 6 7 
 
HOW LIMITED HAVE YOU BEEN DURING THE LAST 2 WEEKS DOING 
THESE ACTIVITIES AS A RESULT OF YOUR ASTHMA? 
 
  Totally 
limited 
Extremely 
limited 
Very 
limited 
Moderate 
limitation 
Some 
limitation 
A little 
limitation 
Not at all 
limited 
12 Strenuous 
activities 
(such as 
hurrying, 
exercising, 
running up 
stairs, sports) 
1 2 3 4 5 6 7 
13 Moderate 
activities 
(such as 
walking, 
housework, 
gardening, 
shopping, 
climbing 
stairs) 
1 2 3 4 5 6 7 
14 Social 
activities 
(such as 
talking, 
playing with 
pets / 
children, 
visiting 
friends / 
relatives) 
1 2 3 4 5 6 7 
15 Work-related 
activities* 
(tasks you 
have to do at 
work) 
1 2 3 4 5 6 7 
 
*If you are not employed or self-employed, these should be tasks you have to do most 
days. 
 
Mini-AQLQ Domain Code:  Symptoms (1, 4, 6, 8, 10); Activity limitations (12, 13, 
14, 15); Emotional function (3, 5, 9); Environmental stimuli (2, 7, 11).  
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Asthma Control Test 
 
Take this test if you are 12 years or older. Share the score with your healthcare 
provider. 
 
Step 1: Write the number of each answer in the score box provided. 
Step 2: Add up each score box for the total. 
Step 3: Take the completed test to your healthcare provider to talk about your score. 
 
If your score is 19 or less, your asthma symptoms may not be as well controlled as 
they could be. No matter what the score, bring this test to your healthcare provider to 
talk about the results. 
 
1.  In the past 4 weeks, how much of the time did your asthma keep you 
from getting as much done at work, school or at home? 
 
SCORE 
 All of 
the time [1] 
 
Most of the 
time [2] 
Some of the 
time [3] 
A little of 
the time [4] 
None of the 
time [5] 
 
……………… 
2. During the past 4 weeks, how often have you had shortness of breath? 
 
 
 More than 
once a day 
[1] 
 
Once a day 
[2] 
3 to 6 times 
a week [3] 
Once or 
twice a 
week [4] 
Not at all 
[5] 
 
 
……………… 
3. During the past 4 weeks, how often did your asthma symptoms 
(wheezing, coughing, shortness of breath, chest tightness or pain) wake 
you up at night or earlier than usual in the morning? 
 
 
 4 or more 
nights a 
week [1] 
 
2 to 3 nights 
a week [2] 
Once a 
week [3] 
Once or 
twice [4] 
Not at all 
[5] 
 
 
……………… 
4. During the past 4 weeks, how often have you used your rescue inhaler 
or nebulizer medication (such as salbutamol)? 
 
 
 3 or more 
times per 
day [1] 
 
1 or 2 times 
per day [2] 
2 to 3 times 
per week 
[3] 
Once a 
week or less 
[4] 
Not at all 
[5] 
 
 
……………… 
5. How would you rate your asthma control during the past 4 weeks? 
 
 
 Not 
controlled 
at all [1] 
Poorly 
controlled 
[2] 
Somewhat 
controlled 
[3] 
Well 
controlled 
[4] 
Completely 
controlled 
[5] 
 
 
……………… 
 
        TOTAL:      ……………… 
 
